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IN VITRO CHARACTERIZATION OF WILD-TYPE AND RIFAMYCIN-
RESISTANT MYCOBACTERIUM TUBERCULOSIS RNA POLYMERASES 
 
by 
Sumandeep Kaur Atwal 
 
Chair: George A. Garcia 
 
Rifampin (a semi-synthetic rifamycin derivative) is one of the first-line anti-
tuberculosis drugs.  Rifampin inhibits transcription by binding to the !-subunit of the 
RNA polymerase (RNAP).  The majority of the clinically-relevant Mycobacterium 
tuberculosis (MTB) rifamycin-resistant (RifR) mutations result from amino acid 
substitutions of one of the following three residues: !Asp435, !His445, and !Ser450 in a 
highly conserved 27 amino acid region of the RNAP !-subunit. 
The core subunits of wild-type and RifR mutants (Asp435Val, His445Tyr, 
Ser450Leu) of MTB RNAP were overexpressed in and purified from E. coli.  The 





 fold) losses of affinity for rifamycins were observed for the 
RifR mutants from both bacteria.  Additional studies with efflux pump-deficient E. coli 
(EC2880) confirm that the differential sensitivity of MTB and E. coli to rifamycin 
antibiotic activity is due to rifamycin efflux from E. coli, rather than any differences in 
! xiii 
the target RNAPs.  The activities of C-8 modified rifamycins are consistent with X-ray 
crystal structures that show Ser450 acting as a hydrogen bond donor to the C-8 hydroxyl 
of rifamycins and that rifamycin resistance in the Ser450 mutants is likely due to loss of 
this hydrogen bond and loss of affinity.  A series of novel benzoxazinorifamycin 
analogues displayed superior affinity toward wild-type and RifR mutants of the MTB 
RNAP than rifampin and rifalazil (RifR mutants, but not WT), but the IC50 values were 
still in the 10
-6
 M (!M) range with the RifR MTB RNAPs. 
Rifampin exhibits significant drug-drug interactions via potent induction of 
cytochrome P450 3A4 (CYP3A4).  Selected commercially available rifamycins and our 
synthetic analogues were screened in the human pregnane X receptor (hPXR) activation 
assay to determine their extents of hPXR activation as an indicator of potential for 
CYP3A4 induction.  One of our analogues exhibited very low (similar to rifalazil) 
activation of hPXR, while the others did show significant activation and some 
cytotoxicity. 
The results of these studies have provided encouraging evidence that rifamycins 
with improved activity against RifR MTB RNAP and lower drug-drug interaction 





Even after successful prevention and control efforts, infectious diseases remain 
the second leading cause of death in developing countries and the third leading cause of 
death in developed countries (1, 2).  These diseases include tuberculosis, HIV/AIDS, 
diarrheal diseases, and acute lower respiratory infections (1).  After the “era of antibiotics” 
(1930-1970s), infectious diseases seemed to be controlled and the attention was shifted to 
the threat of chronic diseases.  In the 1980s, pharmaceutical companies considered the 
number of antibiotics to be sufficient, and the development of new drugs was redirected 
away from antibiotics (2, 3).  Unfortunately due to antimicrobial resistance, infectious 
diseases have reemerged as important human health threats.  This has become an issue of 
great global concern because antimicrobial resistance reduces the effectiveness of current 
antibiotics leading to a greater risk of death and the possibility of returning to the pre-
antibiotic era.  Many factors may enhance antibiotic resistance including the incorrect use 
of antimicrobials (i.e., not completing the full course; poor quality antibiotics are used at 
sub-therapeutic dosing) (4).  Three major mechanisms of resistance are: inability of an 
antibiotic to permeate through cell wall or increased efflux, modification of the target that 
reduces the affinity for antibiotics, and inactivation of antibiotics by molecular 
modification (3).  Since infectious diseases have been neglected for the past few decades, 
the development of new antibiotics has been a slow process.  It is crucial to understand 
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the mechanisms of resistance and interactions of antibiotics with the resistance targets to 
allow for more potent and effective antibiotics to be designed and synthesized. 
Mycobacterium tuberculosis and Tuberculosis 
Tuberculosis (TB), an infectious disease caused by Mycobacterium tuberculosis 
(MTB), is a worldwide health threat being one of the most widespread and persistent 
bacterial infections (5, 6).  In 2009, approximately 9.4 million new cases of TB were 
reported, along with 1.7 million deaths caused by TB.  Furthermore, the emergence of 
antibiotic resistant MTB strains has increased to half a million cases (5, 7).  TB is the 
leading cause of death in persons with HIV infection due to the fact that the one infection 
accelerates the progression of the other (5, 8, 9). 
 
Figure I-1:  Stages of Mycobacterium tuberculosis (MTB) Infection.  TB exists as either 
latent or active infection.  There is a 5-10% chance of the latent form 
developing into the active infection.  Patients with the drug-susceptible TB 
recover 95% of the time (denoted by two asterisks) with a 5% chance of 
relapse.  If TB is untreated this results in high mortality (50%; denoted by 
two asterisks). 
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The TB infection exists in two forms (Figure I-1), active TB and latent TB, with 
one-third of the world’s population being infected with the latent/dormant form where 
there is ~5% (~10% for HIV/AIDs patients) chance of it converting to the active form (9, 
10).  Latent TB is not infectious and exists in a nonreplicative metabolic state in hypoxic 
environments thus making it difficult for antibiotics to be effective against it.  On the 
other hand, active TB is infectious and can be transmitted from the infected host to a 
healthy individual via air by coughing, sneezing, and talking (5, 9). 
Anti-TB Drugs and Resistant TB 
The hydrophobic and waxy cell wall that is rich in mycolic acids, provides a 
formidable barrier to the penetration of drugs through the MTB cell envelop, thus 
limiting the number of effective anti-TB drugs.  The current anti-TB treatment includes 
the following first-line drugs: rifampin, isoniazid, pyrazinamide, ethambutol, and 





 per bacterium per cell division), the anti-TB drugs are given in combination and 
the extensive treatment usually lasts six to nine months (12-16).  The recommended 
regimen for a drug-susceptible strain is the combination of isoniazid, rifampin, 
pyrazinamide, and ethambutol (optional) for the first two months.  During the next four to 
seven months (continuation phase), only rifampin and isoniazid (the two most potent 
anti-TB drugs) are administered (12, 17, 18).  Approximately 95% of patients infected 
with a drug-susceptible strain can be cured in six months with only these four first line 
anti-TB drugs with only a 5% chance of relapse (10).  
Unfortunately, alternative regimens have to be implemented for multidrug-
resistant TB (MDR-TB) strains that are resistant to both rifampin and isoniazid (7, 19).  
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This therapy (usually lasting 18-24 months) consists of second line antibiotics (Table I-1) 
that are usually more expensive, more difficult to administer, less effective, and have 
more toxic side effects than first line drugs, which limit their usefulness (11-14, 18).  
Some of the side effects include nephrotoxicity, hepatotoxicity and dysglycaemia (20).  
The cure rate of MDR-TB with suboptimal therapy is only 50-70%, with 30% exhibiting 
treatment failure (10, 19).  Furthermore, strains that are MDR and resistant to any 
fluoroquinolone and at least one of the injectable drugs (kanamycin, capreomycin, or 
amikacin) are classified as extensively drug-resistant TB (XDR-TB) with very high 
mortality rates (7, 19).  Treatment failure is usually observed due to nonadherence to drug 
regimen, drug resistance, or malabsorption of drugs (18).  To improve patient compliance, 
the directly observed therapy short course (DOTS) has been introduced where the 
patients are observed to ingest each dose in order to complete therapy and decrease the 
chance of acquired resistance (5). 
Table I-1:  Anti-Tuberculosis Drugs, MICs, Mechanism of Action 
 
Drugs  MIC (!M) Mechanism of Action 
(First line)    
Rifampin 0.06 – 0.12 Inhibition of RNA synthesis 
Isoniazid 0.15 – 1.5 Inhibition of cell wall mycolic acid 
synthesis 
Pyrazinamide 130 – 410 Disrupts membrane potential via 
accumulation of pyrazinoic acid 
Streptomycin 3.4 – 13.8 Inhibition of protein synthesis 
Ethambutol 4.9 – 25 Inhibition of cell wall arabinogalactan 
synthesis 
(Second line)    
Amikacin/kanamycin 3.7 – 7.5 Inhibition of protein synthesis 
Fluoroquinolones 1.1 – 5.7 Inhibition of DNA gyrase/DNA synthesis 
Ethionamide 15 – 60 Inhibition of mycolic acid synthesis 
Capreomycin/viomycin 2.9 – 5.9 Inhibition of protein synthesis 
p-aminosalicylic acid 3.3 – 50 Inhibition of folate biosynthesis pathway 
and mycobactin synthesis (unclear) 
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Recently, a new resistant strain has been identified as totally drug-resistant (TDR) 
TB; therefore, the issue of resistance and the necessity for new antibiotics is becoming of 
even greater concern (21).  The existing anti-TB drugs are inadequate to address the issue 
of resistance; furthermore, anti-TB drugs with a new mechanism of action have not been 
introduced since rifampin in the 1960s (10, 19).  The classes of anti-TB drugs currently in 
clinical trials (Phase 1 and 2; Figure I-2) include the following: diarylquinolines, 
nitroimidazoles, diamines, !-lactams, oxazolidinones, fluoroquinolones, and rifamycins, 
with only a 10% chance of any of these agents advancing to Phase 3 (10, 13, 14, 21).  
Unfortunately, mutations that confer resistance have already been identified for some of 
these drugs (13). 
 
 
Figure I-2:  The nine current anti-TB drugs in the clinical pipeline.  The different classes 
the antibiotics belong to are listed in parentheses.  (Reproduced and modified 
with permission from Koul 2011 (10)) 
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Targeting the RNAP 
An alternative to determining new classes of antibiotics/novel targets that are 
more potent is to chemically modify existing anti-TB drugs since their targets are already 
known.  Rifampin (one of the most effective anti-TB drugs) inhibits RNA synthesis by 
binding to the bacterial DNA-dependent RNA polymerase (RNAP), a nucleotidyl 
transferase enzyme (22-25).  RNAP is a vital enzyme responsible for transcription, an 
essential cellular process responsible for translating DNA into RNA in all organisms (3, 
26).  The core RNAP is composed of four different subunits (!2""’#); whereas, the 
holoenzyme is formed upon the binding of the sigma factor (!) to the core enzyme (Table 
I-2) (24, 25).  The inhibition of bacterial RNAP leads to cell death thus making RNAP an 
attractive target.  Additionally, bacterial RNAP is highly conserved among other 
prokaryotes but not eukaryotes hence allowing for therapeutic selectivity (16, 27).  
Furthermore, a bacterial RNAP inhibitor has the potential of being a broad-spectrum 
antibacterial drug because of the high level of conservation (27).  The best characterized 
bacterial RNAP is the E. coli enzyme and to a lesser extent that of Bacillus subtilis (22).  
Other selective and non-selective RNAP inhibitors include the following: streptolydigin, 
myxopyronin, sorangicin, CBR703, guanosine tetraphosphate, tagetitoxin, lipiarmycin, 
daunomycin, marcellomycin, and microcin J25; however, rifampin was the first 
rifamycin to be approved for clinical use (23-25, 27).  
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Table I-2:  Composition of the DNA-dependent RNAP holoenzyme 
 
 
History and Development of Rifampin and Rifamycins 
Rifampin is a semi-synthetic rifamycin derivative.  Rifamycins belong to the 
greater ansamycin class of polyketide natural products (16, 25, 28-31).  The generic 
ansamycin structure is composed of a flat aromatic ring system (naphthalene or benzene) 
and a 17-atom aliphatic ansa bridge connecting two non-adjacent atoms of the ring 
system (29).  A mixture of rifamycins (Rifamycins A – E) was first isolated from 
Amycolatopsis mediterranei (previously classified as Streptomyces mediterranei and 
Nocardia mediterranea) where rifamycin B was the only stable product isolated in pure 
crystalline form (5-10% of the mixture) (16, 28, 29).  The pathway from the weakly 
active rifamycin B to the more active rifamycin SV is illustrated in Figure I-3.  In brief, 
rifamycin B is spontaneously oxidized to rifamycin O that is then hydrolyzed to 
rifamycin S with the loss of glycolic acid, and under mild reduction conditions, the more 
active rifamycin SV is formed (28, 31).  Rifamycin SV is also a biosynthetic precursor of 
rifamycin B in the polyketide synthesis pathway (16, 25).   
Subunit Gene MW of MTB 
subunits (kDa) 
Function 
! rpoA 37.7 Assembly of the enzyme and the 
recognition of regulatory factors 
" rpoB 129.9 Chain initiation and elongation 
 "' rpoC 146.7 Binds to the DNA template and 
contains most of the active site 




 rpoD 57.8 Recognizes and initiates transcription 
from promoters of house-keeping 
genes (SigA, note there are 13 sigma 
factors in MTB) 
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Figure I-3:  Biological Transformation of rifamycin B into rifamycin SV 
Although rifamycin SV was active, an improved rifamycin derivative was 
required with better oral absorption, prolonged antibacterial levels in blood, and greater 
antimicrobial activity (28).  Several rifamycin derivatives have been synthesized, and the 
following relationships between structures of rifamycins and their antibacterial activities 
have been determined (some of the positions mentioned below are numbered on the 
rifamycin S structure in Figure I-3) (32):  
• Both naphthohydroquinone and naphthoquinone rifamycin derivatives were 
equally active 
• Acetylation of the hydroxyl group at position C8 resulted in an inactive rifamycin 
• Opening of the ansa bridge resulted in loss of all activity 
• Hydrogenation of the double bonds of the ansa bridge decreased activity 
• Epoxidation of the C16-C17 and C18-C19 double bonds reduced activity 
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• Acetylation of –OH groups C21 and C23 led to inactive derivatives 
• Hydrolysis of the acetoxyl group at C25 involved no loss of activity  
• Substituents added to C3 and/or C4 position increased activity 
Certain modifications of critical groups resulted in a decrease or loss of activity, 
and the minimal requirements for an active rifamycin were the hydroxyl groups at C21 
and C23 of the ansa ring, the polar groups at C1 and C8 of the naphthol ring, and the 
specific ansa configuration (29, 30, 32).  Modifications at C3 and C3/C4 of the aromatic 
ring are well tolerated and such derivatized rifamycins are active (29, 32).  Rifampin (a 
C3 derivative) was found to be the most active with the following favorable qualities: 
broad-spectrum antibiotic, unique mechanism of action, good oral absorption, active 
against latent TB, and reduced TB therapy from 18 to 9 months (28, 30, 33). 
Rifampin was first reported to inhibit the initiation of E. coli RNA synthesis by 
Hartmann and colleagues (34, 35).  Rifampin binds tightly to the RNAP to form a stable 
noncovalent 1:1 complex with a binding constant in the range of 10
-8
 M (36).  The 
binding of rifampin had no effect on promoter binding or the formation of the first 
phosphodiester bond but decreased the binding affinity of NTPs (by a factor of two) 
under in vitro conditions (36-38).  Rifampin was able to bind to both the core RNAP and 
the holoenzyme (with a slightly higher affinity for the holoenzyme); therefore, the sigma 
factor is not required for binding (39).  The rate of inhibition decreased in the presence of 
DNA template since the enzyme was protected to a certain degree.  No inhibition was 
observed when rifampin was added after the addition of nucleotides since transcription 




Figure I-4:  A cartoon of the “steric occlusion” model.  In this overlay of two structures, 
rifampin (carbon atoms, orange; oxygen, red; nitrogen, blue) is bound to the 
! subunit of the RNAP (RNAP and nucleic acids are omitted for clarity).  
The active site is indicated by the Mg2+ ion (the magenta sphere) and the 9bp 
RNA/DNA hybrid (+1 to -8) is only numbered from +1 to -5.  The first 
nucleotide (green) binds at the +1 position as the chain grows, it is able to 
translocate to positions -1 and -2 (seen in yellow).  However, the triphosphate 
of the first nucleotide clashes with the rifampin (illustrated in pink; -3 to -8) 
upon the addition of another nucleotide thus inhibiting RNA synthesis and 
releasing dinucleotides.  (Reproduced with permission from Campbell 2001 
(41)) 
 
McClure and Cech proposed the “steric occlusion” model as the principal 
mechanism of action.  The 5’ phosphates of the 5’ NTP clash with the bound rifampin 
thus inhibiting the formation of the second phosphodiester bond.  The RNAP is unable to 
translocate and dinucleotides are released.  If transcription is initiated by NDP or NMP, 
the third phosphodiester bond is inhibited.  The 3.3 Å crystal structure of Thermus 
aquaticus core RNAP in complex with rifampin supports the steric occlusion theory 
(Figure I-4) (41). 
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Figure I-5:  The two pathways involved in the inhibition of RNAP via “allosteric 
mechanism”.  The ! pathway (on the left) is activated when the ansa bridge 
and the ! subunits interact.  The allosteric signal (blue lightning bolt) from 
this pathway inhibits the formation of the second phosphodiester bond.  
The signal from the " pathway (the purple lightning bolt; on the right) is 
activated when the C3/C4 rifamycin tail interacts with the hairpin loop of 
the " factor ("HL) and inhibits the formation of the first phosphodiester 
bond.  Both pathways release the catalytic Mg
2+
 ion (magenta sphere; bent 
arrow) thus releasing unstably bound RNAs (yellow) from the initiation 
complex.  (The other components of the complex are as follows: core 
RNAP, gray; DNA template strand, red; DNA nontemplate strand, blue; 
RNA, yellow; " and hairpin loop; magenta.)  (Reproduced with permission 
from Artsimovitch 2006 (46)) 
 
However, the steric occlusion theory alone is not sufficient to explain the 
difference in activity with different rifamycin derivatives that only vary at the C3 and 
C3/C4 positions (42-45).  It was observed that the rifamycin analogues with C3 tail 
modifications inhibited the formation of the second phosphodiester bond; whereas, the 
analogues with C3/C4 tail modifications inhibited the formation of the first 
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phosphodiester bond.  Artsimovitch and colleagues proposed the “allosteric inhibition 
mechanism” with two pathways (the ! pathway and the " pathway) to explain these 
differences (Figure I-5) (44).  The ! pathway is activated by the interactions of the ansa 
bridge with the ! residues and inhibits the formation of the second or third 
phosphodiester bond.  Whereas, the " pathway inhibits the formation of the first 
phosphodiester bond where the C3/C4 tail interacts with the hairpin loop of the " factor 
("HL) and this induces an allosteric signal (over 19 Å) and decreases the affinity for the 
catalytic Mg2+ ion thus slowing down transcription (44, 46).  These two pathways were 
supported by the crystal structures of Thermus thermophilus RNAP in complex with 
rifapentine (C3 rifamycin; ! pathway) and rifabutin (C3/C4 rifamycin; " pathway). 
Feklistov et al. reinvestigated the “allosteric mechanism” and found no evidence 
to support the hypothesis.  The predominant effect of rifamycins was the inhibition of the 
formation of the second or third phosphodiester bond, consistent with the original steric 
occlusion model theory (37, 47).  The results of Feklistov et al. are compelling and the 
steric occlusion model seems to be the most logical working hypothesis.  This model 
suggests that if one were to incorporate new binding interactions between the rifamycin 
and the RNAP, one could achieve higher affinity and efficacy. 
Rifamycin-resistance 
The rifamycin-resistant (RifR) mutations arise spontaneously at a frequency of  
10-8 where approximately 95% of these mutations are within 4 regions of the ! subunit 
(N-terminal cluster and clusters I, II, III; Figure I-6) (16, 41, 48).  Rifamycin resistance is 
mainly due to single amino acid substitutions and a few deletions or insertions of residues 
that alter the rifamycin binding site thus reducing the affinity for rifamycins (43, 49, 50).  
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All but one of the 15 different residues that have been identified from MTB RifR clinical 
isolates mapped to the 27 amino acid region of cluster I (also known as the Rifamycin 
Resistance Determining Region (RRDR)), a highly conserved region among prokaryotic 
RNAPs (42, 49). 
 
Figure I-6:  Selected Sequences from Rifamycin-resistance Determining Regions of the 
RNAP ! Subunits from E. coli, Thermus aquaticus (Taq), and 
Mycobacterium tuberculosis (MTB) (Cluster N and Clusters I, II, and III).  
The 12 amino acids of the ! subunit that interact directly with rifampin are 
indicated with + above the E. coli sequence.  The 15 RifR mutation positions 
that have been identified in MTB RifR clinical isolates are indicated with * 
below the MTB amino acid sequence.  The three most frequently mutated 
residues are seen within the boxes.  (Data from Campbell 2001) 
 
From the co-crystal structure of Taq RNAP and rifampin, it was determined that 
the rifamycin binding site is located ~12.1 Å away from the active site (38, 41).  
Rifampin binds to the ! subunit and directly interacts with twelve ! subunit residues (via 
hydrogen bonding or van der Waals interactions) as can be seen in Figure I-7 (41, 51).  
The four critical groups at C1, C8, C21, and C23 of the rifamycins (discussed earlier) are 
involved in hydrogen bond interactions to ensure protein binding.  Most of these twelve 
residues are found within the RRDR, and mutations of 11 out of the 12 residues result in 
RifR strain (Figure I-6) (16, 41). 
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Figure I-7:  Interaction of Rifampin with the Amino Acids of Thermus aquaticus RNA 
polymerase (RNAP) in the Antibiotic-Enzyme Complex.  The amino acid 
numbering is for MTB rpoB.  The amino acids interact with rifampin via 
van der Waals and hydrogen-bonding interactions.  The oxygens of rifampin 
that form hydrogen bonds are numbered as in Figure I-3.  The three most 
prevalent RifR mutation sites (re: Figure I-6) are circled.  (Reproduced and 
modified with permission from Campbell 2001 (41)) 
 
Among these residues, the individual substitutions of three residues (Asp435, 
His445, and Ser450; MTB numbering; Figures I-6 and I-7) together account for more 
than 84% of MTB RifR strains found in clinical isolates.  The most abundant amino acids 
substituted in place of these residues are as follows: 435 Val, 445 Tyr, and 450 Leu, 
respectively (42, 49).  The three wild-type residues interact with the critical groups of 
rifampin via hydrogen bonds (Figure I-7): Asp435 and His445 H-bond with the hydroxyl 
at C21 and Ser450 H-bonds with the hydroxyl at C8.  Mutations of these residues lead to 
the loss of important interactions; therefore, rifampin is unable to bind as tightly to the 
RifR RNAP, consistent with the results and conclusions of Feklistov et al. (47).  These 
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resistant mutants are able to survive well with little decrease in fitness, most likely due to 
the distance between the rifamycin binding site and the RNAP active site (52). 
 
 
Figure I-8:  The hPXR ligand-binding pocket with rifampin bound.  The hPXR residues 
are shown in magenta.  (Reproduced with permission from Chrencik 2005 
(53)) 
 
One of the drawbacks of rifampin is that it is a potent agonist of the human 
pregnane X receptor (hPXR), which is responsible for transcriptional regulation of certain 
drug metabolizing enzymes and transporters (54).  Most importantly, the activation of 
hPXR by rifampin leads to the up-regulation of expression of cytochrome P450 3A4 
(CYP3A4), which results in metabolic clearance of drugs, failure of therapy, and reduced 
efficacy (53, 54).  The relative potency of CYP3A4 induction is rifampin > rifapentine > 
rifabutin > rifalazil (a benzoxazinorifamycin derivative) where rifalazil does not induce 
the expression of CYP3A4 at ~10
5
 x its IC50 for WT RNAP (55).  Additionally, not all 
PXRs from different species are activated by rifampin (e.g., mouse and rat PXRs).  
Recently, the x-ray crystal structures of activators bound to the ligand-binding domain of 
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hPXR have been determined including one with RMP bound (Figure I-8)!  From these 
structures, it was concluded that the hPXR ligand-binding pocket is large, flexible, and 
capable of adapting itself to bind a large variety of ligands (53).  Also, rifampin is one of 
the largest hPXR activators and fills the binding pocket quite well, most likely the reason 
for its very potent activation of hPXR. 
Due to the existence of resistant mutants and other unfavorable properties of 
rifampin (i.e., heptatoxicity, flu-like syndrome, induction of cytochrome p450, and 
inhibition of hepatic transporters), a more effective rifamycin that will shorten treatment 
time, target resistant strains, be active against the latent form of TB, and eliminate drug-
drug interactions is highly desirable (10, 55).  In the past 40 – 50 years several rifamycin 
derivatives have been synthesized with the focus on C3 or C3/C4 modified rifamycin 
derivatives to produce a more effective antibiotic (29)!  However, there have been only 
three other rifamycins approved in the United States along with rifampin: rifapentine, 
rifabutin, and rifaximin (Figure I-9).  While these rifamycins have improved antibacterial 
activity, they still exhibit cross-resistance with RifR mutants (42, 55).  Recently, a new 
class of rifamycin derivatives, the benzoxazinorifamycins, have been shown to 
demonstrate more potent activity against mycobacteria and are effective against certain 
RifR strains, especially rifalazil (56, 57).  But due to serious side effects during clinical 
trials, the development of rifalazil has been halted (55). 
Although many rifamycin derivatives have been synthesized, it has been observed 
that the pharmacokinetic properties of rifamycins can be improved, the drug-drug 
interactions can be reduced/eliminated, levels of toxicities can be changed, and potency 
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against resistant strains can be improved.  Most importantly the availability of the crystal 
structure allows for a structure-based approach to develop improved rifamycins (55).!!
!
Figure I-9:  Rifamycins approved in the United States.  The C3 rifamycin derivatives are 
shown on top and the C3/C4 derivatives are on the bottom. 
 
Research Objectives 
There is an urgent need for anti-TB drugs that are effective against antibiotic 
resistant strains.  The current treatment consists of anti-TB drugs that are 50 years old and 
that are ineffective against antibiotic resistant TB strains (MDR and XDR).  Due to the 
difficulties of discovering new drugs against novel targets, in many cases focus has 
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returned to modifying existing antibiotics interacting with known, effective targets.  In 
order to modify antibiotics to control the resistant strains, a better understanding of 
resistance needs to be achieved at the molecular level.  The resistance mechanisms of 
known drugs (i.e., rifampin and other rifamycins) need to be thoroughly understood, thus 
leading to improved drug design and better understanding of the RifR mutants to guide 
further research. 
The overall focus of this dissertation is to understand the molecular interactions 
between rifampin and rifamycin analogues and the wild-type and RifR mutant MTB 
RNAPs.  Although studies have been conducted previously using the E. coli RNAP, it is 
important to characterize the MTB RNAP with rifampin and other rifamycins.  Even 
though there is a high level of conservation of the rpoB gene and the rifamycin binding 
site among prokaryotes, the sensitivity toward rifampin has been observed to be different 
for different bacterial strains (41, 58).  Harshey et al. were able to purify MTB RNAP 
from MTB H37Rv strain and reported that MTB RNAP was 1000 times more sensitive to 
rifampin than E. coli RNAP (58).  Furthermore, the three most prevalent RifR mutations 
(D435V, H445Y, and S450L) have been clinically isolated and studied in resistant MTB 
strains, but no in vitro studies of purified RifR MTB RNAPs with rifamycins have been 
reported. 
This dissertation is focused on the detailed in vitro characterization of wild-type 
and RifR mutants of the MTB RNAP to elucidate the molecular interactions that are 
responsible for resistance.  The ultimate goal is to provide information that can help drive 
the development of novel rifamycins that overcome the issue of resistance.  The primary 
questions addressed in each chapter of this dissertation are listed below. 
 19 
• Chapter II:  How does the sensitivity of the MTB RNAPs (WT and selected RifR 
mutants) to rifamycins compare to that of E. coli RNAPs and how does this 
correlate with the differential sensitivities of MTB and E. coli to rifamycins?  
• Chapter III:  Do any of our novel C8 rifamcyin analogues (probing the interaction 
between S450 and the C8 OH) result in a more potent/effective rifamycin against 
the RifR MTB RNAP (S450L)? 
• Chapter IV:  Do any of our novel, structure-based designed benzoxazinorifamycin 
analogues result in a more potent/effective rifamycin against the wild-type and 
RifR MTB RNAPs? 
• Chapter V:  Can a dansyl-conjugated rifamycin be used as a fluorescent probe for 
a direct binding assay? 
• Appendix:  Can a MTB promoter based plasmid assay be developed for use in a 
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In vitro Investigation of Wild-type and Rifamycin-resistant Mutants  
of the Mycobacterium tuberculosis RNA polymerase 
 
Rifampin (RMP) is a first line anti-tuberculosis drug that inhibits the prokaryotic 
RNA polymerase (RNAP) by binding to the ! subunit.  Previously, the interaction of 
RMP with various prokaryotic RNAPs has been investigated but in vitro data for wild-
type (WT) and rifamycin-resistant (RifR) MTB RNAPs is lacking (1-6).  The various 
bacterial RNAPs have been reported to possess different levels of sensitivity towards 
RMP (1, 3, 4, 7).  Even though the rifamycin-binding site is conserved among 
prokaryotes, differences in key residues that directly interact with RMP lead to 
differential inhibition (1).  RMP is a broad spectrum antibiotic with more potent activity 
against Gram-positive bacteria (particularly mycobacteria) than Gram-negative bacteria 
(6, 8).  Additional factors include permeability issues where the reduced penetration of 
RMP through the outer membrane of Gram-negative bacteria has been invoked to explain 
the lower sensitivity to RMP (6). 
Even though the RifR mutations in MTB have been clinically isolated and studied 
in RifR MTB strains, no in vitro studies of purified RifR MTB RNAPs with rifamycins 
have been reported (9, 10).  Previously, Harshey and colleagues have isolated WT MTB 
RNAP (!""’#) from MTB H37RV cells and reported that RMP is a thousand-fold more 
potent against MTB RNAP than E. coli RNAP and the difference in sensitivity to 
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RMP could be due to the differences in the beta subunits (7).  Recently, the MTB RNAP 
(!""’#) has been reconstituted as recombinant proteins expressed in E. coli, but the 
activity of the MTB RNAP in the presence of rifamycins was not assessed (11).  In order 
to understand rifamycin resistance further, it is important to obtain in vitro data for WT 
and the three most prevalent RifR MTB RNAPs.  The individual substitutions of three 
residues (Asp435, His445, and Ser450; MTB numbering) together account for more than 
84% of MTB RifR strains found in clinical isolates.  The most abundant amino acids 
substituted in place of these residues are as follows: 435 Val, 445 Tyr, and 450 Leu, 
respectively (9, 10). 
Due to the increase of RifR strains, the focus has been on synthesizing improved 
rifamycins that are active against RifR mutations.  Many of the modifications on 
rifamycin resulted in decrease or loss of activity, but alterations at C3 and C3/C4 
positions of the aromatic ring are well tolerated (6).  Therefore, the focus over the past 40 
or so years has been to synthesize C3 or C3/C4 modified rifamycin derivatives to produce 
a more effective antibiotic.  However, there have only been three other rifamycins 
approved in the United States along with RMP: rifapentine (RPN), rifabutin (RBN), and 
rifaximin (RFX), where these rifamycins have improved antibacterial activity but still 
exhibit cross-resistance with RifR mutants (Figure II-1) (12-18). 
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Figure II-1:  Structures of Key Rifamycins (typical rifamycin numbering system is shown 
with Rifamycin S). 
 
To better understand the interaction between the rifamycins and wild-type/RifR 
mutant MTB RNAPs, we report here the cloning and expression and in vitro activity of 
MTB RNAP.  The three most prevalent RifR mutations (Asp435Val, His445Tyr, 
Ser450Leu) found in the MTB clinical isolates were generated to express the mutant ! 
subunit of the RNAP in the rpoB gene via site directed mutagenesis.  We also report the 
results of the in vitro screen of three key rifamycins (RMP, RBN, and RFX) along with 
the MICs of these rifamycins in MTB and E. coli.  These results will help to inform the 
development of novel rifamycins with enhanced activity against RNAPs containing 




Materials and Methods 
Reagents 
Unless otherwise specified, all reagents were purchased from Sigma-Aldrich (St. 
Louis, MO).  Gelase
TM





Universal RNA Polymerase template were from Epicentre (Madison, WI).  The QIAprep 
Spin Miniprep and Maxiprep Kit were from Qiagen (Valencia, CA).  Carbenicillin 
(disodium salt), Corning microplates, bactotryptone, and yeast extract were from Fisher 
Scientific (Hampton, NH).  The E. coli BL21 (DE3) CodonPlus-RIPL and Epicurian coli 
XL2-Blue Ultracompetent cells were from Agilent Technologies (Santa Clara, CA).  All 
restriction enzymes and Vent! DNA polymerase were from New England Biolabs 
(Ipswich, MA).  SeaPlaque! Agarose was from Lonza (Rockland, ME).  T4 DNA Ligase, 
Quanti-iT
TM
 RiboGreen RNA Reagent, RNaseOUT
TM
 Recombinant Ribonuclease 
Inhibitor, pEXP-5-NT/TOPO! TA Expression Kit, and all synthetic oligonucleotides 
were from Invitrogen (Carlsbad, CA).  Lysonase
TM
 Bioprocessing Reagent and Ni-NTA 
His•Bind! resin were from Novagen (San Diego, CA).  The nucleotide triphosphates 
(NTPs) were from Roche Applied Science (Indianapolis, IN).  PhastGel Precast Gels and 
SDS Buffer Strips were from VWR (Arlington Heights, IL).  The Bio-Rad Protein Assay 
kit was from Bio-Rad (Hercules, CA).  The avirulent Mycobacterium tuberculosis strain 
(H37Ra) was a generous gift from the TB center of Colorado State University.  The 
pVS10 vector, containing the E. coli rpo genes encoding the RNAP subunits, was a 
generous gift from Professor Irina Artsimovitch (Ohio State University).  The plasmids 
containing the individual MTB rpo genes (pSR52 (rpoA ), pJF09 (rpoB), pJF10 (rpoC)) 






 mutations) was a generous gift from Dr. Michael Hubband 
(Pfizer Scientific). 
Cloning MTB rpo Genes into an E. coli Co-overexpression Plasmid 
For in vitro studies, the wild-type MTB core RNAP was obtained from the co-
overexpression plasmid pMTBRP-5 (Figure II-4).  The MTB core RNAP subunit 
encoding genes (rpoA  (!), rpoB ("), rpoC ("’), and rpoZ (#)) were amplified from 
pSR52, pJF09, pJF10, and genomic MTB H37Ra DNA, respectively (Figure II-2).   
 
Figure II-2:  PCR amplified MTB genes on 1% agarose gel: lane 1, 100 bp DNA ladder; 
lane 2, MTB rpoA  (1044 bp); lane 3, MTB rpoZ (333 bp); lane 4, MTB 
rpoB (3519 bp); lane 5, MTB rpoC (3951 bp); lane 6, 1 kb DNA ladder 
 
The individual genes were then cloned into pEXP5-NT/TOPO vector to generate 
pEXP5-NT/TOPO(rpoA ), pEXP5-NT/TOPO(rpoB), pEXP5-NT/TOPO(rpoC), pEXP5-
NT/TOPO(rpoZ).  Reactions were performed according to the manufacturer’s 
instructions and then chemical transformation of the resulting plasmids into host cells 
was carried out.  Each one of the MTB RNAP genes was PCR amplified with Vent$ 
DNA polymerase using specific primers introducing unique restriction enzyme sites to 
assist in gene cloning.  The oligonucleotides used for PCR amplification are listed in 
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Table II-A2 in Appendix II-1.  The pVS10 plasmid encodes the E. coli rpoA -rpoB-
rpoC[His6]-rpoZ ORFs under the control of a single T7 promoter and terminator 
sequence and was used as the template where the E. coli rpo genes were replaced with 
MTB rpo genes following the scheme presented in Figure II-3.  The PCR product of the 
1.0 kb MTB rpoA  was digested with NcoI and NdeI and cloned into pVS10 treated with 
NcoI and NdeI replace of E. coli rpoA.  The E. coli rpoB and rpoC genes were replaced 
with a 165 bp linker in order to facilitate the incorporation of the smaller MTB rpoZ gene.  
The resultant plasmid, pMTBRP-1 and the 0.3 kb rpoZ gene were treated with AflII and 
NotI.  The ribosome-binding site (RBS) was introduced to the beginning of the rpoZ ORF 
producing pMTBRP-3.  Additional alterations had to be made to the ORFs of rpoC and 
rpoB to eliminate internal restriction sites and/or to correct PCR induced mutations by 
site directed mutagenesis before being amplified with PCR primers.  The amplification of 
rpoB gene was divided into two parts where a hexahistidine tag was introduced first and 
then the unique restriction site to the 3’ end of the rpoB ORF.  After these changes the 
plasmid containing the 4.0 kb rpoC gene and pMTBRP-3 were treated with AvrII and 
AscI.  The rpoC cassette was subcloned into the treated plasmid to form pMTBRP-4.  
The plasmid containing the 3.5 kb rpoB gene and pMTBRP-4 were digested with AvrII 
and BmtI.  Sequences confirmed that the resultant plasmid, pMTBRP-5, contained the 




Figure II-3:  Construction Scheme for expression vectors for wild-type MTB RNAP 
(pMTBRP-5) and rifamycin-resistant mutants (pMTBRP-6, 7, 8). 
 
Construction and Preparation of MTB RNAP Mutant Plasmids 
The single nucleotide mutations (D435V (GAC-GTC), H445Y (CAC-TAC), and 
S450L (TCG-TTG)) were independently incorporated into pEXP-5/TOPO (rpoB) by 
PCR site-directed mutagenesis using the primers listed in Table II-A2 in Appendix II-1.  
The resultant plasmids were transformed into Epicurian coli XL2-Blue ultracompetent 
cells.  After verification of mutant rpoB by DNA sequencing, the plasmids containing the 
mutant rpoB genes and the wild-type pMTBRP-5 were digested with AvrII and SbfI and 
ligated to create the MTB mutant RNAP vectors: pMTBRP-6(D435V), -7(H445Y), and -
8(S450L) (Figure II-3 and II-4). 
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Figure II-4:  Co-overexpression Vector pMTBRP-5 Containing the MTB rpoA (!)-
rpoB(")-rpoC("’)-rpoZ(#) Genes Encoding the 4 Subunits of the Wild-
type MTB Core RNAP.  The hexahistidine tag is fused to the C-terminus 
of rpoB gene for purification.  Artsimovitch and colleagues’ co-
overexpression plasmid, pVS10 (expressing the E. coli core RNAP), was 
used as a template for the construction of pMTBRP-5. 
 
Expression and Purification of MTB Core RNAPs 
The co-expression vectors (pMTBRP-5, 6, 7, 8) were transformed into E. coli 
BL21(DE3) CodonPlus-RIPL cells.  The cells were grown in 500 mL of 2xTY liquid 
cultures containing 100 !g/mL carbenicillin and 30 !g/mL chloramphenicol at 37
o
C with 
vigorous shaking until cell density reached OD600nm=0.5-0.6.  The protein was induced by 
the addition of isopropyl "-D-thiogalactoside (IPTG) to a final concentration of 1 mM.  
The cultures were allowed to incubate for an additional 20-24 hours at 19
o
C.  The cells 
were harvested by centrifugation (6000xg, 15 min, 4
o
C).  The cell pellet of each 500 mL 
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culture was re-suspended in 10 mL of Ni
2+
-NTA bind buffer (300 mM NaCl, 50 mM 
NaH2PO4, 10 mM imidazole, pH 8.0).  The freeze/thaw method was followed to lyse the 
cells, and it was repeated a total of three times.  The sample was supplemented with 10 
!L of Lysonase
TM
 Bioprocessing Reagent and 100 !M of phenylmethylsulfonyl fluoride 
(PMSF), and then the resulting lysate was cleared by centrifugation (21,000xg, 30 min, 
4
o
C).  All further purification steps were performed at 4
o
C.  The lysate was incubated 
with 2 mL Ni
2+
-NTA His•Bind Resin overnight with gentle shaking.  Each supernatant-
resin mixture was applied to individual columns.  The columns were washed twice with 4 
mL of Ni
2+
-NTA wash buffer (300 mM NaCl, 50 mM NaH2PO4, 20 mM imidazole, pH 
8.0), and the protein was then eluted in 6 mL of Ni
2+
-NTA elute buffer (300 mM NaCl, 
50 mM NaH2PO4, 250 mM imidazole, pH 8.0).  The MTB RNAPs were concentrated to a 
final volume of ~500 !L and then sterile-filtered with 0.22-!m syringe before being 
applied to a HiPrep 16/60 Sephacryl S-200 HR (GE Healthcare) column and the running 
buffer was RNAP storage buffer (10 mM Tris-HCl (pH 7.9), 0.1 mM EDTA, 0.1 mM 
DTT, 0.1 M NaCl).  The fractions containing the MTB RNAP were pooled together and 
concentrated to a final volume of ~100-200 !L using Amicon Centrifugal Filter Units 
(MWCO=100 kDa).  The enzyme was mixed with one volume of 100% glycerol and 
stored in liquid nitrogen.  The final concentration of the enzymes was determined via 
Bradford assay using the Bio-Rad Protein Assay Kit. 
Construction, Expression and Purification of Wild-type and Mutant E. coli RNAPs 
The corresponding RifR mutations (D516V (GAC-GTC), H526Y (CAC-TAC), 
and S531L (TCG-TTG); E. coli numbering) were introduced to the wild-type E. coli 
rpoB gene of pVS10 via site-directed mutagenesis.  For the construction of the E. coli 
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mutant RNAP expression vectors, the plasmids containing the mutant rpoB genes and the 
wild-type pVS10 were digested with XbaI and SbfI and ligated to create pVS10 (D516V), 
pVS10 (H526Y), and pVS10 (S531L) following the general laboratory protocol.  These 
plasmids were then confirmed by DNA sequencing.  The E. coli RNAPs were purified in 
the same fashion as the MTB RNAPs with a few modifications.  The E. coli expression 
vectors were transformed into E. coli BL21 (DE3) strain.  The cells were grown in 500 
mL of 2xTY liquid culture containing 100 !g/mL carbenicillin at 37
o
C until OD600nm 
reached ~0.6, at which point the protein production was induced with 1 mM IPTG.  The 
cells were grown for an additional 4 hours at 37
o
C and harvested by centrifugation 
(6000xg, 15 min, 4
o
C).  The cell pellets were resuspended in 10 mL of bind buffer and 
supplemented with 10 !L Lysonase
TM
 Bioprocessing Reagent and 100 !M PMSF.  The 
cell suspension was incubated at room temperature for 20 min before the cells were 
disrupted by sonication (seven 13-sec pulses) on ice.  The resulting lysate was cleared as 
described above.  The lysate was incubated with 2 mL Ni
2+
-NTA His•Bind Resin with 
gentle shaking for 1 h.  The mixture was then applied to the column.  The protein was 
purified from the column as described above and then concentrated before being applied 
to a size exclusion column.  The fractions containing the E. coli RNAP were pooled 
together and concentrated to a final volume of ~300-500 !L using Amicon Centrifugal 
Filter Unit (MWCO=100 kDa).  The enzyme was mixed with one volume of 100% 
glycerol and stored in liquid nitrogen.  The concentration of the enzymes was determined 
as stated before for MTB RNAPs. 
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Determination of the in vitro Transcriptional Activity of MTB RNAPs 
The activity of the WT and RifR mutant MTB and E. coli RNAPs was measured 




 Universal RNA 
Polymerase template in the absence and presence of rifamycins (Figure II-5).  The 
supplier’s protocol for end-point detection using RiboGreen (a fluorescent nucleic acid 
dye) was followed.  The assays were performed on a SpectraMax M5 (Molecular 
Devices) microplate reader using 96-well half-area black plates.  The in vitro 
transcription conditions were as follows for a 25 !L reaction: RNAP (10 nM), E. coli 
RNAP 5X reaction buffer (200 mM Tris-HCl (pH 8.0), 250 mM KCl, 50 mM MgCl2, 
0.05% Triton X-100), DTT (8 mM), RNase inhibitor (1.12 U/!L), Kool NC-45 template 
(80 nM), and NTP solution (500 !M of each NTP).  The reaction was initially incubated 
at 37
o
C for 10 min in the absence of Kool NC-45 template and NTP solution to ensure 
the binding of RNAP and rifamycin.  Then the template was added and the reaction was 
initiated upon the addition of the NTPs.  Aliquots were taken every 30 min for 2 h from 
each reaction and quenched in TE buffer (10 mM Tris-HCl (pH 7.5), 1 mM EDTA).  The 
amount of RNA synthesized was measured by the addition of 1:200 diluted RiboGreen 
(an ultrasensitive fluorescent nucleic acid stain).  The excitation and emission 
wavelengths for RiboGreen were 480 nm and 520 nm, respectively. 
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Figure II-5:  RNAP Rolling Circle Transcription Assay.  RNAP is pre-incubated with 
varying concentrations of rifamycins.  The 45mer DNA nanocircle, Kool 
NC-45 Template, binds to the free bacterial RNAP.  In the absence of 
rifamycins, the RNAP is able to transcribe multiple copies of the 45 base 
template (indicated by the green ticks on the growing RNA strand).  The 
concentration of RNA is detected using a fluorescent dye, RiboGreen and 
an RNA concentration standard curve as described in Materials and 
Methods. 
 
Inhibitory Effect of Rifamycins on MTB and E. coli RNAPs 
Dose response studies with different rifamycins were performed on WT and RifR 
RNAPs after it had been confirmed that the enzymes were active.  Each of the rifamycins 
(RMP, RBN, RFX-Figure II-1) was tested in duplicate where the concentration ranges 
were as follows for the different enzymes: for wild-type MTB RNAP (1.56-100 nM 
rifamycins); for wild-type E. coli RNAP (3.12-200 nM rifamycins); for MTB RNAP 
(D435V) (78-5000 !M RMP and 39-5000 !M RBN/RFX), for MTB RNAP (H445Y) 
(19.5-2500 !M RMP and 78-5000 !M RBN/RFX), for MTB RNAP (S450L) (19.5-2500 
!M RMP and 4-2500 !M RBN/RFX), for E. coli RNAP (D516V and S531L) (78-10000 
!M RMP, 4-2500 !M RBN, and 39-5000 !M RFX), for E. coli RNAP (H526Y) (78-
20000 !M RMP and 39-10000 !M RBN/RFX). 
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An RNA standard curve was made using varying concentrations of tRNA, and the 
curve was used to convert the fluorescence values to the amount of RNA synthesized.  
The replicate data points were averaged and both the original data points and the average 
values were plotted as function of log concentration versus percent activity.  The average 
values were then fit by non-linear regression to a modified four parameter logistic 
equation (below) as described (http://www.curvefit.com/introduction89.htm) using 
Kaleidagraph (Synergy Software, Essex, VT): 
y = M3 + [(100 – M3)/(1 + 10
[(M0-M1)*M2]
)], 
where M3 is the lower limit of the assay, and 100 is the upper limit of the assay, M0 is 
the log of the rifamycin concentration, M1 is the log of the IC50, and M2 is the Hill slope.  
The data were normalized such that the upper limit of the raw data (manually set to either 
the no inhibitor value or to the average of the first two-three data points) was 100% 
activity.  M1, M2 and M3 were fit by the regression.  The logIC50s and their standard 
errors (of the fit) are reported in Table II-A4 in Appendix II-1. 
Determination of Minimal Inhibitory Concentration (MIC) of Rifamycins Against 
MTB and E. coli Strains 
The MIC values of RMP for Mycobacterium tuberculosis (H37Rv) were 
determined by Dr. Scott Franzblau (Institute for Tuberculosis Research, University of 
Illinois, Chicago) using two different assays (Table II-2).  The Microplate Alamar Blue 
Assay (MABA) was conducted as described earlier (19).  The second assay was Low 
Oxygen-Recovery Assay (LORA) where MTB was adapted to low oxygen conditions 
and kept under an anaerobic environment for 10 days to resemble the conditions for the 
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latent form of MTB (20).  The RMP concentration ranged from 0.04-4.9 !M for MABA 
and 0.15-19 !M for LORA. 
The MIC of each rifamycins was also determined for E. coli by the microdilution 
method described previously (21).  In brief, the wild-type E. coli strains (DH5! and TG2) 
and mutant E. coli strain (EC2880) were grown on LB plates.  A colony was grown in 
2xTY media at 37
o
C for 3-4 h until the culture reached the McFarland 0.5 standard 
(OD625nm 0.08-0.13) corresponding to approximately 1 x 10
8
 cfu/mL.  The susceptibilities 
of these strains to rifamycins (Rifamycin SV, RMP, RBN, RFX) were determined by 
adding 50 !L aliquots of culture to 50 !L serial two-fold dilutions of rifamycins.  
Concentrations of the rifamycins were 0.049-100 !M for DH5! and TG2 strains and 
0.006-12.5 !M for EC2880 strain.  Rifamycins were initially dissolved in DMSO and the 
two-fold dilutions were made in 2xTY media.  Drug-free controls consisted of 50 !L 
culture and 2xTY media; whereas, the positive control consisted of 50 !L culture and 20 
!g/mL carbenicillin.  The assays were performed on a SpectraMax M5 (Molecular 
Devices) microplate reader using sterile 96-well polystyrene plates.  The plates were 
covered and incubated at 37
o
C for 20 hours.  OD600nm absorbance was measured on the 
SpectraMax M5 microplate reader.  MIC90 values were defined as the concentration of 
rifamycin that results in 90% inhibition of growth. 
Results 
Construction of pMTBRP-5, 6, 7, and 8 vectors 
To investigate the activity and inhibition of MTB RNAP, we have constructed a 
co-overexpression vector to express the MTB RNAP, pMTBRP-5 (Figure II-4).  To allow 
for simple expression, assembly, and purification of MTB RNAP, the co-overexpression 
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vector pVS10 (expressing the E. coli RNAP) was used as the template.  The MTB rpo 
genes (encoding the MTB RNAP subunits) were initially modified to introduce unique 
restriction sites to the ends of each rpo gene open reading frame (ORF) and then 
subcloned into pVS10, replacing the E. coli rpo genes.  To facilitate cloning further, 
additional modifications were made to the rpoB and rpoC ORFs to introduce silent 
mutations to eliminate internal restriction sites and/or to correct PCR induced mutations 
(see Materials and Methods).  A hexahistidine tag was introduced to the 3’ end of the 
rpoB ORF, which allowed for the purification of the assembled MTB RNAP from other 
proteins.  The resultant pMTBRP-5 vector contained a single T7 RNAP promoter before 
the rpoA  ORF and a T7 terminator following the rpoZ ORF where each rpo gene was 
preceded by a ribosome-binding site.  To assess the affect of the three most prevalent 
amino acid substitutions found in clinical isolates (D435V, H445Y, S450L), point 
mutations were introduced to the MTB rpoB gene.  The altered genes were subcloned 
individually, replacing the wild-type MTB rpoB gene in the pMTBRP-5, resulting in the 
following mutant vectors: pMTBRP-6 (D435V), pMTBRP-7 (H445Y), and pMTBRP-8 
(S450L). 
Expression of MTB RNAPs 
Initially when the pMTBRP-5 plasmid was transformed into an expression cell 
line only a single distinct band was observed corresponding to the MTB ! subunit with a 
molecular weight of approximately 38 kDa (Figure II-6).  (The identity of MTB ! 
subunit was confirmed by Michigan Proteome Consortium via mass spectrometry, Table 
II-A3 in Appendix II-1.) Along with testing different expression cell lines (BL21(DE3), 
HMS174(DE3), and JM109(DE3)), the temperature and IPTG concentration was also 
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varied, but the MTB ! subunit was the only over-expressed subunit observed.  Since the 
wild-type and RifR MTB RNAPs are heterologous proteins, the plasmids were then 
expressed in E. coli BL21 (DE3) CodonPlus-RIPL strains.  During the expression trials, 
the lower temperature induction (19
o
C) was found to be optimal for greater protein 
expression levels. 
 
Figure II-6: SDS-PAGE of pMTBRP-5 expressed in HMS174(DE3) cells at 25
o
C. Lane 1, 
LMW; lane 2, uninduced sample; lane 3, 0.5 mM IPTG induced sample; lane 
4, 1 mM IPTG induced sample; lane 5, 2.5 mM IPTG induced sample; lane 6, 
5 mM IPTG induced sample, lane 7, sample via autoinduction  
 
The freeze/thaw method was preferred over sonication for cell lysis because that 
resulted in a greater yield of protein.  Although impurities were present, the specific 
activity was comparable (Figure II-7B); therefore, these contaminating proteins did not 
affect the activity of the enzyme.  The purities of these MTB enzyme preparations after 
chromatography were confirmed by SDS-PAGE analysis (Figure II-7C left), and the 
concentration of each enzyme was determined via Bradford assay.  This approach yielded 
~0.05 to 0.3 mg MTB RNAP which was sufficient for the assay which only required 0.1 
!g of enzyme for each reaction. 
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Figure II-7.  (A) SDS-PAGE of wild-type MTB and E. coli RNAPs prepared via 
sonication or freeze/thaw method: lane 1, LMW std; lane 2, MTB RNAP 
(sonication) [0.5 !M]; lane 3, MTB RNAP (freeze/thaw) [3.5 !M]; lane 4, 
E. coli RNAP (sonication) [4.1 !M]; lane 5, E. coli RNAP (freeze/thaw) 
[2.2 !M].  (B) Activity of wild-type MTB and E. coli RNAPs prepared 
using different purification methods (red: sonication method; blue: 
freeze/thaw method).  (C) SDS-PAGE of WT and Mutant RNAPs After 
Size Exclusion Chromatography. (On the left) lane 1, LMW std; lane 2, 
MTB RNAP (WT) [2.2 !M]; lane 3, MTB RNAP (D435V) [3.5 !M]; lane 
4, MTB RNAP (H445Y) [0.8 !M]; lane 5, MTB RNAP (S450L) [2.0 !M] 
(On the right) lane 1, LMW std; lane 2, E. coli RNAP (WT) [4.1 !M]; 
lane 3, E. coli RNAP (D516V) [1.6 !M]; lane 4, E. coli RNAP (H526Y) 
[4.4 !M]; lane 5, E. coli RNAP (S531L) [4.1 !M] (Note the intensity of ! 
and !’ band on SDS-PAGE is due to the larger size and the overlapping of 
these two subunits.) 
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Additionally, the corresponding RifR mutations were introduced to the E. coli 
rpoB gene in pVS10 and the E. coli RNAPs were expressed in E. coli BL21 (DE3) strains.  
For E. coli RNAPs, lower temperature induction was not necessary because optimal 
protein yield was obtained after 4 h induction at 37
o
C.  The cells were disrupted via 
sonication, and the enzyme was purified by metal ion affinity chromatography and gel 
filtration (Figure II-7C right).  The highest yield of E. coli RNAP was obtained via the 
sonication method; whereas, the lowest yield was obtained of MTB RNAP for this same 
method.  The expression levels of MTB core RNAP subunits in the E. coli host were 
lower even with freeze/thaw method compared to levels observed for the E. coli core 
RNAP subunits. 
Activity of the RNAPs and Determination of IC50 values 
The activities of the overexpressed enzymes were assessed using an in vitro 
rolling circle transcription assay (Figure II-5).  The core RNAP transcribed a small 45 
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template.  To achieve optimal RNAP activity, the pH of the reaction buffer was varied 
where the optimal pH was determined to be 8.0 (data not shown).  The MTB RNAPs 
from pMTBRP-5, 6, 7, and 8 were active; however, the magnitude of activity of the MTB 
RNAPs was approximately 10 fold less than the corresponding E. coli RNAPs (data not 
shown).  Although the activity was lower, the fluorescent dye (RiboGreen) was sensitive 




Figure II-8:  Example Dose-Response Plot for Rifampin–MTB RNAP (WT) IC50 
Determination.  All of the individual data points (x) and the average data 
points (•) were plotted.  The average data were fit by nonlinear regression 
to determine the IC50 values.  The concentrations of rifampin were 1.56-
100 nM. 
 
The inhibition of the different MTB RNAPs by rifamycins was investigated via 
dose-response studies with three of the rifamycins shown in Figure II-1: RMP, RBN, and 
RFX.  Each compound was tested in duplicate in dilutions ranging in concentrations 
specified in Materials and Methods.  The data were plotted (% activity vs log rifamycin 
concentration) and then fit by nonlinear regression (Figure II-8).  This was then repeated 
with the E. coli RNAPs.  The logIC50 values and their standard errors (of the fit) are 
reported in Table II-A4 in Appendix II-1.  The standard errors of the logIC50s roughly 
translate into a 20-25% error in the IC50 values.  The Hill slopes are all very close to one 
(mean Hill slope = 1.07).  Note that for seven of the inhibitor•enzyme combinations, the 
data plateaued above zero.  In these cases the regression was allowed to fit the lower limit.  
The reason for the lack of complete inhibition in these cases is unclear, but may have to 
do with the processive nature of the RNAP reaction.  That is, a small fraction of enzyme 
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may enter the elongation phase and, due to the insensitivity of the elongation phase to 
rifamycin inhibition, it may generate a long enough strand of RNA to give an above-zero 
lower limit. 
The apparent IC50 values are listed on Table II-1.  As shown in Table II-1, 
rifamycins inhibit the wild-type MTB and E. coli RNAPs in the 10
-9
 M (nM) range.  
Whereas, the IC50 values for the RifR mutants of MTB and E. coli were in the 10
-6
 M 
(!M) range.  The most frequently observed MTB RifR mutant in clinical isolates, S450L 
(9, 10), was inhibited at lower concentrations of rifamycins relative to the other MTB 
mutants.  Additionally, the MTB D435V and S450L mutants were the most sensitive to 




Table II-1.  In vitro RNAP IC50 Values (!M) for Selected Rifamycins 
RNAP Rifampin Rifabutin Rifaximin 
MTB (WT) 0.017 0.023 0.007 
MTB !(D435V) 465 171 506 
MTB !(H445Y) 610 1200 506 
MTB !(S450L) 109 20 113 
E. coli (WT) 0.012 0.042 0.058 
E. coli !(D516V) 233 13 296 
E. coli !(H526Y) 1130 1360 1520 
E. coli !(S531L) 171 4.9 85 
IC50 is the concentration of rifamycin resulting in 50% inhibition of transcription.  Errors 
of the logIC50 values are reported in Table II-A4 in Appendix II-1 as described in 
Materials and Methods.  The errors of the IC50 values are approximately ±25%. 









; E. coli (H526Y): > 122 !M
1




 Jin et al., J. Mol. Biol 202 , 45-58, 1988. (only observed S531F mutation in E. coli RifR 
strains rather than S531L) 
2
 Feklistov et al., PNAS 105 (39) , 14820-14825, 2008 
MICs of Rifamycins 
The MICs of rifamycins against the MTB H37RV strain were determined using 
two different assays (Microplate Alamar Blue Assay (MABA) and Low Oxygen-
Recovery Assay (LORA)) and are reported in Table II-2.  Higher MIC values for RMP 
were observed for LORA compared to MABA, where the former assay resembled the 
environment in which the latent MTB resides. 
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Table II-2. MIC Values (!M) for Selected Rifamycins Against MTB Clinical Isolates 
!










 0.3 " 0.018 
RNAP !(D435V)
2
 38.9 " 0.6 
RNAP !(H445Y)
2 > 78 # 37.8 
RNAP !(S450L)
2
 > 78 37.8 
1
 MIC90 is the concentration of rifamycin that results in 90% inhibition of growth. 
(Data from Prof. Scott G. Franzblau (UIC).) 
2
 MIC99 is the concentration of rifamycin that results in 99% inhibition of growth. 
(Williams et al., Antimicrobial Agents and Chemotherapy 42 (7) , 1853-1857, 1998.) 
 
The susceptibility of E. coli wild-type strains (DH5" and TG2) and mutant strain 
(EC2880) to rifamycins is summarized in Table II-3.  The MIC values of the different 
rifamycins were analyzed and correlated to what has been previously reported for MTB 
and E. coli (Tables II-2 and II-3).  The MICs of rifamycins against wild-type E. coli 
strains were approximately 100-500 fold greater than the MICs observed for EC2880.  
RMP and RBN had comparable MICs to one another when assayed in the wild-type and 
mutant E. coli strains; whereas, MICs of RFX were 2-4 fold higher compared to RMP 
and RBN against these strains. 
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Rifamycin S Rifampin Rifabutin Rifaximin 
WT 
TG2 > 92 6.25 6.25 25 
DH5! > 100 25 12.5 50 
DH5!
1 573 (Rif SV) 7.60 14.76 NR 
"tolC 
EC2880 0.78 0.05 0.10 0.20 
D21f/tolC
1 
1.12 (Rif SV) 0.12 0.06 NR 
MIC90 is the concentration of rifamycin that results in 90% inhibition of growth.  Results 
from this study are in bold.  NR: not reported. 
Comparative data for Rifampin in E. coli isolates
2
: E. coli (wt): <12.2 !M; E. coli 
(D516V): " 1220 !M; E. coli (H526Y): " 1220 !M; E. coli (S531F): " 1220 !M. 
1
 Feklistov et al., PNAS 105 (39) , 14820-14825, 2008. 
2
 Jin et al., J. Mol. Biol 202 , 45-58, 1988. 
 
Discussion 
The three aforementioned RifR mutants have been identified from clinical isolates 
and these strains have been studied.  However, no in vitro studies of purified MTB RifR 
RNAPs have been reported.  Herein, we describe a co-overexpression system for wild-
type and RifR MTB RNAPs in E. coli and its use to investigate the effect of the mutation 
on inhibition by rifamycins.  Artsimovitch and colleagues developed a co-overexpression 
plasmid for the E. coli core RNAP (pVS10, !2##’$) (22).  We adopted the same concept 
and used pVS10 as the template to construct our co-overexpression plasmid for the MTB 
core RNAP (pMTBRP-5; Figure II-4).  However, we encountered a few obstacles using 
the co-overexpression method.  Due to the enormous size of the plasmid (~14.4 kb), the 
number of unique sites present was limited.  After multiple trials, optimal PCR conditions 
were obtained to modify the MTB ORFs to incorporate unique sites.  Additionally, the 
large size of the plasmid made the integration of the MTB rpoZ gene (~0.3 kb) difficult.  
Therefore, a 165 bp linker was designed (containing the unique restriction enzyme sites 
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required to subclone in MTB rpoB and rpoC genes) and introduced to replace the E. coli 
rpoB and rpoC genes.  The reduced size of the plasmid facilitated the incorporation of 
MTB rpoZ.  After following the multi-step scheme illustrated in Figure II-3, the E. coli 
rpo genes were replaced by MTB rpo genes.  The resulting plasmid, pMTBRP-5, was 
verified via DNA sequencing.  The plasmid was then transformed into an expression cell 
line and successfully purified via nickel affinity chromatography and gel filtration.  A 
hexahistidine tag fused to the C-terminus of the ! subunit allowed for the separation of 
the target enzyme from contaminating E. coli RNAP.  The resulting MTB RNAP was 
pure enough for a microtiterplate-based in vitro transcription assay.  In previous studies, 
the wild-type MTB RNAP has been obtained from crude extracts of MTB H37RV cells 
and from in vitro reconstitution by renaturation of mixtures of denatured subunits (7, 11).  
Altogether, the co-overexpression method allowed for the purification of the assembled 
core RNAP in a convenient manner avoiding the denaturing and renaturing steps required 
to obtain RNAP from crude extracts or via reconstitution from individual subunits.  To 
determine how the RifR mutants influence inhibition by rifamycins, the three most 
prevalent mutations found in clinical isolates (D435V, H445Y, S450L) were introduced 
individually to the MTB rpoB ORF to yield the following vectors: pMTBRP-6 (D435V), 
-7 (H445Y), -8 (S450L) (Figure II-3 and II-4).  The mutations were also introduced to the 
corresponding residues in E. coli rpoB (D516V, H526Y, S531L) of pVS10.  The activity 
of the wild-type and RifR RNAPs of MTB and E. coli was assessed via in vitro rolling 
circle transcription assay (Figure II-5), which confirmed that these enzymes were active.  
A single-stranded nanocircle is used as the DNA template.  Previously, nanocircle 
templates have proven to be efficient substrates for various bacterial and phage RNAPs 
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(23, 24).  The RNAP produced long RNA repeats of the nanocircle in the absence of 
RNAP inhibitor, and RiboGreen was used to measure the amount of RNA transcribed. 
It has been reported that MTB is more sensitive to RMP than E. coli and other 
prokaryotes (25).  Previously, Zenkin et al. reconstituted a chimeric E. coli RNAP 
containing MTB Clusters I and II of ! subunit and concluded that the difference in 
sensitivity of MTB and E. coli to rifamycins was not due to these regions of MTB RNAP 
involved in forming the rifamycin binding pocket (4).  Here, the co-overexpression of 
MTB and E. coli RNAPs allowed for the direct comparison of the sensitivity of these 
enzymes to rifamycins.! !The activity of the wild-type and RifR RNAPs of MTB and E. 
coli was assessed in the presence of rifamycins via dose-response studies (Figure II-8).  
The representative rifamycins evaluated in this study included: RMP (a C3 rifamycin 
derivative) and RBN and RFX (C3/C4 modified rifamycins).  As can be seen from the 
IC50 values in Table II-1, rifamcyins bind tightly to the wild-type MTB and E. coli 
RNAPs and inhibit the enzymes in the 10
-8
 M (10 nM) range.  Whereas for the RifR 




 fold loss of affinity for all four 
rifamycins was observed where these different mutants were inhibited at much higher 
concentrations of rifamycins (10
-4
 M range).  The three residues mutated in these RifR 
mutants are among the twelve amino acid residues of the ! subunit that directly interact 
with RMP via hydrogen bonds (1).  The single amino acid substitutions disrupt critical 
interactions that contribute to rifamycin binding and potentially change the shape and 
conformation of the rifamycin-binding site.  This leads to the weaker binding of the 
rifamycins, explaining the decreased susceptibility of the enzyme to inhibition by 
rifamycins.  Even though the C3/C4 modified rifamycins (RBN and RFX) have enhanced 
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antibacterial activity (17), they still inhibit RifR mutant RNAPs only in the 10
-5
 M (1-100 
!M) range in vitro.  Therefore, cross-resistance still exists between these rifamycins for 
these RifR mutant RNAPs.  Our results are similar to what has previously been reported 
for wild-type E. coli RNAP and RMP with IC50 values in 10
-9
 M (nM) range; however, 
our data for resistant mutants indicates lower affinity for RMP, where the values are ~100 
fold higher for the mutants (Table II-1) (2, 5).  Feklistov et al. conducted in vitro 
transcription assays using a system containing an E. coli holoenzyme (with a sigma factor 
bound to the E. coli core RNAP) and a promoter-containing DNA fragment (2).  The 
sigma factor recruits the RNAP to bind to the specific DNA promoter.  In our studies, we 
used the isolated core RNAP and a nanocircle template (a nonnative template without a 
specific promoter).  Even with these differences, Feklistov and colleagues observed a 
high increase in the IC50 value (2000-fold) for RMP with the RifR E. coli RNAP 
(D516V) compared to WT E. coli RNAP (2). 
The MICs were greater than the IC50 values reported with these rifamycins for the 
different RifR mutants, which could be due to permeation, stability, or other factors.  The 
MICs of RMP for wild-type MTB H37RV strains were determined at the Institute for 
Tuberculosis Research (ITR/UIC) using Microplate Alamar Blue Assay (MABA) and 
Low Oxygen-Recovery Assay (LORA), where the latter assay is a model for the latent 
form of MTB.  Williams et al. reported the MICs for rifamycins against the wild-type 
MTB H37RV strain and the clinical isolates containing the specific prevalent mutations 
(Table II-2) (26).  The group also generated recombinant clones with only the specific 
mutations and obtained similar values as the ones reported with the clinical isolates, 
which confirmed that any additional mutations that might be present in the clinical 
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isolates did not affect the MICs of rifamycins.  Yang et al. conducted a similar study and 
obtained comparable MICs for these three prevalent mutant isolates and found that 8% of 
RifR strains are susceptible to RBN (17). 
Comparing MTB RifR mutants, the most frequently observed mutation in clinical 
isolates (S450L) had the lowest IC50 values for the different rifamycins compared to the 
other MTB mutants; whereas, H445Y mutant resulted in the highest IC50 values (Table 
II-1).  The D435V mutant had intermediate IC50 values, but the lowest MIC values 
among the different mutants.  As seen in Table II-2, D435V was the most sensitive to 
RBN from the MIC data; whereas the other two mutants (H445Y and S450L) were still 
resistant to these rifamycins.  RBN has better antibacterial activity against rifamycin 
sensitive strains and some rifamycin resistant strains but still exhibit substantial cross 
resistance in vitro (17, 26). 
Our data are consistent with the structural model for rifamycin binding to RNAP 
(1).  In this model, hydrogen bonds are predicted between the rifamycin core and each of 
the three amino acids probed in this study.  Mutations of aspartate 435 and histidine 445 
(if it is protonated) would be expected to generate the greatest loss of binding energy due 
to the loss of a hydrogen bond between a charged moiety and an uncharged moiety.  
While mutation of serine 450 would be expected to exhibit less loss of binding energy 
because no charged moieties are involved.  The effects of these mutations (e.g., the 
magnitude of binding energy lost) could be modified depending on the geometry of the 
hydrogen bonds lost.  However, our data does qualitatively correlate with the proposed 
loss of binding energy as the aspartate and histidine mutants are 6 to 10-fold less 
sensitive to the rifamycins (Table II-1), consistent with a greater loss of binding energy.  
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This correlation suggests that the structural model is fairly robust and can help to 
interpret biochemical data such as in our study.  (We should note that a new, complete 
model for the E. coli RNAP has been reported (27); however, this report does not discuss 
the rifamycin-binding pocket.  Sequence comparisons indicate that the rifamycin-binding 
pocket is highly conserved and therefore the thermophilic RNAP structure (1) should be a 
robust model for interpreting our biochemical data.) 
It is generally perceived that the differential sensitivities of eubacterial organisms 
(e.g., E. coli vs. MTB) towards rifamycins are not due to changes in the RNAP itself but 
are due to other factors.  Our results, along with those of Zenkin and colleagues with the 
chimeric (! subunit) E. coli/MTB RNAP, provide experimental evidence consistent with 
this perception.  Our results reported herein show that the E. coli and MTB RNAPs 
exhibit similar sensitivities to rifamycins.  Therefore, the differential sensitivity must be 
due to off-target activity or other factor(s).  It is well estalblished that efflux pumps (i.e., 
TolC) are responsible for the active export of antibiotics in Gram-negative bacteria (28).  
Therefore, to experimentally assess the relationship between the E. coli TolC protein and 
the export of rifamycins, the MIC values for wild-type E. coli strains (DH5" and TG2) 




) were determined 
for this same set of rifamycins.  As reported in Table II-3, the MIC values of these 
rifamycins are significantly lower for the mutant EC2880 strain compared to the wild-
type strains (DH5" and TG2), suggesting that TolC efflux pumps are involved in the 
export of rifamycins explaining the lower sensitivity of E. coli towards rifamycins.  The 
tolC knockout leads to retention of rifamycins therefore resulting in lower MICs.  The 
EC2880 MIC values were comparable to what has been reported previously for E. coli 
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D21f/tolC (Table II-3) (2) and to the MIC values observed for the wild-type MTB H37RV 
strain (Table II-2) (26).  The wild-type MTB H37RV strain was more sensitive to C3/C4 
modified rifamycins (RBN).  Whereas, the wild-type E. coli strains had higher MIC 
values for all rifamycins studied (Table II-3).  RMP and RBN had similar MICs in each 
instance (e.g., wild-type and mutant). 
Conclusions 
We have developed a system where we can perform in vitro inhibition assays 
using the M. tuberculosis RNAP and three Rif-resistant mutants.  This system was used 
to characterize the in vitro activity of a series of known rifamycins, with results 
consistent with MIC data and previous reports.  We have also provided experimental 
evidence that the differential sensitivity of E. coli vs MTB organisms to rifamycins 
results from E. coli efflux pump activity, consistent with previous general perceptions. 
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Table II-A1.  Plasmids and Bacterial Strains. 




     pET21 vector containing E. coli rpoA, rpoB, rpoC, and rpoZ genes encoding  
the wild-type E. coli RNAP subunits 
pVS10 (D516V)    pVS10 plasmid containing D516V mutation in E. coli ! subunit 
pVS10 (H526Y)    pVS10 plasmid containing H526Y mutation in E. coli ! subunit 
pVS10 (S531L)    pVS10 plasmid containing D516V mutation in E. coli ! subunit 
pSR52
2
     pET16b vector containing the MTB rpoA gene 
pJF09
2
      pET16b vector containing the MTB rpoB gene 
pJF10
2
      pET30a vector containing the MTB rpoC gene 
pMTBRP-5     Overexpression vector containing MTB rpoA, rpoB, rpoC, and rpoZ genes encoding  
the wild-type MTB RNAP subunits 
pMTBRP-6     pMTBRP-5 plasmid containing D435V mutation in MTB ! subunit 
pMTBRP-7     pMTBRP-5 plasmid containing H445Y mutation in MTB ! subunit 





 Avirulent strain 
Mycobacterium tuberculosis H37Rv
 
 Virulent strain 
XL2-Blue Ultracompetent Cells endA1 supE44 thi-1 hsdR17 recA1 gyrA96 relA1 lac [F’ proAB lacI
q






E. coli BL21(DE3) F
-






) "(DE3 [lacI lacUV5-T7 gene 1 ind1 sam7 nin5]) 










 gal "(DE3) endA Hte [argU proL Cam
r





 Belogurov et al., Molecular Cell 26, 117-129, 2007. 
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Table II-A2.  Oligonucleotides Used for Plasmid Construction. 
Oligonucleotides   Primer Sequence (5’-3’) 
(MTB PCR Primers) 
NdeI FWD rpoA  gaagctCATATGctgatctcacagcgccccaccctgtccg 
NcoI REV rpoA   gaagctCCATGgctaaagctgttcggtttcggcgtagtcc 
AvrII FWD rpoB  cagcgaCCTAGGaaccctatggcagattcccgccagagcaaaacagccg 
Histag REV rpoB (A)  gcgacagctttaATGGTGATGGTGATGGTGcgcaagatcctcgacacttgcgg 
BmtI REV rpoB (B)  cttGCATGCtagcgggtttagtaattttgcgacagctttaatggtgatgg 
AvrII/NheI FWD rpoC cagcgaCCTAGGgtactaGCTAGCgttaggggaaagggagttacatgctcgacgtcaacttcttcgatg 
AscI REV rpoC   gagctGGCGCGCCtagcggtagtcgctgtagccgtagtcgtcc 
AflI FWD rpoZ  gaagctCTTAAGgtgagtatctcgcagtccgacgcgtcgttggccg 
AflI FWD rpoZ (+RBS) agctCTTAAGaaggagattaagtatgagtatctcgcagtccgacgcgtcgt 







(MTB Quik-Change Primers) 
rpoB(1) FWD   gacgccggaggagcggctgctgcgtgccatcttcggtgagaaggcccgcg 
rpoB(1) REV   cgcgggccttctcaccgaagatggcacgcagcagccgctcctccggcgtc 
rpoB(2) FWD (-StuI)  gagatggagtgctgggccatgcaggcGtacggtgctgcctacaccctgcag 
rpoB(2) REV (-StuI)  ctgcagggtgtaggcagcaccgtaCgcctgcatggcccagcactccatctc 
rpoC(1) FWD (-NcoI)  cggcgagtacttcaccggtgGcatgggcgcggagtcgatcc 
rpoC(1) REV (-NcoI)  ggatcgactccgcgcccatgCcaccggtgaagtactcgccg 
rpoC(4) FWD (-NcoI)  gcgtgtgcgcgacctgctacgggcgttcGatggccaccggcaagctggtcg 
rpoC(4) REV (-NcoI)  cgaccagcttgccggtggccatCgaacgcccgtagcaggtcgcgcacacgc 
rpoB(C552R) FWD   gacggtcgcttcgtcgagccgCgcgtgctggtccgccgcaag 






Table II-A2.  (Continued) 
Oligonucleotides   Primer Sequence (5’-3’) 
(MTB Quik-Change Primers) 
rpoB(D435V) FWD  cagctgagccaattcatggTccagaacaacccgctgtcggg 
rpoB(D435V) REV  cccgacagcgggttgttctggAccatgaattggctcagctg 
rpoB(H445Y) FWD  ccgctgtcggggttgaccTacaagcgccgactgtcggcg 
rpoB(H445Y) REV   cgccgacagtcggcgcttgtAggtcaaccccgacagcgg 
rpoB(S450L) FWD  ccacaagcgccgactgtTggcgctggggcccggcg 
rpoB(S450L) REV  cgccgggccccagcgccAacagtcggcgcttgtgg 
(E. coli Quik-Change Primers) 
rpoB(D516V) FWD  cagctgtctcagtttatggTccagaacaacccgctgtctg 
rpoB(D516V) REV  cagacagcgggttgttctggAccataaactgagacagctg 
rpoB(H526Y) FWD  caacccgctgtctgagattacgTacaaacgtcgtatctccgcac 
rpoB(H526Y) REV   gtgcggagatacgacgtttgtAcgtaatctcagacagcgggttg 
rpoB(S531L) FWD  gattacgcacaaacgtcgtatctTGgcactcggcccaggcggtctgac 























1 31.1 99.0 1266.72 sp|P66701|RPOA_
MYCTU 
DNA-directed RNA polymerase subunit 
alpha OS=Mycobacterium tuberculosis 




1 31.1 99.0 1003.56 same as above same as above GYVPAVQNR 
1 31.1 99.0 1611.93 same as above same as above IDGVLHEFTTVPGVK 
1 31.1 99.0 1330.79 same as above same as above IPVDSIYSPVLK 
1 31.1 99.0 2088.15 same as above same as above MLISQRPTLSEDVLTDNR 
1 31.1 99.0 1954.02 same as above same as above SLVVSSEEDEPVTMYLR 
1 31.1 99.0 1485.91 same as above same as above TLLSSIPGAAVTSIR 
1 31.1 99.0 1118.68 same as above same as above TLVELFGLAR 
1 31.1 99.0 1248.70 same as above same as above EGVHTVGELVAR 
 
a
The rank of the specified protein relative to all other proteins in the list of detected proteins 
b
The number of matching amino acids (from peptides) divided by the total number of amino acids in the sequence (expressed as a 
percentage) 
c
The confidence for the peptide identification (expressed as a percentage) 
d
The monoisotopic m/z for the ion fragmented in this cycle and experiment, as determined by the instrument 
e
The accession number of the detected protein 
f
The name of the detected protein 
g

















RNAP Rifampin Rifabutin Rifaximin 
MTB (WT) -1.759 (±0.059, 1.41) -1.639 (±0.059, 1.19) -2.131 (±0.076, 0.84) 
MTB !(D435V) 2.667 (±0.095, 1.13) 2.233 (±0.109, 0.81) 2.704 (±0.101, 0.87) 
MTB !(H445Y) 2.785 (±0.496, 1.0)
 4
 3.08 (±0.113, 1.06)
 4
 2.929 (±0.087, 1.03) 
MTB !(S450L) 2.037 (±0.062, 1.35) 1.291 (±0.104, 1.15)
 4
 2.053 (±0.075, 1.85)
 4
 
E. coli (WT) -1.912 (±0.069, 1.10) -1.377 (±0.050, 1.34) -1.239 (±0.061,0.73) 
E. coli !(D516V)  2.368 (±0.055, 0.76) 1.111 (±0.039, 1.21)
 4
 2.471 (±0.089, 0.68) 
E. coli !(H526Y) 3.052 (±0.058, 1.04) 3.133 (±0.513, 0.70)
 4
 3.183 (±0.049, 0.88) 
E. coli !(S531L) 2.233 (±0.060, 0.82) 0.693 (±0.037, 1.81)
 4
 1.931 (±0.098, 0.82) 
 
1
 The log IC50 values are such that the IC50 values will be in !M.  Negative log IC50 values reflect IC50 values less than !M (e.g., in 
the nM range).  Values were fit to a four parameter logistic regression model with the top and bottom limits set at 100 and 0 
respectively. 
2
 The average error is ~10 %, which roughly translates to 20-25% in the IC50. 
3
 The average Hill slope is 1.07. 
4
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Synthesis and Structure-Activity Relationships of Novel Substituted 8-amino, 8-thio, 
and 1,8-pyrazole Congeners of Antituberculars Rifamycin S and Rifampin 
 
Rifamycins have been used to treat tuberculosis (TB) for the past 40 years.  
Rifampin (RMP), along with other rifamycins, is a potent inhibitor of DNA-dependent 
RNA polymerase (RNAP), an essential enzyme involved in gene expression (1-3).  Since 
first introduced in the 1960’s, RMP has been effectively used to treat both forms of TB 
(active and latent) and has reduced TB treatment from 18 to 9 months (4-6).  
Unfortunately, RMP has a number of shortfalls that include issues of resistance, 
hepatotoxicity, flu-like syndrome at higher doses, and drug-drug interactions (1, 7). 
Due to these limiting characteristics of RMP, it is necessary to develop new 
derivatives that are: 1) successful against resistant strains (MDR and XDR); 2) effective 
against both forms of TB; 3) able to reduce the length of TB therapy; 4) unable to induce 
cytochrome P450 (CYP) (1, 8).  Previously, structure-activity relationship studies have 
led to the synthesis of numerous rifamycin derivatives; however, only a few rifamycins 
have been approved in the United States with improved potency and antibacterial activity 
than RMP (1, 9). 
Although many rifamycin derivatives have been investigated, the recent 
availability of crystal structures (RMP bound to Thermus aquatic RNAP; rifabutin and 
rifapentine bound to Thermus thermophilus RNAP) provides information on how to 
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improve the design of rifamycins (10, 11).  There are twelve ! subunit residues that 
directly interact with RMP via hydrogen bonds and van der Waals interactions (10).  The 
most frequently mutated residue in clinical isolates that results in rifamycin-resistant 
(RifR) RNAP is Ser450, which forms a hydrogen bond with the rifamycin hydroxyl at C-
8.  Previously, acetylation of the C-8 hydroxyl resulted in an inactive rifamycin 
derivative; however, this position has not been fully investigated (1, 12). 
To further investigate the C-8 position, a series of novel rifamycin S (Rif S) and 
RMP analogues incorporating 8-amino, 8-thio, and 1,8-pyrazole substituents were 
synthesized (Figure III-1 and III-2).  The analogues were screened against the virulent 
strain, MTB H37RV, to quantify their antitubercular activity under both aerobic and 
anaerobic conditions.  The inhibition of wild-type (WT) Mycobacterium tuberculosis 
(MTB) RNAP and RifR MTB RNAP (S450L) by select C-8 analogues was assessed via 
an in vitro rolling circle transcription assay.  The MIC90 values were determined for these 
analogues against E. coli strains.  Additionally, representative analogues were evaluated 
in the human pregnane X receptor (hPXR) activation assay.  Our goal is to use this 
information to not only investigate the molecular mechanisms responsible for resistance 
but also to guide the development of new analogues with potential for enhanced activity 




Figure III-1:  Synthesis of C-8 analogues of Rifamycin S.  (The detailed synthesis of 




Figure III-2:  Synthesis of C-8 analogues of Rifampin and Rifampin S.  (The detailed 
synthesis of these analogues is described in Appendix III-1) 
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Materials and Methods 
Reagents 
All of the reagents were the same as the ones specified in Chapter II.  The hPXR 
activation and cell viability in 96-well format assay was from Puracyp, Inc.  Rifamycin S 
was from AAPharmaSyn LLC.  Rifampin was from Boche Scientific. 
Determination of Minimal Inhibitory Concentration (MIC) of C-8 Analogues Against 
MTB H37Rv Strains 
The analogues were screened against the MTB virulent strain (H37Rv) under both 
aerobic and anaerobic conditions (Table III-1).  Briefly, the 8-day Microplate Alamar 
Blue Assay (MABA) (13) was used to give an assessment of activity against replicating 
MTB.  The 11-day high-throughput, luminescence-based Low-Oxygen-Recovery Assay 
(LORA) (14) was used to measure activity against bacteria in a non-replicating state that 
models clinical persistence.  Minimum inhibitory concentrations (MIC90) are defined as 
the lowest compound concentration effecting >90% growth inhibition. 
Expression and Purification of WT MTB RNAP and RifR MTB RNAP (Ser450Leu) 
Both the WT and RifR MTB RNAP (Ser450Leu) were expressed and purified as 
described in Chapter II. 
Inhibition Studies via Rolling Circle Transcription Assay 
The IC50 values were determined for RMP (1), Rif S (2), and RMP S (6) and the 
following C-8 rifamycin analogues: 3, 4a, 4c, 4i, 4j, 7, 9b (Figures III-1 & III-2, Table 
III-1).  The dose response curves (Figure III-3) were constructed by using the in vitro 
rolling circle transcription assay as described in Chapter II.  The assays were performed 
on Synergy H1 Hybrid Multi-Mode Microplate Reader (BioTek) using 96-well half-area 
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black plates.  Each of the rifamycin analogues was tested in duplicate against the wild-
type MTB RNAP and the MTB RNAP (S450L) mutant.  The concentration ranges used 
for the wild-type MTB RNAP were as follows: for 1 (1.56-100 nM); for 2 (3.13-200 
nM); for 3 (6.25-400 nM); for 4a (1.56-100 !M); for 4c (0.08-5 !M); for 4i (0.1-800 
!M); for 4j (3.13-200 nM); for 6 (1.56-100 nM); for 7 (25-1600 nM); for 9b (12.5-800 
nM).  The concentration ranges used for the MTB RNAP (S450L) mutant were as 
follows: for 1 (0.02-2.5 mM); for 2 (0.01-2.5 mM); for 3 (0.08-5 mM); for 4a (0.08-5 
mM); for 4c (0.04-2.5 mM); for 4i (0.04-2.5 mM); for 4j (0.01-2.5 mM); for 6 (0.01-2.5 
mM); for 7 (0.01-2.5 mM); for 9b (0.01-2.5 mM).  The reaction was allowed to continue 
for 2 h for WT MTB RNAP or 1.5 h for RifR MTB RNAP (S450L) and aliquots were 
taken every 30 min and quenched in TE buffer.  RiboGreen (an ultrasensitive fluorescent 
nucleic acid stain) was used to determine the amount of RNA synthesized (!ex=480 nm; 
!em=520 nm).  The IC50 value for each rifamycins was calculated by non-linear 
regression as described in Chapter II, and the logIC50s and their standard errors (of the fit) 
are reported below in Table III-A1 in Appendix III-3. 
Minimal Inhibitory Concentration 90% (MIC90) Against E. coli Strains 
Initially all analogues were assayed against a WT E. coli strain (TG2), a mutant E. 
coli strain (EC2880), and an avirulent strain of Shigella (BS103), data not shown.  Then 
the MIC90 values of selected rifamycins (reported in Table III-2) were determined for E. 
coli strains DH5" and TG2 (wild-type lab strains) and EC2880 (tolC
-
 mutant, gift of Dr. 
M. Hubband, Pfizer Inc.).  The strains were grown on LB plates.  A colony was grown in 
2xTY media at 37
o
C for 3-4 h until the culture reached OD625nm 0.08-0.13.  The assays 
were performed using sterile 96-well polystyrene plates.  Each well contained 50 !L 
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aliquots of culture and 50 !L serial two-fold dilutions of rifamycin analogues (1, 2, 3, 4a, 
4c, 4i, 4j, 6, 7, 9b).  The compounds were initially dissolved in DMSO and then serial 
dilutions were made in 2xTY media.  The concentrations of the rifamycins were 0.049-
100 !M for DH5! and TG2 strains and 0.006-12.5 !M for EC2880 strain.  The plates 
were covered and incubated at 37
o
C for 16-20 h.  OD600nm absorbance was measured on 
Synergy H1 Hybrid Multi-Mode Microplate Reader (BioTek).  The error of the reported 
MIC90 values is within one 2-fold dilution. 
Human Pregnane X Receptor (hPXR) Activation Assay 
The manufacturer’s protocol for the hPXR activation and cell viability assay was 
followed for the 96 well plate assay.  Briefly, the DPX2 cells were thawed in a 37°C 
water bath and mixed thoroughly with culture media.  Then 100 !L of cell mixture was 
transferred into each well and the plate was incubated overnight in a 5% CO2 incubator at 
37°C.  The following day, the dosing media was thawed in a 37ºC water bath.  The 
dilutions of rifamycin derivatives (8a, 9a, and 10a) and RMP (1, positive control) were 
prepared as described in the manual.  The 96 well plate was removed from the incubator 
and liquid from each well was discarded before adding 100 !L of the dilutions to the 
specific wells.  Each dilution of the rifamycin derivative was tested in triplicate.  The 
plate was placed in the 5% CO2/37ºC incubator again for 24 h.  The next day, the 
CellTiter-Fluor Buffer and CellTiter-Fluor
TM
 were thawed at room temperature before 
adding 5 !L of CellTiter-Fluor
TM
 to 10 mL of CellTiter-Fluor Buffer.  The wells of the 
96 well plate were emptied again and 100 !L of CellTiter-Fluor
TM
 reagent was added to 
each well.  The plate was incubated for 1 h in the 5% CO2/37ºC incubator.  The Synergy 
H1 Hybrid Multi-Mode Microplate Reader (BioTek) was used to measure fluorescence 
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(!ex=390 nm; !em=505 nm).  To obtain luminescence readings, the contents of ONE-
Glo
TM
 Assay Buffer were added to the ONE-Glo
TM
 Assay Substrate and then 100 !L of 
mixture was transferred into each well.  The plate was read after 5 min where the 
luminometer was set for 5 sec pre-shake with 5 sec/well read time.  The Relative 
Luminescence Units (RLU) and Relative Fluorescence Units (RFU) were determined as 
outlined under the “Quantitation of PXR Receptor Activation” section of the manual.  
The normalized luciferase activity (RLU/RFU) was divided by the normalized DMSO 
control to represent the data as ‘fold activation’ relative to the control.  The replicate data 
points were averaged and both the original data points and the average values were 
plotted as a function of log concentration versus hPXR Activation.  The average values 
were then fit by non-linear regression to a modified four parameter logistic equation 
using Kaleidagraph (Synergy Software, Essex, VT): 
y = 1+ [(M3– 1)/(1 + 10
[(M1-M0)*M2]
)], 
where M3 is the EMAX, and 1 is the lower limit of the assay, M0 is the log of the 
rifamycin concentration, M1 is the log of the EC50, and M2 is the Hill slope.  The data 
were normalized such that the lower limit was set to 1.  M1, M2, and M3 were fit by the 
regression. 
Chemistry and Synthesis of C-8 Analogues 
All of the C-8 rifamycin analogues were synthesized by Ms. Yafei Jin and Prof. 
Hollis Showalter.  See Appendix III-1 for details. 
Structure-based Modeling Studies 
The structure-based modeling was performed by Dr. Paul Kirchhoff.  See 




MIC90 values of C-8 Analogues Against MTB H37Rv Strains 
The antitubercular activity of these C-8 Rif S and RMP analogues was assessed 
via MABA and LORA (Table III-1).  Under aerobic conditions within the Rif S series 
(MABA), analogues incorporating C-8 amine substituents (4a – 4j) displayed modest 
MIC90 values (1.4 – >5.6 !M) relative to the parent Rif S (2) (0.03 !M).  A similar 
pattern of activity was observed under anaerobic conditions (LORA).  The LORA MIC90 
values were ~3 to 16 fold greater than the MABA MIC90 values, and only analogue 4c  
displayed modest activity (5.4 !M).  The thioether derivative (4j) within the Rif S series 
was the only analogue with modest (and essentially equivalent) potency in both MABA 
and LORA (2.0 !M vs. 1.3 !M, respectively).  Amine adducts within the RMP S (8a – 
8f) and RMP (10a – 10f) series displayed similar potencies as the Rif S series in the 
MABA (MIC90 values 3.6 – >4.7 !M) and the LORA (MIC90 values 13.7 – >19.2 !M), 
with a 3.5 – > 5 fold differential between the two assays.  Core-modified pyrazole 
analogues within both Rif S (5) and RMP S (9a, 9b) series are weakly to moderately 
active with MIC90 values of 3.9 – >5.4 !M in the MABA and >18.6 !M in the LORA.  
Surprising and especially noteworthy are the potencies of the tosylated intermediates.  Rif 
S tosylate (3) exhibited MIC90 values of 0.20 !M in the MABA and 3.0 !M in the 
LORA, and the MIC90 values for RMP S tosylate (7) were 0.24 !M and 4.8 !M, 
respectively.  To determine if these values were due to a prodrug effect from simple 
sulfonate hydrolysis to parent compounds 2  and 6 , respectively, we subjected each 
tosylate to conditions utilized for MIC determinations (2xTY media, 37ºC, 24 h) and the 
RNAP assay (RNAP 5X reaction buffer, 37ºC, 2 h).  At the end of the assay period, the 
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medium was extracted with ethyl acetate and the organic extract was analyzed by thin-
layer chromatography for the presence of either parent phenol or corresponding tosylate.  
In all cases, only the presence of tosylate was observed. 
Table III-1.  Screening Results of Rifamycin Analogues vs. MTB 
No. Class C-8 Substituent MTB MIC90 (!M)
a 
   MABA LORA 
2 Rif S hydroxyl 0.03 0.4 
3 Rif S tosyloxy 0.20 3.0 
4a Rif S amino 1.41 22.2 
4b Rif S methylamino > 5.6 20.6 
4c Rif S dimethylamino 1.8 5.4 
4d Rif S ethylamino 5.5 21.4 
4e Rif S methoxyamino 3.8 12.5 
4f Rif S N-(2-propenyl)amino 5.2 18.3 
4g Rif S (2-hydroxyethyl)amino 5.32 > 21.7 
4h Rif S benzylamino 2.4 > 20.4 
4i Rif S cycloheptylamino 2.2 > 20.2 
4j Rif S methylthio 2.0 1.3 
5 Rif S pyrazole 2-hydroxyethyl > 5.4 > 21.7 
6 RMP S hydroxyl 0.07 0.5 
7 RMP S tosyloxy 0.24 4.8 
8a RMP S methylamino 3.64 > 19.2 
8b RMP S ethylamino > 4.7 > 18.9 
8c RMP S N-(2-propenyl)amino > 4.7 > 18.6 
8e RMP S (2-hydroxyethyl)amino > 4.6 > 18.5 
8f RMP S benzylamino > 4.4 > 17.6 
8g RMP S cycloheptylamino 3.9 13.7 
9a RMP S 
pyrazole 
methyl > 4.8 > 19.3 
9b RMP S 
pyrazole 
2-hydroxyethyl 3.9 > 18.6 
10a RMP methylamino 4.0 > 19.1 
10b RMP ethylamino > 4.7 > 18.8 
10c RMP N-(2-propenyl)amino > 4.6 > 18.6 
10d RMP (2-hydroxyethyl)amino > 4.6 > 18.5 
10e RMP benzylamino > 4.4 > 17.5 
10f RMP cycloheptylamino 3.8 > 17.4 
1 (RMP) hydroxyl 0.13 1.9 
Isoniazid N/A
b 
0.39 > 128 
PA824 N/A 0.66 2.3 
Moxifloxacin N/A 0.64 4.3 
a
 The MIC90 is defined as the minimum concentration of the compound required to 
inhibit 90% of bacterial growth; 
b
 N/A = not applicable 
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Inhibition Studies via Rolling Circle Transcription Assay 
The inhibition of WT MTB RNAP and RifR MTB RNAP (S450L) by these novel 
C-8 rifamycin derivatives was assessed via dose-response studies.  Each analogue was 
tested in duplicate in dilutions ranging in concentrations specified in the Materials and 
Methods section.  The data were plotted (log rifamycin concentration vs. % activity) and 
then fit by nonlinear regression (Figure III-3), and the apparent IC50 values are listed in 
Table III-2.  For the WT MTB RNAP, RMP (1), Rif S (2), thioether 4j and RMP S (6) 
show the highest potency with IC50 values in the low nM range.  The IC50 values for 
RMP (1) and Rif S (2) were determined to be less than 10 nM.  However, the amount of 
enzyme used in each reaction was 10 nM (the lowest concentration that could be used 
confidently).  Under these conditions, it is possible that a 10 nM IC50 value may simply 
reflect the “titration” of the enzyme by an inhibitor with a much lower true IC50 value.   
 
 
Figure III-3:  Example of a Dose-Response Curve.  All of the individual data point (x) 
and the average data points (!) were plotted.  The average data were fit by 




Therefore, any IC50 value determined to be less than 10 nM was reported simply as “< 
0.01” !M. 
As mentioned above, the tosylated intermediates 3 & 7 have comparable MTB 
MIC90 values for both MABA and LORA; however, the IC50 value with WT MTB RNAP 
for 7 was ~7-fold greater than that for 3.  The IC50 value of 3 (21 nM) was >2-fold greater 
than the IC50 value of Rif S (<10 nM) with the WT MTB RNAP.  Owing to the fact that 
the MABA MIC90 value for 3 was 5-fold greater than that for Rif S, a parallel decrease in 
potency was observed for both the MIC90 and IC50 values for 3 in comparison with Rif S.  
However for compound 7, this trend was not as quantitative.  The IC50 value with WT 
MTB RNAP for 7 (142 nM) was more than 10-fold greater than the IC50 value for RMP S 
(13 nM); whereas, the MABA MIC90 value of 7 was only ~3-fold greater than that for 
RMP S.  Surprisingly for the MTB RNAP (S450L) mutant, a lower IC50 value was 
observed for 7 (~9 fold lower) than the IC50 value of 3.  Within the Rif S series, the 
amino analogues (4a, 4c, and 4i) that had exhibited modest MIC90 values under aerobic 
conditions have much more variable IC50 values (~70-2000 fold greater than Rif S).  
These analogues have comparable IC50 values against the MTB RNAP (S450L) mutant, 
which are still 3-8 fold greater than Rif S.  The thioether derivative (4j) also exhibited 
modest MABA MIC90 values, but the IC50 values are comparable to the IC50 values 
observed for the controls (1, 2, 6) with both WT MTB RNAP and the mutant.  Although 
the pyrazole analogue (9b) was weakly active microbiologically with higher MTB MIC90 
values, the IC50 value is comparable to that observed for 7 for WT MTB RNAP (both 
about 10-20 fold higher than those for RMP, RMP S and Rif S).  In general, all rifamycin 
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analogues have MTB MIC90 values that are higher than their IC50 values for the MTB 
RNAP with the exception of 4i. 










E. coli MIC90 (!M)
b 
   TG2 DH5!  EC2880 
1 < 0.01  52.1 12.5 12.5 0.1 
2 < 0.01  36.0 100 > 100 0.78 
3 0.021 982 > 100 > 100 3.125 
4a 4.4 186 > 100 > 100 12.5 
4c 0.503 270 > 100 > 100 12.5 
4i 15.4 127 > 100 > 100 > 12.5 
4j 0.015 37.5 > 100 > 100 > 12.5 
6 0.013 46.5 12.5 25 0.1 
7 0.142 111 > 100 > 100 12.5 
9b 0.139 29.9 > 100 > 100 > 12.5 
a
 The IC50 is defined as the concentration that results in 50% inhibition of transcription.  
The log IC50 values and their standard errors (of the fit) are reported in Table III-A1 in 
Appendix III-3. 
b
 The MIC90 is defined as the minimum concentration of the compound required to 
inhibit 90% of bacterial growth 
 
MIC90 values of C-8 Analogues Against E. coli Strains 
The MIC90 values of a subset of C-8 analogues were determined using WT E. coli 





) (Table III-2).  The E. coli MIC90 value for compound 3 was only 4-fold greater 
than that observed for Rif S, which parallels compound 3’s IC50 value that is 3-4 higher 
than that for Rif S.  Interestingly, the analogues with MTB MABA MIC90 values of 1.8 
!M or lower had E. coli MIC90 values of 12.5 !M or less for the mutant strain but no 
correlation could be made for WT E. coli strains. 
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Human Pregnane X Receptor (hPXR) Activation Assay 
To assess the ability of specific rifamycins to activate the human pregnane X 
receptor (hPXR), the hPXR activation assay system from Puracyp, Inc. was used.  The 
results are shown in Figure III-4 and Table III-3 for analogues 8a, 9a, and 10a. 
 
Figure III-4:  The hPXR Activation Assay.  Concentrations of positive control (RMP, 
red) and selected rifamycin analogues (8a, 9a, and 10a, blue, green and 
black respectively) versus fold PXR activation. 
 
RMP exhibited a high maximal degree of activation (9.5 fold) and an EC50 of 5.6 
!M (Figure III-4 left).  The methylamino derivatives of RMP S (8a) and RMP (10a) were 
fit to a dose-response curve that revealed a 6.9 and 8.9-fold maximal activation of hPXR 
and an EC50 of 2.1 and 4.1 !M, respectively (Figure III-4 right; Table III-3).  These 
analogues did exhibit loss of cell viability at 25 !M (such that the 100 !M data point was 
not used in the dose-response curve fit).  The RMP S pyrazole derivative (9a) showed ~2 
fold hPXR activation at 6.25 !M and dramatic loss of cell viability above 6.25 !M (such 
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that no hPXR activation was seen).  The loss of cell viability could be observed from the 
lower RFU values obtained from the assay (Table III-4). 








1  5.6 9.5 
8a 2.1 6.9 
9a - - 
10a 4.1 8.9 
a EC50 is defined as the half maximal effective concentration. 
b ECMAX is the maximal effective concentration of the compound. 
 
Table III-4.  Mean Relative Fluorescence Units (RFU)a for RMP (1) and C-8 Analogues 














20 39860 100 10339 5139 4510 
10 43506 25 29469 6083 20902 
5 46648 6.25 46186 33527 38109 
1 45714 1.56 44676 39444 39274 
0.5 42223 0.39 49578 48660 41326 
0.1 46084 0.098 48519 47122 44851 
a RFU is a measure of cell viability in the assay.  For controls, 1% DMSO = 46021; 
Dosing media = 42907. 
 
Structure-based Modeling Studies 
Modeled poses were generated by Dr. Kirchhoff for each of the analogues listed 
in Table III-2.  Modeling was based on the 2.5 Å resolution structure of rifabutin 
complexed with the Thermus thermophilus RNAP holoenzyme (PDB ID: 2a68) (11) and 
described more in detail in Appendix III-2.  Modeled poses for Rif S (2) and amino 
analogue (4i) are shown in Figure III-5.  RNAP is shown as a molecular surface within 5 
Å of the inhibitors and shaded to indicate areas of lipophilicity (green), hydrogen bonding 
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(magenta) and mild polar (blue).  This figure illustrates how the loss of the C-8 hydroxyl 




Figure III-5:  RNAP is shown as a molecular surface within 5 Å of the inhibitors (carbon 
atoms shown in gray) and shaded to indicate areas of lipophilicity (green), 
hydrogen bonding (magenta) and mild polar (blue).  (A) Rif S (2).  (B) 
Cycloheptylamino analogue (4i). 
 
Discussion 
Previously, the acetylation of the C-8 hydroxyl has led to an inactive rifamycin 
derivative (12); however, this position has not been fully investigated.  No C-8 rifamycin 
analogues derived from amine or sulfur nucleophiles have been reported other than the 
synthesis of Rif S ammonia adduct 4a reported in the patent literature (15).  Additionally, 
there is no account of any ring fusions onto the 1,8-carbon positions.  Hence the 
syntheses of pyrazoles 5 , 9a, and 9b represent the first reports of such a core 
modification.  Herein, we explore the SAR of the C-8 position by incorporating 8-amino, 
8-thio, and 1,8-pyrazole substituents. 
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The MIC90 values of these C-8 analogues against WT MTB H37RV strains were 
determined at the Institute for Tuberculosis Research (ITR/UIC) using Microplate 
Alamar Blue Assay (MABA) and Low Oxygen-Recovery Assay (LORA), where the 
latter assay is a model for the latent form of MTB.  The MIC90 values (for both MABA 
and LORA) were higher for the amine and pyrazole derivatives compared to their parent 
scaffolds.  The unsubstituted NH2 analogue (compare 4a vs. 4b – 4i) was observed to be 
the best within this small series, although there is no significant variation from the 
smallest to the largest substituent.  The addition of small polar functionality (e.g., 4e , 4g) 
or bulky lipophilic moieties (e.g., 4h, 4i) seemed to impart minimal effect on potency.  
However, the tosylated (3  and 7) and thioether (4j) derivatives displayed surprisingly 
low MIC90 values (but still higher than parent scaffolds), which are corroborated by 
excellent potency toward the target RNAP enzyme.  In general, enhanced antitubercular 
activity was not observed with these C-8 analogues. 
From the crystal structure of RMP bound to Thermus aquaticus RNAP, it was 
observed that there are twelve ! residues in close proximity that directly interact with 
RMP (10).  Mutations of most of these residues lead to RifR RNAPs.  The most 
frequently mutated residue found in MTB clinical isolates is the Ser450 residue, which 
directly interacts with the C-8 hydroxyl via hydrogen bond (10, 16).  Therefore, these C-8 
rifamycin analogues were screened against both WT MTB RNAP and RifR RNAP 
(Ser450Leu) via an in vitro rolling circle transcription assay.  As shown in Table III-2, 
the control rifamycins (1, 2, and 6) inhibited WT MTB RNAP in the 10
-9
 M (nM) range; 
whereas, the IC50 values for the RifR MTB RNAP (Ser450Leu) were in the 10
-6
 M ("M) 
range (consistent with what has been observed previously (17)).  Unfortunately, no 
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analogues tested here resulted in a more potent rifamycin derivative against the RifR 
MTB RNAP (S450L) mutant. 
All rifamycin analogues have MTB MIC90 values that are higher than their IC50 
values for the MTB RNAP with the exception of 4i.  This differential between IC50 and 
MTB MIC90 may be due in some cases (where the differential is large) to the molecules 
not equilibrating efficiently across the cell envelop or to the more trivial explanation (in 
cases where the differential is small) that the IC50 is a 50% inhibition point whereas the 
MIC90 is a 90% inhibition point.  In the case of 4i, the analogue has an MTB MIC90 that 
is approximately 8-fold smaller than the IC50.  One possibility is that the cycloheptyl 
moiety of 4i may help to concentrate the analogue within the MTB cell. 
In addition to determining the MTB MIC90 values, the MIC90 values for WT E. 
coli strains (DH5! and TG2) and mutant E. coli strain (EC2880-tolC deficient) were 
determined for select C-8 analogues (Table III-2).  The MIC90 values were lower for the 
mutant strain compared to the WT strains, but these values were still higher than the 
values observed for the control compounds (1, 2, and 6).  This observation is consistent 
with previous postulates that the lower sensitivity of Gram-negative bacteria to 
rifamycins is due to the removal of rifamycins from the interior of the cell via TolC-
dependent efflux pumps. 
One of the clinical liabilities of RMP (1) includes its induction of cytochrome 
P450 3A4 (CYP3A4), which is mediated by the human pregnane X receptor (PXR) (1, 
8).  Activation of hPXR was seen for the representative analogues (8a, 9a, and 10a) to a 
certain concentration before cytotoxicity was observed at higher concentrations.  From 
this data, it seems unlikely that any of these analogues are Cyp inhibitors. 
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To gain better understanding of the SAR, structure-based modeling studies were 
conducted.  Modeling was based on the 2.5 Å resolution structure of rifabutin complexed 
with the Thermus thermophilus RNAP holoenzyme (PDB ID: 2a68) (11). Since the 
rifamycin binding site is highly conserved among bacteria, this structure provides a good 
foundation for understanding how proposed rifamycin analogues may interact with the 
MTB RNA polymerase. 
Conclusions 
In summary, a novel series of rifamycin S and rifampin analogues incorporating 
substituted 8-amino, 8-thio, and 1,8-pyrazole substituents were synthesized.  The 
compounds were screened for inhibition of WT MTB RNAP and RifR MTB RNAP 
(S450L) as well as antitubercular effects under both aerobic and anaerobic conditions.  
The data show that our modification of the C-8 position of the parent scaffolds resulted in 
diminished activity.  The enzymatic and microbiological data are consistent with 
modeling and computational studies which support the C-8 hydroxyl acts as a hydrogen 
bond acceptor/donor with S450 and that Rif resistance in the S450L mutant is due to loss 
of this hydrogen bond. 
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Our strategy was to first activate the C-8 peri-phenolic functionality of readily 
available Rif S (2) as a sulfonate ester, and then displace this with selected nitrogen 
nucleophiles through an addition-elimination mechanism (Figure III-1).  Given that the 
rifamycin framework is embellished with so much functionality, including free hydroxyl 
groups at C-21 and C-23 (Figure III-5), we first needed to work out conditions for 
selective functionalization of the C-8 phenolic moiety.  Thus, the reaction of Rif S (2) 
with sulfonyl chlorides representing a range of reactivity (p-toluenesulfonyl, p-
chlorosulfonyl, methanesulfonyl) and triflic anhydride was evaluated under different 
temperature and solvent conditions.  Of these, only p-toluenesulfonyl and p-
chlorosulfonyl sulfonate esters formed cleanly under optimum conditions (Hunig’s base, 
acetonitrile, room temperature) with tosylate 3  formed in 84% yield.  Subsequent 
reactions of these with amines and hydrazines indicated that the p-chlorosulfonate ester 
was susceptible to cleavage to Rif S, whereas the p-toluenesulfonate ester provided the 
desired C-O bond displacement.  With this finding, condensation of 3  was then carried 
out with a range of amines to provide adducts 4a-4i  in 11-51% yields, and with (2-
hydroxyethyl)hydrazine to give annulated pyrazole product 5  in very low (5%) yield.  
We also tested tosylate displacement with a single thiol (methanethiol sodium salt), 
which provided analogue 4j in poor yield.  Having developed the chemistry for Rif S, we 
then applied it toward making related analogues of RMP (1 , Figure III-2).  Thus, 
oxidation of RMP with potassium ferricyanide provided rifampin S (RMP S, 6) in 65% 
yield.  Tosylation of the 8-hydroxyl function was conducted as described above to give 
 
 84 
key intermediate 7  in nearly quantitative yield.  Amination of 7  was then carried out with 
several of the same amines utilized above to give adducts 8a – 8f  in 35-60% yields and 
pyrazoles 9a (33% yield) and 9b (40% yield).  Disappointingly, an attempt to make the 
simple unsubstituted pyrazole congener derived from hydrazine was unsuccessful.  
Similarly, we were unable to secure a highly sought for analogue derived from ammonia 
displacement of tosylate 7 .  Utilizing the same conditions that gave 4a led to a product in 
46% yield that both mass spec and NMR data showed incorporation of the NH2 function, 
but without loss of the C-8 tosyloxy moiety.  The NMR spectrum was too complex to 
make a definitive structural assignment.  Candidate possibilities include Michael addition 
of ammonia to the dienone function or to the imino double bond of the side chain 
hydrazone.  The quinone function of each RMP S amine adduct was then reduced with 
ascorbic acid to the hydroquinone form, providing corresponding RMP C-8 amine 
congeners 10a – 10f  in 51 – 93% yield.  The full range of synthesized compounds is 
shown in Table III-1. 
No effort was made to optimize the reaction conditions that provided amine, thiol, 
or pyrazole adducts from tosylates 3  or 7 , and product yields in general represent a single 
run for each target compound.  All compounds were rigorously purified by preparative 
silica gel chromatography, and their structural assignments were supported by diagnostic 
peaks in the 
1
H NMR spectra and by mass spectrometry. 
General Chemical Methods.  
1
H NMR spectra were recorded on Bruker 500 MHz and Varian 300 MHz 
spectrometers.  Chemical shifts are reported in ! (parts per million: ppm), by reference to 
the hydrogen residues of deuterated solvent as internal standard (CDCl3: ! = 7.28 ppm; 
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CD3OD: ! = 3.31).  Signals are described as s, d, t, dd, m, and dt for singlet, doublet, 
triplet, doublet of doublets, multiplet, and doublet of triplets, respectively.  All coupling 
constants (J) are given in Hertz (Hz).  Mass spectra were recorded on a Micromass LCT 
time-of-flight instrument utilizing the electrospray ionization mode.  Reactions were 
monitored by thin-layer chromatography (TLC) using pre-coated silica gel 60 F254 
plates.  Chromatography was performed with silica gel GHLF plates (250 microns).  
Rifamycin S was obtained from AAPharmaSyn, Ann Arbor, MI, and rifampin from 
Bosche Scientific.  Reagents and monomers were purchased from common vendors and 
were used without purification.  Glassware was oven-dried before use for reactions run 
under anhydrous conditions.  
8-( p-Toluenesulfonyloxy)rifamycin S (3) 
Into an ice-cold solution of rifamycin S (2, 696 mg, 1.0 mmol) in acetonitrile (5 
mL) was added diisopropylethylamine (155 mg, 1.2 mmol).  Then, p-toluenesulfonyl 
chloride (210 mg, 1.1 mmol) was added to the reaction mixture portion-wise.  This 
resultant mixture was slowly warmed to room temperature.  After stirring for 2 h, it was 
diluted with dichloromethane (40 mL).  This solution was washed with 1N aqueous 
NH4Cl (3 x 30 mL), followed by saturated brine (30 mL), dried over anhydrous sodium 
sulfate and evaporated in vacuo to dryness to yield 3 as a light brown solid (717 mg, 





H NMR (500 MHz, CDCl3): ! 8.28 (s, 1H), 7.90 (d, J = 8.2 Hz, 2H), 7.84 (s, 
1H), 7.41 (d, J = 8.1 Hz, 2H), 6.39 (dd, J = 10.5, 15.7 Hz, 1H), 6.24 (d, J = 10.5 Hz, 1H), 
6.15 (dd, J = 6.8, 15.3 Hz, 1H), 5.98 (d, J = 12.3 Hz, 1H),  5.10 (dd, J = 4.8, 12.3 Hz, 
1H), 4.95 (d, J = 10.3 Hz, 1H), 3.88 (d, J = 4.3 Hz, 1H), 3.69 (d, J = 9.7 Hz, 1H), 3.37 (br 
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s, 2H), 3.07 (s, 3H), 3.00 (d, J = 7.7 Hz, 1H), 2.50 (s, 3H), 2.34 (m, 1H), 2.18-2.02 
(complex pattern), 1.78 (s, 3H), 1.67 (m, 2H), 1.26 (m, 1H), 1.08 (d, J = 6.7 Hz, 3H), 
0.87 (d, J = 6.9 Hz, 3H), 0.68 (d, J = 6.8 Hz, 3H), 0.06 (d, J = 7.0 Hz, 3H). 
8-(Methylamino)rifamycin S (4b) 
Methylamine (105 !L of 2 M solution in THF, 0.21 mmol) was added drop-wise 
to an ice-cold solution of 8-(tosyloxy)rifamycin S (3; 170 mg, 0.2 mmol) in acetonitrile 
(5 mL).  The resulting mixture was stirred at room temperature for 18 h before being 
diluted with dichloromethane (25 mL).  This solution was washed with 1 N aqueous 
NH4Cl (2 x 15 mL) followed by saturated brine (15 mL), dried over anhydrous sodium 
sulfate and concentrated to yield a crude black solid (150 mg).  Purification by 
preparative TLC (1:3 hexanes / ethyl acetate, v/v) afforded 4b as a dark purple solid (57 




H NMR (300 MHz, CDCl3): ! 10.02 (m, 1H), 
8.55 (s, 1H), 7.74 (s, 1H), 6.41 (dd, J = 10.6, 15.6 Hz, 1H), 6.24 (m, 2H), 6.02 (dd, J = 
6.6, 15.4 Hz, 1H), 5.06 (dd, J = 7.6, 8.3 Hz, 1H), 4.72 (d, J = 10.5 Hz, 1H), 3.88 (d, J = 
4.3 Hz, 1H), 3.65 (d, J = 9.7 Hz, 1H), 3.55 (s, 1H), 3.37 (d, J = 5.4 Hz, 3H), 3.13 (s, 3H), 
3.00 (m, 1H), 2.53 (s, 3H), 2.39 (m, 1H), 2.13 (m, 1H), 2.07 (s, 3H), 2.05-1.90 (complex 
pattern), 1.79 (m, 3H), 1.71 (s, 3H), 1.64-1.49 (complex pattern), 1.03 (d, J = 7.0 Hz, 
3H), 0.86 (d, J = 6.9 Hz, 3H), 0.69 (d, J = 6.9 Hz, 3H), 0.28 (d, J = 7.1 Hz, 3H). 
Prepared in similar fashion were the following rifamycin S analogues: 
8-Aminorifamycin S (4a) 
From 7N ammonia in methanol, crude product was obtained as a deep red solid.  
Purification by preparative TLC (1:1 hexanes / ethyl acetate) gave 4a as an orange solid 




H NMR (300 MHz, CDCl3): ! 8.62 (s, 
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1H), 7.79 (s, 1H), 6.40 (dd, J = 10.2, 15.6 Hz, 1H), 6.25 (d, J = 10.4 Hz, 1H), 6.20 (d, J = 
12.4 Hz, 1H), 6.01 (dd, J = 6.7, 15.5 Hz, 1H), 5.07 (dd, J = 7.1, 12.4 Hz, 1H), 4.71 (d, J = 
10.8 Hz, 1H), 3.81 (d, J = 3.7 Hz, 1H), 3.65 (m, 2H), 3.39 (dd, J = 2.5, 7.6 Hz, 1H), 3.11 
(s, 3H), 2.99 (m, 3H), 2.40-1.59 (complex pattern), 1.03 (d, J = 6.9 Hz, 3H), 0.87 (d, J = 
6.9 Hz, 3H), 0.69 (d, J = 6.8 Hz, 3H), 0.24 (d, J = 7.0 Hz, 3H). 
8-(Dimethylamino)rifamycin S (4c) 
From dimethylamine (5.6M in ethanol), crude material was obtained as a purple 
solid.  Purification by preparative TLC (1:1 hexanes / ethyl acetate) gave 4c as a purple-




H NMR (300 MHz, CD3Cl): ! 
8.59 (s, 1H), 7.76 (s, 1H), 6.53 (dd, J = 11.9, 15.8 Hz, 1H), 6.26 (d, J = 12.1 Hz, 1H), 
6.23 (dd, J = 6.9, 15.8 Hz, 1H), 6.10 (d, J = 12.3 Hz, 1H), 5.10 (dd, J = 5.1, 12.3 Hz, 1H), 
5.00 (d, J = 10.3 Hz, 1H), 4.03 (d, J = 4.1 Hz, 1H), 3.74 (d, J = 9.6 Hz, 1H), 3.60 (s, 1H), 
3.51 (m, 1H), 3.11 (s, 3H), 3.05 (s, 6H), 3.01 (m, 1H), 2.37 (s + m, 3H + 1H), 2.09 (s, 
3H), 2.08 (s, 3H), 1.83-1.69 (complex pattern), 1.03 (d, J = 7.0 Hz, 3H), 0.91 (d, J = 6.9 
Hz, 3H), 0.71 (d, J = 6.8 Hz, 3H), 0.20 (d, J = 7.0 Hz, 3H). 
8-(Ethylamino)rifamycin S (4d) 
From ethylamine, crude product was obtained as a purple solid.  Three 
purifications by preparative TLC (1:1 hexanes / ethyl acetate) gave 4d as a deep red solid 




H NMR (300 MHz, CD3OD): ! 7.60 (s, 
1H), 6.32 (m, 1H), 6.31 (s, 1H), 6.27 (d, J = 11.9 Hz, 1H), 6.02 (m, 1H), 5.22 (dd, J = 
6.5, 11.2 Hz, 1H), 5.08 (d, J = 10.8 Hz, 1H), 4.95 (d, J = 6.5 Hz, 1H), 4.83 (s, 1H), 3.82 
(m, 4H), 3.33 (m, 2H), 3.14 (m, 1H), 3.10 (s, 3H), 2.51 (s, 3H), 2.35 (m, 1H), 2.12 (m, 
1H), 2.05 (s, 3H), 1.99 (s, 3H), 1.85-1.56 (complex pattern), 1.36 (tr, d = 7.1 Hz, 3H), 
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1.02 (d, J = 7.1 Hz, 3H), 0.90 (d, J = 6.9 Hz, 3H), 0.72 (d, J = 6.9 Hz, 3H), 0.16 (d, J = 
7.1 Hz, 3H). 
8-(Methoxyamino)rifamycin S (4e) 
From methoxylamine hydrochloride and N,N-diisopropylethylamine, crude 
product was obtained as a deep red solid.  Purification by preparative TLC (1:1 hexanes / 





NMR (500 MHz, CDCl3): ! 11.86 (s, 1H), 8.50 (s, 1H), 7.78 (s, 1H), 6.42 (dd, J = 10.0, 
15.6 Hz, 1H), 6.28 (d, J = 10.0 Hz, 1H), 6.23 (d, J = 12.5 Hz, 1H), 6.01 (dd, J = 6.6, 15.6 
Hz, 1H), 5.10 (dd, J = 7.5, 12.3 Hz, 1H), 4.74 (d, J = 10.4 Hz, 1H), 4.25 (m, 1H), 3.86 (s, 
3H), 3.72 (m, 3H), 3.63 (m, 2H), 3.50 (m, 1H), 3.39 (m, 1H), 3.14 (s, 3H), 3.01 (m, 1H), 
2.50 (s, 3H), 2.37 (m, 1H), 2.10-1.27 (complex pattern), 1.04 (d, J = 6.9 Hz, 3H), 0.87 (d, 
J = 6.9 Hz, 3H), 0.70 (d, J = 6.8 Hz, 3H), 0.25 (d, J = 7.0 Hz, 3H). 
8-(Allylamino)rifamycin S (4f) 
From allylamine, 120 mg of crude deep brown solid was obtained.  Purification 
by preparative TLC (1:1 hexanes / ethyl acetate) gave 4f as a deep red solid (19 mg, 13 




H NMR (300 MHz, CDCl3): ! 9.99 (m, 1H), 8.53 (s, 
1H), 7.76 (s, 1H), 6.44 (dd, J = 10.3, 15.6 Hz, 1H), 6.26 (d, J = 9.1 Hz, 1H), 6.18 (d, J = 
12.4 Hz, 1H), 6.02 (m, 2H), 5.35 (dd, J = 10.4, 16.8 Hz, 2H), 5.05 (dd, J = 7.1, 12.4 Hz, 
1H), 4.77 (d, J = 10.3 Hz, 1H), 4.31 (m, 1H), 3.89 (d, J = 4.3 Hz, 1H), 3.67 (d, J = 9.8 
Hz, 1H), 3.56 (s, 1H), 3.41 (dd, J = 1.8, 6.7 Hz, 1H), 3.19 (m, 1H), 3.10 (s, 3H), 3.05 (m, 
2H), 2.46 (s, 3H), 2.37 (m, 3H), 2.19-1.50 (complex pattern), 1.02 (d, J = 7.0 Hz, 3H), 




8-((2-Hydroxyethyl)amino)rifamycin S (4g) 
From (2-hydroxyethyl)amine, 150 mg of crude deep red solid was obtained.  
Purification by preparative TLC (1:1 hexanes / ethyl acetate) gave 4g as a deep red solid 




H NMR (300 MHz, CDCl3): ! 10.19 (m, 
1H), 8.56 (s, 1H), 7.73 (s, 1H), 6.32 (dd, J = 10.5, 15.8 Hz, 1H), 6.21 (m, 2H), 6.00 (dd, J 
= 6.8, 15.8 Hz, 1H), 5.10 (dd, J = 6.0, 12.3 Hz, 1H), 4.74 (d, J = 10.5 Hz, 1H), 3.87 (m, 
5H), 3.67 (d, J = 9.5 Hz, 1H), 3.48 (m, 1H), 3.56 (s, 1H), 3.40 (dd, J = 2.4, 7.5 Hz, 1H), 
3.12 (s, 3H), 3.03 (m, 2H), 2.50 (s, 3H), 2.34 (m, 1H), 2.19-1.50 (complex pattern), 1.03 
(d, J = 7.0 Hz, 3H), 0.86 (d, J = 6.9 Hz, 3H), 0.69 (d, J = 6.8 Hz, 3H), 0.25 (d, J = 7.0 Hz, 
3H). 
8-(Benzylamino)rifamycin S (4h) 
From benzylamine hydrochloride and N,N-diisopropylethylamine, 130 mg of 
crude black solid was obtained.  Purification by preparative TLC (1:1 mixture of hexanes 





H NMR (300 MHz, CDCl3): ! 10.28 (m, 1H), 8.48 (s, 1H), 7.76 (s, 1H), 7.37 
(m, 5H), 6.38 (dd, J = 10.2, 15.6 Hz, 1H), 6.24 (d, J = 10.3 Hz, 1H), 6.15 (d, J = 12.4 Hz, 
1H), 6.06 (dd, J = 7.0, 15.4 Hz, 1H), 5.06 (dd, J = 6.6, 12.4 Hz, 1H), 4.93-4.81 (m, 2H), 
3.96 (d, J = 4.3 Hz, 1H), 3.69 (d, J = 9.8 Hz, 1H), 3.61 (s, 1H), 3.44 (dd, J = 1.6, 6.5 Hz, 
1H), 3.12 (s, 3H), 3.06 (m, 2H), 2.46 (s, 3H), 2.35 (m, 3H), 2.20-1.61 (complex pattern), 
1.05 (d, J = 7.2 Hz, 3H), 0.87 (d, J = 6.9 Hz, 3H), 0.71 (d, J = 6.8 Hz, 3H), 0.25 (d, J = 




8-(Cycloheptylamino)rifamycin S (4i) 
From cycloheptylamine, 160 mg of crude deep red solid was obtained.  
Purification by preparative TLC (1:1 hexanes / ethyl acetate) gave 4i as a deep red solid 




H NMR (300 MHz, CDCl3): ! 10.03 (d, J = 
8.5 Hz, 1H), 8.51 (s, 1H), 7.74 (s, 1H), 6.46 (dd, J = 10.6, 15.8 Hz, 1H), 6.26 (d, J = 9.8 
Hz, 1H), 6.15 (dd, J = 6.8, 15.7 Hz, 1H), 6.10 (d, J = 11.9 Hz, 1H), 5.06 (dd, J = 5.9, 12.4 
Hz, 1H), 4.90 (d, J = 10.6 Hz, 1H), 4.17 (m, 1H), 3.90 (d, J = 4.2 Hz, 1H), 3.73 (d, J = 
9.3 Hz, 1H), 3.56 (s, 1H), 3.46 (dd, J = 1.9, 6.6 Hz, 1H), 3.11 (s, 3H), 3.01 (m, 2H), 2.41 
(s, 3H), 2.36 (m, 2H), 2.18-1.52 (complex pattern), 1.03 (d, J = 7.0 Hz, 3H), 0.88 (d, J = 
6.9 Hz, 3H), 0.70 (d, J = 6.8 Hz, 3H), 0.17 (d, J = 7.0 Hz, 3H). 
8-Methylthiorifamycin S (4j) 
From reaction with sodium methanethiol in place of an amine.  Purification by 
preparative TLC (7:3 hexanes / ethyl acetate) gave 4j as an orange solid (5 mg, 13%). 




H NMR (500 MHz, CDCl3): ! 8.46 (s, 1H), 7.83 (s, 1H), 
6.41 (dd, J = 9.9, 15.8 Hz, 1H), 6.25 (d, J = 9.6 Hz, 1H), 6.16 (d, J = 12.4 Hz, 1H), 6.06 
(dd, J = 7.4, 15.7 Hz, 1H), 5.11 (dd, J = 6.4, 12.4 Hz, 1H), 4.75 (d, J = 10.3 Hz, 1H), 3.73 
(d, J = 4.1 Hz, 1H), 3.58 (m, 2H), 3.45 (d, J = 6.5 Hz, 1H), 3.12 (s, 3H), 2.98 (m, 1H), 
2.65 (s, 3H), 2.49 (s, 3H), 2.36-1.58 (complex pattern), 1.02 (d, J = 7.0 Hz, 3H), 0.88 (d, 
J = 6.9 Hz, 3H), 0.69 (d, J = 6.8 Hz, 3H), 0.21 (d, J = 7.1 Hz, 3H). 
1-(2-Hydroxyethyl)-1H-benzo[cd]indazol-5-one congener of rifamycin S (5) 
From (2-hydroxyethyl)hydrazine hydrochloride and N,N-diisopropylethylamine, 
158 mg of crude deep orange solid was obtained.  Two purifications by preparative TLC 







H NMR (500 MHz, CDCl3): ! 8.12 (s, 1H), 7.33 (s, 1H), 6.35 (dd, J = 
10.5, 15.5 Hz, 1H), 6.26 (d, J = 10.5 Hz, 1H), 6.06 (m, 2H), 4.98 (dd, J = 7.1, 12.4 Hz, 
1H), 4.77 (m, 1H), 4.69 (m, 1H), 4.45 (d, J = 9.7 Hz, 1H), 4.42 (m, 1H), 4.23 (m, 1H), 
3.64 (br s, 1H), 3.52 (d, J = 10.0 Hz, 1H), 3.28 (dd, J = 2.1, 6.9 Hz, 1H), 3.18 (br s, 1H), 
3.03 (s, 3H), 2.90 (d, J = 9.6 Hz, 1H), 2.76 (s, 3H), 2.34 (m, 1H), 2.19 (s, 2H), 2.15 (s, 
3H), 2.05 (m, 2H), 2.00 (s, 3H), 1.79 (s, 3H), 1.78-1.60 (complex pattern), 1.27 (m, 4H), 
0.99 (d, J = 7.0 Hz, 3H), 0.85 (d, J = 6.9 Hz, 3H), 0.55 (d, J = 6.9 Hz, 3H), -0.30 (d, J = 
7.0 Hz, 3H). 
Rifampin S (6) 
To a solution of rifampin (1; 200 mg, 0.24 mmol) in ethyl acetate (4 mL) was 
added aqueous 0.1 M sodium phosphate buffer (pH = 7.4, 4 mL) followed by potassium 
ferricyanide (400 mg, 1.2 mmol).  The suspension was stirred vigorously at room 
temperature for 1.5 h, and then diluted with dichloromethane (50 mL).  This solution was 
washed with phosphate buffer (3 x 30mL) followed by saturated brine (30 mL), dried 
over anhydrous sodium sulfate and concentrated in vacuo to dryness to give 6 as a purple 
black solid (128 mg, 65%).  The compound was pure enough to be utilized directly in the 




H NMR (500 MHz, CDCl3): ! 12.77 (br s, 1H), 
10.56 (br s, 1H), 7.80 (s, 1H), 7.23 (m, 1H), 6.84 (m, 1H), 6.39 (d, J = 10.8 Hz, 1H), 6.10 
(d, J = 12.0 Hz, 1H), 5.94 (dd, J = 5.8, 15.0 Hz, 1H), 5.15 (d, J = 9.2 Hz, 1H),  5.08 (dd, J 
= 5.3, 12.0 Hz, 1H), 3.97 (br s, 1H), 3.89 (d, J = 7.8 Hz, 1H), 3.44 (s, 1H), 3.29 (m, 3H), 
3.10 (s, 3H), 3.02 (m, 4H), 2.58 (s, 3H), 2.44 (m, 2H), 2.37 (s, 3H), 2.30 (s, 3H), 2.11-
1.34 (complex pattern), 1.06 (d, J = 7.0 Hz, 3H), 0.89 (d, J = 7.0 Hz, 3H), 0.56 (d, J = 6.7 
Hz, 3H), 0.16 (d, J = 6.5 Hz, 3H). 
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8-(p-Toluenesulfonyloxy)rifampin S (7) 
This compound was prepared from 6 by the same procedure described above to 
make 8-(p-toluenesulfonyloxy)rifamycin S (3).  The product (194 mg, quantitative yield) 





H NMR (500 MHz, CDCl3): ! 11.11 (s, 1H), 8.11 (d, J = 7.5 Hz, 2H), 
7.82 (s, 1H), 7.41 (d, J = 7.9 Hz, 2H), 6.81 (dd, J = 11.3, 15.4 Hz, 1H), 6.46 (d, J = 10.9 
Hz, 1H), 6.05 (d, J = 12.3 Hz, 1H), 5.96 (dd, J = 5.2, 15.8 Hz, 1H), 5.09 (dd, J = 5.3, 12.5 
Hz, 1H), 5.03 (d, J = 10.1 Hz, 1H), 3.81 (d, J = 9.5 Hz, 1H), 3.45 (d, J = 4.1 Hz, 1H), 
3.20 (m, 4H), 3.04 (s, 3H), 2.99 (d, J = 7.5 Hz, 1H), 2.56 (br s, 4H), 2.49 (s, 3H), 2.39 (br 
s, 4H), 2.35 (s, 3H), 2.10-1.84 (complex pattern), 1.80 (s, 3H), 1.67 (m, 1H), 1.64 (m, 
1H), 1.36 (m, 1H), 1.02 (d, J = 6.8 Hz, 3H), 0.84 (d, J = 6.8 Hz, 3H), 0.53 (d, J = 6.6 Hz, 
3H), -0.01 (d, J = 6.7 Hz, 3H). 
The following compounds were prepared in similar fashion to that described for 
8-(methylamino)rifamycin S (4b) described above: 
8-(Methylamino)rifampin S (8a) 
From methylamine, 180 mg of crude red-purple solid was obtained.  Purification 
by preparative TLC (8:92 methanol / dichloromethane) gave 8a as a deep red solid (100 




H NMR (500 MHz, CDCl3): ! 10.77 (s, 1H), 
9.37 (s, 1H), 7.79 (s, 1H), 6.82 (dd, J = 11.4, 15.0 Hz, 1H), 6.34 (d, J = 11.0 Hz, 1H), 
6.12 (d, J = 12.5 Hz, 1H), 5.90 (dd, J = 4.7, 15.7 Hz, 1H), 5.18 (d, J = 10.1 Hz, 1H), 5.09 
(dd, J = 5.9, 12.4 Hz, 1H), 3.98 (d, J = 7.9 Hz, 1H), 3.40 (d, J = 5.7 Hz, 1H), 3.32 (d, J = 
5.4 Hz, 3H), 3.25 (m, 4H), 3.10 (s, 3H), 2.98 (d, J = 10.3 Hz, 1H), 2.60 (br s, 4H), 2.51 
(m, 1H), 2.47 (s, 3H), 2.37 (br s, 4H), 2.12 (s, 3H), 2.09 (s, 3H), 1.81 (m, 1H), 1.78 (s, 
 
 93 
1H), 1.73 (m, 1H), 1.46-1.25 (complex pattern), 1.06 (d, J = 6.9 Hz, 3H), 0.94 (d, J = 6.5 
Hz, 3H), 0.52 (d, J = 6.8 Hz, 3H), 0.27 (d, J = 7.0 Hz, 3H). 
8-(Ethylamino)rifampin S (8b) 
From ethylamine, 170 mg of crude purple solid was obtained.  Two purifications 
by preparative TLC (7.5:92.5 methanol / dichloromethane) gave 8b as a purple-black 




H NMR (500 MHz, CDCl3): ! 
10.69 (s, 1H), 9.21 (s, 1H), 7.78 (s, 1H), 6.81 (dd, J = 11.2, 15.9 Hz, 1H), 6.32 (d, J = 
10.6 Hz, 1H), 6.13 (d, J = 12.5 Hz, 1H), 5.90 (dd, J = 4.8, 16.0 Hz, 1H), 5.18 (d, J = 9.8 
Hz, 1H), 5.08 (dd, J = 6.0, 12.5 Hz, 1H), 4.05 (d, J = 4.6 Hz, 1H), 3.98 (d, J = 8.3 Hz, 
1H), 3.59 (s, 1H), 3.38 (d, J = 5.8 Hz, 2H), 3.24 (m, 4H), 3.09 (s, 3H), 2.98 (dd, J = 5.8, 
10.5 Hz, 1H), 2.59 (m, 4H), 2.52 (m, 1H), 2.43 (s, 3H), 2.36 (s, 3H), 2.13 (s, 3H), 2.09 (s, 
3H), 1.80 (m, 1H), 1.75 (s, 3H), 1.69 (m, 1H), 1.46-1.27 (complex pattern) 1.36 (t, J = 
7.1 Hz, 3H), 1.06 (d, J = 6.9 Hz, 3H), 0.87 (d, J = 7.2 Hz, 3H), 0.51 (d, J = 6.8 Hz, 3H), 
0.27 (d, J = 7.0 Hz, 3H). 
8-(Allylamino)rifampin S (8c) 
From allylamine, 170 mg of crude purple-red solid was obtained.  Purification by 
preparative TLC (7.5:92.5 methanol / dichloromethane) gave 8c as a purple-black solid 




H NMR (500 MHz, CDCl3): ! 10.73 (s, 
1H), 9.35 (s, 1H), 7.79 (s, 1H), 6.80 (dd, J = 11.4, 15.6 Hz, 1H), 6.33 (d, J = 10.7 Hz, 
1H), 6.13 (d, J = 12.5 Hz, 1H), 6.00 (m, 1H), 5.90 (dd, J = 5.8, 16.0 Hz, 1H), 5.37 (d, J = 
17.1 Hz, 1H), 5.29 (d, J = 10.3 Hz, 1H), 5.18 (d, J = 9.9 Hz, 1H), 5.09 (dd, J = 6.0, 12.5 
Hz, 1H), 4.04 (d, J = 4.5 Hz, 1H), 3.98 (d, J = 8.4 Hz, 1H), 3.57 (br s, 1H), 3.39 (d, J = 
6.0 Hz, 2H), 3.25 (m, 4H), 3.09 (s, 3H), 2.98 (dd, J = 3.6, 10.6 Hz, 1H), 2.59 (m, 4H), 
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2.52 (m, 1H), 2.41 (s, 3H), 2.37 (s, 3H), 2.12 (s, 3H), 2.09 (s, 3H), 1.82 (m, 1H), 1.75 (s, 
3H), 1.69 (m, 1H), 1.46-1.27 (complex pattern), 1.06 (d, J = 6.9 Hz, 3H), 0.94 (d, J = 7.1 
Hz, 3H), 0.52 (d, J = 6.8 Hz, 3H), 0.27 (d, J = 7.0 Hz, 3H). 
8-((2-Hydroxyethyl)amino)rifampin S (8d) 
From (2-hydroxyethyl)amine, 180 mg of crude deep purple solid was obtained.  
Two purifications by preparative TLC (7.5:92.5 methanol / dichloromethane) gave 8d as 




H NMR (500 MHz, 
CDCl3): ! 10.90 (s, 1H), 8.66 (m, 1H), 7.77 (s, 1H), 6.79 (dd, J = 10.9, 15.8 Hz, 1H), 
6.35 (d, J = 10.8 Hz, 1H), 6.19 (dd, J = 0.9, 12.5 Hz, 1H), 5.91 (dd, J = 5.1, 15.9 Hz, 1H), 
5.18 (d, J = 9.9 Hz, 1H), 5.15 (dd, J = 6.3, 12.5 Hz, 1H), 3.99 (d, J = 5.8 Hz, 2H), 3.74 
(m, 1H), 3.68 (m, 1H), 3.63 (m, 2H), 3.41 (d, J = 6.5 Hz, 2H), 3.26 (m, 4H), 3.07 (s, 3H), 
2.98 (dd, J = 5.1, 10.4 Hz, 1H), 2.60 (m, 4H), 2.55 (m, 1H), 2.37 (br s, 6H), 2.14 (s, 3H), 
2.08 (s, 3H), 1.80 (m, 1H), 1.76 (s, 3H), 1.37 (m, 1H), 1.06 (d, J = 7.0 Hz, 3H), 0.96 (d, J 
= 7.2 Hz, 3H), 0.50 (d, J = 6.8 Hz, 3H), 0.27 (d, J = 7.0 Hz, 3H). 
8-(Benzylamino)rifampin S (8e) 
From benzylamine hydrochloride and N,N-diisopropylethylamine, 180 mg of 
crude black solid was obtained.  Purification by preparative TLC (7.5:92.5 methanol / 





H NMR (500 MHz, CDCl3): ! 10.71 (s, 1H), 9.61 (m, 1H), 7.79 (s, 1H), 7.38 
(m, 4H), 7.31 (m, 1H), 6.88 (dd, J = 10.8, 15.1 Hz, 1H), 6.33 (d, J = 10.7 Hz, 1H), 6.09 
(dd, J = 1.0, 12.5 Hz, 1H), 5.92 (dd, J = 4.9, 15.9 Hz, 1H), 5.18 (d, J = 10.1 Hz, 1H), 5.07 
(dd, J = 5.8, 12.5 Hz, 1H), 4.81 (m, 2H), 4.09 (d, J = 4.6 Hz, 2H), 4.01 (d, J = 8.2 Hz, 
1H), 3.64 (br s, 1H), 3.39 (d, J = 5.7 Hz, 2H), 3.25 (m, 4H), 3.07 (s, 3H), 3.00 (dd, J = 
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4.6, 10.1 Hz, 1H), 2.59 (m, 4H), 2.53 (m, 1H), 2.40 (s, 3H), 2.37 (s, 6H), 2.11 (s, 3H), 
2.09 (s, 3H), 1.83 (m, 1H), 1.74 (s, 3H), 1.41 (m, 1H), 1.07 (d, J = 6.9 Hz, 3H), 0.95 (d, J 
= 7.1 Hz, 3H), 0.54 (d, J = 6.8 Hz, 3H), 0.21 (d, J = 7.0 Hz, 3H). 
8-(Cycloheptylamino)rifampin S (8f) 
From cycloheptylamine, 180 mg of deep red solid was obtained.  Two 
purifications by preparative TLC (7.5:92.5 methanol / dichloromethane) gave 8f as a 




H NMR (500 MHz, 
CDCl3): ! 10.59 (s, 1H), 9.35 (d, J = 8.6 Hz, 1H), 7.78 (s, 1H), 6.84 (dd, J = 10.6, 15.6 
Hz, 1H), 6.33 (d, J = 10.5 Hz, 1H), 6.15 (d, J = 12.5 Hz, 1H), 5.90 (dd, J = 5.0, 15.9 Hz, 
1H), 5.17 (d, J = 9.8 Hz, 1H), 5.09 (dd, J = 6.1, 12.5 Hz, 1H), 4.03 (d, J = 4.5 Hz, 1H), 
3.99 (d, J = 9.0 Hz, 1H), 3.58 (br s, 1H), 3.38 (d, J = 5.9 Hz, 1H), 3.24 (m, 4H), 3.09 (s, 
3H), 2.98 (dd, J = 3.6, 10.1 Hz, 1H), 2.59 (m, 4H), 2.52 (m, 1H), 2.38 (s, 3H), 2.37 (s, 
3H), 2.09 (s, 3H), 2.06 (s, 3H), 2.04 (m, 4H), 1.82 (m, 1H), 1.76 (s, 3H), 1.69 (m, 1H), 
1.73-1.23 (complex pattern), 1.06 (d, J = 6.9 Hz, 3H), 0.94 (d, J = 7.4 Hz, 3H), 0.51 (d, J 
= 6.8 Hz, 3H), 0.26 (d, J = 7.1 Hz, 3H). 
1-Methyl-1H-benzo[cd]indazol-5-one congener of rifampin S (9a) 
From methylhydrazine hydrochloride and N,N-diisopropylethylamine, a crude 
deep brown was obtained.  Two purifications by preparative TLC (8:92 methanol / 




H NMR (500 MHz, CDCl3): ! 13.06 (s, 1H), 8.27 (s, 1H), 6.96 (dd, J = 11.8, 15.4 Hz, 
1H), 6.62 (d, J = 11.3 Hz, 1H), 6.17 (d, J = 12.5 Hz, 1H), 6.02 (dd, J = 5.2, 15.6 Hz, 1H), 
5.09 (dd, J = 5.9, 12.6 Hz, 1H), 4.91 (d, J = 10.6 Hz, 1H), 4.43 (s, 3H), 3.84 (d, J = 9.9 
Hz, 1H), 3.63 (m, 1H), 3.51 (s, 1H), 3.42 (m, 1H), 3.15 (m, 4H), 3.04 (s, 3H), 3.00 (m, 
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1H), 2.78 (s, 3H), 2.56 (m, 4H), 2.41 (m, 1H), 2.35 (s, 3H), 2.12 (s, 3H), 2.05 (s, 3H), 
1.82 (s, 3H), 1.73-1.53 (complex pattern), 1.04 (d, J = 6.9 Hz, 3H), 0.90 (d, J = 7.0 Hz, 
3H), 0.52 (d, J = 6.8 Hz, 3H), -0.53 (d, J = 6.9 Hz, 3H). 
1-(2-Hydroxyethyl)-1H-benzo[cd]indazol-5-one congener of rifampin S (9b) 
From (2-hydroxyethyl)hydrazine hydrochloride and N,N-diisopropylethylamine, 
200 mg of crude black solid was obtained.  Two purifications by preparative TLC (8:92 





H NMR (500 MHz, CDCl3): ! 13.11 (s, 1H), 8.26 (s, 1H), 6.92 (dd, J = 11.5, 
15.4 Hz, 1H), 6.59 (d, J = 11.1 Hz, 1H), 6.17 (d, J = 12.6 Hz, 1H), 6.03 (dd, J = 5.3, 15.3 
Hz, 1H), 5.09 (dd, J = 6.0, 12.5 Hz, 1H), 4.89 (d, J = 10.3 Hz, 1H), 4.79 (m, 2H), 3.85 (d, 
J = 9.5 Hz, 1H), 3.64 (m, 1H), 3.51 (m, 1H), 3.41 (d, J = 5.6 Hz, 2H), 3.08 (m, 4H), 3.03 
(s, 3H), 3.00 (m, 1H), 2.78 (s, 3H), 2.56 (m, 4H), 2.41 (m, 1H), 2.35 (s, 3H), 2.09 (s, 3H), 
2.05 (s, 3H), 1.82 (s, 3H), 1.80-1.52 (complex pattern), 1.03 (d, J = 7.0 Hz, 3H), 0.90 (d, 
J = 7.0 Hz, 3H), 0.52 (d, J = 6.8 Hz, 3H), -0.54 (d, J = 7.0 Hz, 3H). 
8-(Methylamino)rifampin (10a) 
Ascorbic acid (74 mg, 0.42 mmol) was added to a solution of 8-
(methylamino)rifampin S (8a; 35 mg, 0.04 mmol) in methanol (1.5 mL).  The resulting 
mixture was stirred at room temperature for 2 h and then diluted with dichloromethane 
(15 mL).  This solution was washed with 0.2 N aqueous NH4Cl (3 x 10 mL) followed by 
saturated brine (10 mL), dried over anhydrous sodium sulfate and evaporated in vacuo to 





NMR (500 MHz, CDCl3): ! 12.91 (s, 1H), 12.78 (s, 1H), 12.00 (s, 1H), 10.15 (s, 1H), 
8.36 (s, 1H), 6.68 (dd, J = 11.4, 14.9 Hz, 1H), 6.41 (d, J = 10.8 Hz, 1H), 6.18 (d, J = 12.5 
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Hz, 1H), 5.93 (dd, J = 4.7, 15.2 Hz, 1H), 5.10 (dd, J = 6.3, 12.5 Hz, 1H), 4.98 (d, J = 10.4 
Hz, 1H), 3.81 (d, J = 9.3 Hz, 1H), 3.31 (d, J = 5.0 Hz, 3H), 3.27 (m, 4H), 3.07 (s, 3H), 
3.01 (m, 1H), 2.71 (br s, 4H), 2.42 (m, 4H), 2.38 (s, 3H), 2.37 (m, 1H), 2.09 (s, 3H), 1.42-
1.27 (complex pattern), 1.04 (d, J = 6.9 Hz, 3H), 0.94 (d, J = 7.0 Hz, 3H), 0.61 (d, J = 6.8 
Hz, 3H), -0.17 (d, J = 6.9 Hz, 3H). 
Prepared in similar fashion were the following rifampin analogues: 
8-(Ethylamino)rifampin (10b) 
From 8-(ethylamino)rifampin S (8b), 10b was obtained as an orange solid (41 mg, 




H NMR (500 MHz, CDCl3): ! 12.90 (br s, 1H), 
12.80 (s, 1H), 12.01 (s, 1H), 10.11 (s, 1H), 8.37 (s, 1H), 6.68 (dd, J = 11.9, 15.5 Hz, 1H), 
6.41 (d, J = 11.1 Hz, 1H), 6.18 (d, J = 12.6 Hz, 1H), 5.94 (dd, J = 4.8, 15.5 Hz, 1H), 5.09 
(dd, J = 6.5, 12.6 Hz, 1H), 4.98 (dd, J = 10.5 Hz, 1H), 3.82 (m, 2H), 3.72 (m, 1H), 3.57 
(m, 1H), 3.51 (d, J = 6.4 Hz, 2H), 3.25 (m, 4H), 3.06 (s, 3H), 3.01 (m, 1H), 2.72 (m, 4H), 
2.47 (s, 3H), 2.41 (m, 1H), 2.35 (m, 3H), 2.08 (m, 6H), 1.79 (s, 3H), 1.74 (m, 1H), 1.61-
1.27 (complex pattern) 1.35 (t, J = 7.1 Hz, 3H), 1.04 (d, J = 6.9 Hz, 3H), 0.90 (d, J = 7.0 
Hz, 3H), 0.62 (d, J = 6.8 Hz, 3H), -0.17 (d, J = 6.9 Hz, 3H). 
8-(Allylamino)rifampin (10c) 
From 8-(allylamino)rifampin S (8c), 10c was obtained as an orange solid (24 mg, 




H NMR (500 MHz, CDCl3): ! 12.95 (br s, 1H), 
12.69 (s, 1H), 12.04 (s, 1H), 10.17 (s, 1H), 8.36 (s, 1H), 6.67 (dd, J = 11.4, 15.6 Hz, 1H), 
6.41 (d, J = 10.8 Hz, 1H), 6.19 (d, J = 12.6 Hz, 1H), 5.99 (m, 1H), 5.94 (dd, J = 5.0, 16.3 
Hz, 1H), 5.39 (d, J = 17.4 Hz, 1H), 5.28 (d, J = 10.3 Hz, 1H), 5.10 (dd, J = 6.4, 12.6 Hz, 
1H), 4.99 (d, J = 10.3 Hz, 1H), 4.34 (m, 1H), 3.82 (d, J = 9.6 Hz, 1H), 3.70 (br s, 1H), 
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3.51 (d, J = 5.2 Hz, 2H), 3.20 (m, 4H), 3.07 (s, 3H), 3.02 (m, 1H), 2.66 (m, 4H), 2.42 (m, 
1H), 2.34 (s, 3H), 2.08 (m, 6H), 2.04 (m, 1H), 1.80 (s, 3H), 1.75-1.22 (complex pattern), 
1.04 (d, J = 6.8 Hz, 3H), 0.91 (d, J = 6.6 Hz, 3H), 0.62 (d, J = 6.4 Hz, 3H), -0.17 (d, J = 
6.7 Hz, 3H). 
8-(2-Hydroxyethylamino)rifampin (10d) 
From 8-((2-hydroxyethyl)amino)rifampin S (8d), 10d was obtained as an orange 




H NMR (500 MHz, CDCl3): ! 12.77 
(m, 2H), 11.95 (s, 1H), 10.34 (s, 1H), 8.37 (s, 1H), 6.65 (dd, J = 11.4, 15.3 Hz, 1H), 6.38 
(d, J = 11.2 Hz, 1H), 6.16 (d, J = 12.6 Hz, 1H), 5.90 (dd, J = 4.6, 15.4 Hz, 1H), 5.09 (dd, 
J = 6.4, 12.6 Hz, 1H), 4.97 (d, J = 9.9 Hz, 1H), 3.91 (m, 2H), 3.86 (m, 1H), 3.79 (m, 1H), 
3.72 (m, 2H), 3.49 (d, J = 6.2 Hz, 2H), 3.37 (m, 4H), 3.05 (s, 3H), 3.01 (m, 1H), 2.86 (m, 
4H), 2.56 (s, 3H), 2.42 (m, 1H), 2.35 (s, 3H), 2.07 (m, 6H), 1.79 (s, 3H), 1.72 (m, 1H), 
1.56 (m, 1H), 1.43-1.26 (complex pattern) 1.03 (d, J = 6.9 Hz, 3H), 0.87 (d, J = 6.9 Hz, 
3H), 0.61 (d, J = 6.7 Hz, 3H), -0.20 (d, J = 6.8 Hz, 3H). 
8-(Benzylamino)rifampin (10e) 
From 8-(benzylamino)rifampin S (8e), 10e was obtained as an orange solid (26 




H NMR (500 MHz, CDCl3): ! 12.90 (s, 1H), 
12.70 (s, 1H), 12.00 (s, 1H), 10.46 (m, 1H), 8.36 (s, 1H), 7.35 (m, 5H), 6.65 (dd, J = 
11.3, 15.4 Hz, 1H), 6.38 (d, J = 11.1 Hz, 1H), 6.19 (d, J = 12.6 Hz, 1H), 5.92 (dd, J = 4.7, 
15.5 Hz, 1H), 5.10 (dd, J = 6.5, 12.6 Hz, 1H), 4.99 (d, J = 10.5 Hz, 1H), 4.91 (m, 2H), 
3.81 (d, J = 9.4 Hz, 1H), 3.74 (br s, 1H), 3.51 (d, J = 6.5 Hz, 1H), 3.24 (m, 4H), 3.06 (s, 
3H), 3.03 (m, 1H), 2.70 (m, 4H), 2.44 (s, 3H), 2.40 (m, 1H), 2.37 (s, 3H), 2.08 (s, 3H), 
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2.06 (s, 3H), 1.79 (s, 3H), 1.73 (m, 1H), 1.04 (d, J = 6.7 Hz, 3H), 0.90 (d, J = 6.8 Hz, 
3H), 0.62 (d, J = 6.6 Hz, 3H), -0.16 (d, J = 6.6 Hz, 3H). 
8-(Cycloheptylamino)rifampin (10f) 
From 8-(cycloheptylamino)rifampin S (8f), 10f was obtained as an orange solid 




H NMR (500 MHz, CDCl3): ! 12.90 (br s, 
1H), 12.80 (s, 1H), 12.00 (s, 1H), 10.30 (d, J = 8.3 Hz, 1H), 8.37 (s, 1H), 6.67 (dd, J = 
11.4, 15.5 Hz, 1H), 6.41 (d, J = 11.1 Hz, 1H), 6.18 (d, J = 12.6 Hz, 1H), 5.94 (dd, J = 4.9, 
15.4 Hz, 1H), 5.09 (dd, J = 6.4, 12.5 Hz, 1H), 4.97 (d, J = 10.5 Hz, 1H), 4.09 (m, 1H), 
3.82 (d, J = 9.3 Hz, 1H), 3.71 (br s, 1H), 3.50 (d, J = 6.3 Hz, 1H), 3.24 (m, 4H), 3.06 (s, 
3H), 3.00 (m, 1H), 2.71 (m, 4H), 2.46 (m, 1H), 2.40 (m, 3H), 2.30 (s, 3H), 2.10 (s, 3H), 
2.08 (s, 3H), 2.05 (m, 2H), 1.89 (m, 2H), 1.80 (m, 1H), 1.79-1.27 (complex pattern), 1.04 





Structure-based Modeling Studies 
To gain better understanding of the SAR, we carried out structure-based modeling 
studies. Modeling was based on the 2.5 Å resolution structure of rifabutin complexed 
with the Thermus thermophilus RNAP holoenzyme (PDB ID: 2a68) (11).  Since the 
rifamycin binding site is highly conserved among bacteria, this structure provides a good 
foundation for understanding how proposed rifamycin analogues may interact with the 
MTB RNA polymerase.  Preparation of the structure before modeling was conducted 
using MOE. 
Given the size of the rifamycins, size of the binding site, and the flexibility of the 
ansa ring, accurate docking of these inhibitors to the RNAP complex would be 
challenging using standard docking approaches.  Since most of the rifamycin structure 
remains unchanged, modeled poses of the analogues were generated by mutating 
rifamycin to the analogue and then relaxing the complex through a series of energy 
minimizations as described in the Supplementary Material. 
Modeled poses were generated for each of the structures listed in Table III-2.  A 
QSAR model (not shown) using interaction energies between the inhibitor and RNAP 
complex and two other ligand descriptors produced a very good R2 of 0.90 and a cross 
validation R2 of 0.79.  The good fit of the QSAR model based on energies from the 
structure-based modeling supports the accuracy of the latter.  The robustness of our 
structure-based modeling has also been supported by experimental studies where 




Preparation for the 2a68 structure before modeling 
All water molecules and metal ions more than 12 Å from rifamycin were 
removed.  Residues with missing atoms were rebuilt.  Residues which were not resolved 
in the structure were distant from the binding site and were not modeled in.  All N and C 
termini (either real or as a result of missing residues) were acetylated and amidated 
respectively.  Bond orders were checked for the rifabutin and hydrogen atoms added to it 
and the complex.  
A series of energy minimizations were then used to relax the structure.  The 
positions of the hydrogen atoms were relaxed with energy minimization using the 
MMFF94x forcefield.  Hydrogen atoms, rebuilt residues and termini except for carbon 
alpha atoms were relaxed with energy minimization.  All protein and rifamycin heavy 
atoms were fixed and positions of all hydrogen atoms and water molecules relaxed.  
Positions of the rifamycin atoms were then relaxed.  Finally all atoms within 12 Å from 
rifamycin were relaxed with energy minimization. 
Generation of binding complexes for the analogues 
Rifamycin was modified to form the analogue structure.  A series of energy 
minimizations were then used to relax the structure.  The positions of the hydrogen atoms 
were relaxed with energy minimization using the MMFF94x forcefield.  Atoms added or 
modified to create the analogue and positions of hydrogen atoms were relaxed with 
energy minimization.  Positions of water molecules and hydrogen atoms were relaxed.  
Protein side chains within 12 Å from rifamycin, water molecules and hydrogen atoms 
















(WT MTB RNAP) (MTB RNAP (S450L)) 
1 -2.3986 (0.037, 1.54) 1.7166 (0.026, 1.52) 
2 -2.1734 (0.049, 1.4) 1.5566 (0.082, 1.73) 
3 -1.6795 (0.028, 1.04) 2.9922 (0.086, 1.11) 
4a 0.6441 (0.054, 1.39) 2.2706 (0.103, 0.73) 
4c -0.2984 (0.027, 1.54) 2.4317 (0.109, 0.61) 
4i 1.1879 (0.076, 1.26) 2.1042 (0.113, 1.45) 
4j -1.8199 (0.092, 0.74) 1.5742 (0.064, 1.46) 
6 -1.8767 (0.107, 1.45) 1.6672 (0.034, 1.11) 
7 -0.8462 (0.043, 0.94) 2.0451 (0.075, 0.90) 
9b -0.85567 (0.061, 0.96) 1.4751 (0.065, 0.98) 
 
1
 The log IC50 values are such that the IC50 values will be in !M.  Negative log IC50 
values reflect IC50 values less than !M (e.g., in the nM range).  Values were fit to a 
four parameter logistic regression model with the top and bottom limits set at 100 and 0 
respectively. 
2
 The average error is ~10 %, which roughly translates to 20-25% in the IC50. 
3
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Structure-based Design of Novel Benzoxazinorifamycins with Potent 
Binding Affinity to Wild-type and Rifampin-resistant Mutant 
Mycobacterium tuberculosis RNA polymerases 
 
The emergence of multi-drug resistant TB (MDR-TB) has become of main 
concern with approximately half a million new cases reported in 2008 (1).  MDR-TB 
strains are resistant to rifampin (1 , RMP, Figure IV-1) and isoniazid, the two most 
effective TB drugs.  The treatment of MDR-TB consists of a combination of three or four 
second-line anti-TB drugs that includes a fluoroquinolone (2, 3).  These second-line 
bacteriostatics have more serious side effects and need to be taken for an extended period 
of time (at least 2 years) (2, 3).  Furthermore, TB strains resistant to these agents along 
with RMP and isoniazid are classified as the virtually untreatable extensively drug-
resistant TB (XDR-TB) (1).  Therefore, agents that are non-toxic, well tolerated, effective 
against drug-susceptible and drug-resistant TB, and that will result in shortened TB 
therapy are needed urgently (4-7). 
Benzoxazinorifamycins, a new generation of rifamycin derivatives with a four 
ring structure, have shown improved antimicrobial activity against Mycobacterium 
tuberculosis (MTB) (8, 9).  Amongst the benzoxazinorifamycin derivatives, rifalazil (2a, 
RLZ, Figure IV-1) was selected as the most promising due to its excellent potency (both 
in vivo and in vitro), high tissue affinity, long elimination time from tissues and its 
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relative lack of toxicity in early rodent studies (8-11).  RLZ is an exceedingly potent 
rifamycin derivative being 16 - 256 times more potent than RMP (8, 9, 12-14).  RLZ is 
effective against most rifamycin-resistant (RifR) MTB strains but not all (13, 15-18).  In 
addition to being active against RifR MTB strains, RLZ also has potent activity against 
several other clinically important bacterial pathogens (19-21) 
One major downside of rifamycins is their many drug-drug interactions.  RMP 
and other rifamycins induce the expression of cytochrome P450 3A4 (CYP3A4), a drug-
metabolizing enzyme responsible for eliminating 36% of clinically important drugs, by 
activating the human pregnane X receptor (hPXR) (22).  However, RLZ does not induce 
the expression of CYP3A4 (presumably due to lack of activation of hPXR).  
Unfortunately, RLZ was seen to be quite toxic in a series of phase I (23, 24) and phase II 
(12, 23-25) clinical trials with most adverse effects associated with a flu-like syndrome 
and leucopenia even at lower dose levels.  Hence, its development as a treatment for TB 







Figure IV-1:  Structures of reference agents (1, 2a) and novel benzoxazinorifamycins (2b-2e) 
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Due to the overall favorable properties of RLZ, benzoxazinorifamycin derivatives 
(2b – 2e ; Figure IV-1) where ether tethers had been installed off the 3’-position of the 
“southeastern” part of the benzoxazinorifamycin template were synthesized.  The design 
of these derivatives was based upon the three-dimensional X-ray structures of rifamycins 
bound to RNA polymerase (RNAP) (27, 28) and the human pregnane X receptor (hPXR) 
(22) in order to obtain an analogue with equal or better potency than RLZ against WT 
and RifR mutants of RNA polymerase (RNAP), the multi-subunit target of the 
rifamycins, with potential of making additional interactions with the other RNAP 
subunits.  Furthermore, these analogues were expected to display lowered affinity for and 
therefore lowered activation of the hPXR.  These studies demonstrate proof of principle 
for this subclass of rifamycins and support further expansion of structure-activity 
relationships (SAR) toward uncovering analogues with development potential. 
Materials and Methods 
Reagents 
Chemistry  
All reagents were commercially available and used without further purification.  
Melting points were determined in open capillary tubes on a Laboratory Devices Mel-




C NMR spectra were obtained on Bruker 
500 MHz spectrometers with CDCl3 or d6-DMSO as solvent and chemical shifts are 
reported relative to the residual solvent peak in ! (ppm).  Mass spectrometry analysis was 
performed using a Waters LCT time-of-flight mass spectrometry instrument.  High 
resolution mass spectrometry (HRMS) analysis was performed on an Agilent Q-TOF 
system.  Analytical HPLC was performed on a Perkin Elmer Series 200 system with an 
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Agilent Eclipse plus C18 (4.6 + 7.5 mm, 3.5 mm particle size) column.  The mobile 
phase was a 15 min binary gradient of acetonitrile (containing 0.1 % TFA) and water 
(20–90%).  Thin-layer chromatography (TLC) was performed on silica gel GHLF plates 
(250 microns) purchased from Analtech.  Extraction solutions were dried over MgSO4 
prior to concentration.  (The chemistry scheme and synthesis described in Figure IV-A2 
in Appendix IV-2.) 
Biochemistry 
All the reagents were the same as specified in Chapter II.  The hPXR activation 
and cell viability in 96-well format assay was from Puracyp, Inc.  Rifamycin S was from 
AAPharmaSyn LLC.  Rifampin was from Boche Scientific.   
Computational Modeling of Rifamycin•RNAP Complexes.   
Initially, the rifabutin (RBN) bound to Thermus thermophilus RNAP complex 
was modified (described in Figure IV-A1 in Appendix IV-1).  The proposed analogues 
were then generated using the modified RBN complex where all of the water molecules 
present in the structure were removed.  All residues that did not have one or more atoms 
within approximately 20 Å of the RBN were deleted.  The remaining atoms of RBN, 
which were not modified in the generation of the proposed analogue, were initially fixed 
in space and treated as part of the RNAP holoenzyme.  A LowModeMD (29) 
conformational search algorithm with energy minimization was then employed to 
generate plausible poses (conformations) of the modified portions of RBN.  The 
LowModeMD search was conducted in MOE (30) using default settings.  Hydrogen 
atoms, modified portions of RBN and protein side chains within ~16 Å of the modified 
portions were allowed to move during the conformational search and energy 
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minimizations.  Generated poses were ranked by interaction energies and duplicate poses 
based on a RMSD cutoff removed.  The lowest energy pose was then selected and the 
truncated RNAP complex soaked with water to a surrounding distance of 6 Å.  A series 
of energy minimizations were then conducted using the MMFF94x force field to relax the 
complex.  First, hydrogen atoms and then the water molecules were allowed to relax 
while the entire analogue and all of the RNAP atoms were held fixed.  Second, the 
modified portions of RBN and side chains of RNAP within 16 Å were also allowed to 
relax with the water molecules and hydrogen atoms.  Finally, the entire analogue 
molecule, residues of RNAP within 16 Å, and the water molecules and hydrogen atoms 
were allowed to relax.  The relaxed complexes were then examined to determine how the 
proposed analogue may interact with the sigma factor or other portions of RNAP 
(specifically the ! and !` subunits). 
Synthesis of Analogues 2a – 2e 
The synthetic route utilized to make our target “one-armed” compounds 2b-2d is 
shown in Figure IV-A2 in Appendix IV-2.  A “two-armed” RLZ congener (2e) was also 
synthesized to assess the effect of the additional side chain on biological activity.  The 
complete synthesis is described in Appendix IV-A2. 
Expression and Purification of MTB RNAP (WT and RifR mutants) 
The WT and RifR mutants were prepared as described in Chapter II from the co-
expression vectors (pMTBRP-5, 6, 7, 8) with minor alterations.  For cell lysis, the 
sonication method (used to prepare E. coli RNAPs in Chapter II) was preferred over the 
freeze/thaw method.  For the remainder of the purification steps, the protocol outlined in 
Chapter II was followed. 
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Cloning, Expression and Purification of MTB sigma factor (SigA) 
The pAvitag vector (modified pMSCG7 vector with an Avitag introduced 
between BglII and KpnI sites) was linearized with SspI at 37
o
C for 1 h and the reaction 
product was purified using the Qiagen PCR kit.  The linearized pAvitag vector (1.6-2.0 
!g) was treated with T4 DNA polymerase in 10X T4 polymerase buffer, 5 mM DTT, 4 
mM dGTP in a final reaction volume of 60 !L.  The reaction was incubated for 30 min at 
22
o
C and then for 20 min at 75
o
C before being stored at -20
o
C.  PCR primers were 
designed to amplify the Rv2703/sigA  gene encoding SigA from pSR01 (31).  The 
primers included an overhang sequence that complemented the vector Ligation 
Independent Cloning (LIC) overhangs.  The sigA  gene was purified via Qiagen PCR kit.  
The purified PCR product (0.2 pmol) was incubated with T4 DNA polymerase, 5 mM 
DTT, 4 mM dCTP, 10X T4 DNA polymerase in a final reaction volume of 20 !L.  The 
reaction was incubated for 30 min at 22
o
C and then for 20 min at 75
o
C and stored at -
20
o
C.  The treated sigA  was incubated with treated pAvitag vector (~0.2 pmol) for 10 
min at 22
o
C.  Then 6.25 mM EDTA was added followed by incubation at 22
o
C for 5 min 
before reducing the temperature to 4
o
C.  The annealed pAvitag vector containing sigA  
was transformed into BL21(DE3) CodonPlus RIPL cells. 
For the expression of SigA protein in BL21(DE3) CodonPlus RIPL cells, the cells 
were grown in 500 mL of 2xTY liquid cultures containing 100 !g/mL carbenicillin and 
30 !g/mL chloramphenicol at 37
o
C with vigorous shaking until cell density reached 
OD600nm=0.5-0.6.  The protein was induced by the addition of IPTG to a final 
concentration of 1 mM.  The cultures were allowed to incubate for an additional 20-24 
hours at 19
o
C.  The cells were harvested by centrifugation (6000xg, 15 min, 4
o
C).  The 
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cell pellet of each 500 mL culture was re-suspended in 10 mL of Ni
2+
-NTA bind buffer 
(300 mM NaCl, 50 mM NaH2PO4, 10 mM imidazole, pH 8.0).  The freeze/thaw method 
was followed to lyse the cells, and it was repeated a total of three times.  The sample was 
supplemented with 10 !L of Lysonase
TM
 Bioprocessing Reagent and 100 !M of PMSF, 
and then the resulting lysate was cleared by centrifugation (21,000xg, 30 min, 4
o
C).  All 
further purification steps were performed at 4
o
C.  The lysate was incubated with 2 mL 
Ni
2+
-NTA His•Bind Resin overnight with gentle shaking.  Each supernatant-resin mixture 
was applied to individual columns.  The columns were washed twice with 4 mL of Ni
2+
-
NTA wash buffer (300 mM NaCl, 50 mM NaH2PO4, 20 mM imidazole, pH 8.0), and the 
protein was then eluted in 6 mL of Ni
2+
-NTA elute buffer (300 mM NaCl, 50 mM 
NaH2PO4, 250 mM imidazole, pH 8.0).  The protein was concentrated to a final volume 
of ~500 !L and then sterile-filtered with 0.22-!m syringe before being applied to a 
HiPrep 16/60 Sephacryl S-200 HR (GE Healthcare) column and the running buffer was 
RNAP storage buffer (10 mM Tris-HCl (pH 7.9), 0.1 mM EDTA, 0.1 mM DTT, 0.1 M 
NaCl).  The fractions containing SigA were pooled together and concentrated to a final 
volume of ~500 !L using Amicon Centrifugal Filter Units (MWCO=10 kDa).  SigA was 
mixed with one volume of 100% glycerol and stored in liquid nitrogen.  The final 
concentration of SigA was determined via Bradford assay using the Bio-Rad Protein 
Assay Kit. 
 113 
In vitro Transcriptional Activity of MTB RNAPs and Dose Response Curves 
Dose response studies with RLZ (2a) and analogues (2b-2e) were performed via 
rolling circle transcription assay to determine the IC50 values.  Each of the compounds 
was tested in duplicate (n=2).  The concentration range used for the wild-type MTB 
RNAP (+/- SigA) was 1.56-100 nM for RLZ and analogues (2b-2e).  The concentration 
ranges used for MTB RNAP (D435V) with SigA were as follows: for 2a and 2e (39.1-
2500 !M); for 2b-2d (1.25-80 !M).  The concentration ranges used for MTB RNAP 
(H445Y) with SigA were as follows: for 2a and 2e (20.5-5000 !M); for 2b-2d (8.2-
2000 !M).  The concentration ranges used for MTB RNAP (S450L) with SigA were as 
follows: for 2a (8.2-2000 !M); for 2b (3.3-800 !M); for 2c and 2d (1.64-400 !M); for 
2e  (6.55-1600 !M).  The final concentration of the wild-type MTB RNAP was 10 nM, 
whereas the final concentration of the RifR RNAPs was 100 nM in the reactions.  The 
core RNAP and SigA were incubated for 30 min on ice in 1X RNAP reaction buffer (40 
mM Tris-HCl (pH 8.0), 50 mM KCl, 10 mM MgCl2, 0.01% Triton X-100) before adding 
the test compound and DNA nanocircle template (80 nM).  The reactions were set up as 
outlined in Chapter II.  The IC50 values were determined by non-linear regression and, the 
logIC50s and their standard errors (of the fit) are reported in Table IV-A2 in Appendix 
IV-3). 
Determination of Minimal Inhibitory Concentration (MIC) Against MTB H37Rv 
Strains 
All compounds were evaluated for MIC90 vs. MTB H37RV using the microplate 
Alamar Blue assay (MABA) as previously described (32) except that 7H12 media was 
used (replacing 7H9 + glycerol + casitone + OADC).  The use of this and other redox 
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reagents such as MTT have shown excellent correlation with colony-forming unit (CFU)-
based and radiometric analyses of mycobacterial growth in many laboratories.  The MIC 
is defined as the lowest concentration effecting a reduction in fluorescence (or 
luminescence) of 90% relative to controls.  Isoniazid and rifampin are included as 
positive quality control compounds with expected MIC ranges of 0.025-0.1 and 0.06-
0.125 !g/mL, respectively. 
The Low Oxygen Recovery (LORA) in vitro assay (33) is designed to detect 
compounds which may have the potential for shortening the duration of therapy through 
(more) efficient killing of the non-replicating persistor (NRP) population.  The assay 
involves (1) adaptation of MTB to low oxygen through gradual, monitored, self-depletion 
of oxygen during culture in a sealed fermenter, (2) exposure for 10 days of the low-
oxygen adapted culture to test compounds in microplates that are maintained under an 
anaerobic environment, thus precluding growth and (3) subsequent evaluation of MTB 
viability as determined by the ability to recover.  Recovery/viability is determined either 
by (a) (aerobic) subculture onto solid, drug-free media and determination of colony 
forming units or (b) by the extent to which a luciferase-expressing strain can recover the 
ability to produce luminescence.  Compounds such as isoniazid and ethambutol, which 
are considered to be devoid of “sterilizing activity”, are inactive in this assay while the 
rifamycins and the more potent fluoroquinolones, which do appear to eliminate some 
proportion of the persistor population and thus can affect treatment duration, are active, 
albeit at concentrations higher than the MICs for replicating cultures.  Correlation 
between the CFU and luminescence readout has been good with the exception of the 
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fluoroquinolone class for which luminescence underestimates absolute activity but not 
relative activity. 
Computational Modeling of Rifamycin•hPXR Complexes 
A 2.8 Å resolution crystal structure of hPXR in complex with rifampin is 
available from the Protein Data Bank (PDB ID: 1skx) (22).  Unfortunately, the 1-amino-
4-methylpiperazine tail of RMP and three hPXR loops adjacent to the binding pocket 
(residues 178-209, 229-235, and 310-317) are disordered and unresolved in the structure.  
The missing residues in this and other published hPXR structures make accurate 
modeling of the hPXR and the tails of rifamycins difficult.  Figure IV-4 was created by 
overlaying the naphthalene portions of the four rifamycins generated from the 2a68 
structure onto the naphthalene portion of RMP in complex with hPXR structure 1skx.  
The relative location of synthetic branch point for the analogues described in Figure IV-1 
is also indicated in Figure IV-4.  In addition to the complex with RMP, four other 
relatively complete hPXR structures are available.  The hPXR apo structure (PDB ID: 
1ilg) (34) and hPXR complexes with SR12813 (PDB ID: 1ilh) (34) hyperforin (PDB ID: 
1m13) (35) and colupulone (PDB ID:2qnv) (36) were obtained from the Protein Data 
Bank.  These four hPXR complexes were superimposed onto the hPXR structure of 1skx 
containing the four modeled in rifamycins.  Coordinates were not relaxed with energy 
minimization due to the many missing residues. 
Human Pregnane X Receptor Activation Assay 
To assess the ability of specific rifamycins to activate the hPXR, the hPXR 
activation assay system from Puracyp, Inc. was used.  The manufacturer’s protocol was 
followed for the 96 well plate assay.  Briefly, the DPX2 cells were thawed in a 37°C 
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water bath and mixed thoroughly with culture media.  Then 100 !L of cell mixture was 
transferred into each well and the plate was incubated overnight in a 5% CO2 incubator at 
37 °C.  The following day, the dosing media was thawed in a 37ºC water bath.  The 
dilutions of RLZ (2a) and analogues (2b-2e) and RMP (1 , positive control) were 
prepared as described in the manual.  The 96 well plate was removed from the incubator 
and liquid from each well was discarded before adding 100 !L of the dilutions to the 
specific wells.  Each dilution of the rifamycin derivative was tested in duplicate.  The 
plate was placed in the 5% CO2/37ºC incubator again for 24 h.  The next day, the 
CellTiter-Fluor Buffer and CellTiter-Fluor
TM
 were thawed at room temperature before 
adding 5 !L of CellTiter-Fluor
TM
 to 10 mL of CellTiter-Fluor Buffer.  The wells of the 
96 well plate were emptied again and 100 !L of CellTiter-Fluor
TM
 reagent was added to 
each well.  The plate was incubated for 1 h in the 5% CO2/37ºC incubator.  A Synergy 
H1 Hybrid Multi-Mode Microplate Reader (BioTek) was used to measure fluorescence 
(!ex=390 nm; !em=505 nm).  To obtain luminescence readings, the contents of ONE-
Glo
TM
 Assay Buffer were added to the ONE-Glo
TM
 Assay Substrate and then 100 !L of 
mixture was transferred into each well.  The plate was read after 5 min where the 
luminometer was set for 5 sec pre-shake with 5 sec/well read time.  The Relative 
Luminescence Units (RLU) and Relative Fluorescence Units (RFU) were determined as 
outlined under the “Quantitation of PXR Receptor Activation” section of the manual.  
The normalized luciferase activity (RLU/RFU) was divided by the normalized DMSO 
control to represent the data as ‘fold activation’ relative to the control.  The replicate data 
points were averaged and both the original data points and the average values were 
plotted as a function of log concentration versus PXR activation.  The average values 
 117 
were then fit by non-linear regression to a modified four parameter logistic equation 
using Kaleidagraph (Synergy Software, Essex, VT), 
y = 1+ [(M3– 1)/(1 + 10[(M1-M0)*M2])] 
where M3 is the ECMAX, and 1 is the lower limit of the assay, M0 is the log of the 
rifamycin concentration, M1 is the log of the EC50, and M2 is the Hill slope.  The data 
were normalized such that the lower limit was set to 1.  M1, M2, and M3 were fit by the 
regression. 
Microsome stability and Pharmacokinetic (PK) studies 
 Microsome stability and pharmacokinetics studies were performed in the Institute 
for Tuberculosis Research, University of Illinois, Chicago (see Appendix IV-4). 
Results 
Analogue Design and Synthesis 
Modeling was based on the 2.5 Å resolution structure of RBN in complex with 
the Thermus thermophilus RNAP holoenzyme (PDB ID: 2a68) (28).  From this structure 
and a related complex (PDB ID: 2a69; rifapentine in complex with the T. thermophilus 
RNAP holoenzyme), it was observed that the sigma factor hairpin loop might exist in two 
distinct physiologically relevant conformations, at least in the free holoenzyme.  The 
modeled RLZ/RNAP complex without bound water molecules is shown in Figure IV-2.  
RLZ (2a) is shown with bright green carbon atoms and the different molecular surfaces 
of the RNAP are shown as follows: ! subunit surface is colored white and light blue, !’ 
subunit is brown, and the sigma factor is dark green.  The interaction surfaces at 4.5 Å 
between the tail of analogue 2b and surrounding RNAP are shown in Figure IV-3.  
(Similar poses for RLZ and analogues 2c  – 2e  are shown in Figure IV-A1 (A-D) in 
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Figure IV-2:  The modeled RLZ/RNAP complex without bound water molecules. RLZ 
(2a) is shown with bright green carbon atoms. The RNAP molecular 
surface is shown with ! colored white and light blue, !’ in brown, and the 
sigma factor in dark green. 
 
 
Figure IV-3:  Interaction surfaces at 4.5 Å between the compound tail and surrounding 




Appendix IV-1.)  These representative analogues 2a – 2e  were then synthesized (the 
synthesis is described in Appendix IV-2). 
 
In vitro Inhibition of Wild-type and RMP-resistant Mutant MTB RNAPs   
The inhibition constants of the wild-type and three RifR mutants of the MTB 
RNAP by RLZ (2a) and analogues (2b – 2e) were determined via dose-response studies 
where each compound was tested in duplicate at the specified concentrations in Materials 
and Methods section.  To assess the additional binding of these analogues to the sigma 
factor, the MTB sigma factor (SigA) was expressed and purified and then incubated with 
the core enzyme for 30 minutes on ice to form a holoenzyme before initiating the assay.  
The band corresponding to SigA was observed on the SDS-PAGE after gel filtration of 
the preincubated sample of the core MTB RNAP and SigA, suggesting that the SigA did 
bind to form the holoenzyme (data not shown).  (The IC50 values for these analogues with 
the core RifR RNAPs were not evaluated due to the very low activity observed after 30 
min incubation of enzyme on ice.)  The data were plotted (% activity vs. log 
benzoxazinorifamycin concentration) and then fitted by nonlinear regression. The logIC50 
values and their standard errors (of the fit) are reported, with these roughly translating 
into a 20-25% error in the IC50 values (Table IV-A2 in Appendix IV-3).  The apparent 
IC50 values are listed in Table IV-1.  All of the benzoxazinorifamycins (2a – 2e) inhibit 
the wild-type MTB RNAP in the 10
-9
 M (nM) range.  The IC50 values for RLZ (2a) 
against the RifR mutants of MTB were much higher, in the 10
-4
 M (~100 !M) range.  
The most frequently observed MTB RifR mutant in clinical isolates, S450L, (18, 37) was 
inhibited at 2 to 5-fold lower concentrations of 2b, 2c  & 2e  relative to RLZ with 2d 
being essentially the same as RLZ.  The MTB D435V mutant was inhibited at 5 to 50-
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fold lower concentrations of 2b, 2c, 2d & 2e  relative to RLZ.  For the H445Y mutant, 
Rlz and 2b similar IC50 values; whereas, the other analogues (2c , 2d, 2e) were inhibited 
at 2.5-6 fold higher concentrations. 
Table IV-1:  In vitro RNAP IC50 Values (!M)
a
 for RLZ (2a) and Analogues (2b – 2e) 
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a 
IC50 is the concentration of rifamycin resulting in 50% inhibition of transcription.  
Errors of the logIC50 values are reported as described in the Material and Method Section.  
As a control the mutant RNAPs (D435V, H445Y, and S450L) without SigA were tested 
against RMP where the IC50 values are as follows: 313 !M (D435V), 830 !M (H445Y), 
and 126 !M (S450L).  The standard errors of the logIC50 values roughly translate into a 
20-25% error in the IC50 values. 
 
Activity against M. tuberculosis (H37RV) in Cell Culture 
Under aerobic conditions (MABA), all newly synthesized compounds 2b – 2e  
display superior activities (MIC90 values of 0.02 – 0.08 !M) relative to RMP (0.13 !M), 
but are less potent (5 to 40-fold) than RLZ (< 0.004 !M).  Under anaerobic conditions 
(LORA), activity for “one armed” compounds 2b – 2d (MIC90 values 0.35 – 0.40 !M) is 
essentially equivalent to RMP (0.46 !M), and these range from 4 – 18.5 fold higher than 
in the MABA.  Relative to RLZ, LORA potency for analogues 2b – 2d is lower (at least 
20-fold) with 2e  strikingly poor, being essentially inactive (MIC90 > 6.72 !M).   
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Table IV-2:  MIC90 Values (!M)
a
 of RMP (1) and Benzoxazinorifamycins 2a – 2e  vs. 
MTB 
 
 1 (RMP) 2a (RLZ) 2b 2c 2d 2e 
MABA 0.13 < 0.004 0.02 0.08 0.07 0.08 
LORA 0.46 < 0.017 0.37 0.35 0.40 > 6.72 
a 
The MIC90 is defined as the minimum concentration of the compound required to inhibit 
90% of bacterial growth.  Isoniazid (MABA: 0.24, LORA: >128), moxifloxacin (MABA: 
0.46), streptomycin (MABA: 0.46), and PA824 (LORA: 2.53). 
Human Pregnane X Receptor 
RMP (1) is one of, if not the most, potent activators of hPXR (22).  RMP fills the 
ligand-binding pocket very well.  In Figure IV-4, four known rifamycins (RMP, 
rifapentine, RBN, and RLZ) were modeled in the hPXR binding site with spatial relation 
to resolved hPXR residues.  In particular, there are seven hPXR residues, namely Phe-
237, Ser-238, Leu-239, Leu-240, Pro-241, His-242 and Met-243, in very close proximity 
to the synthetic branch point for our synthesized analogues.  These residues are resolved 
in each of the five hPXR structures and other than one of the Phe-237 rings, have fairly 
conserved relative coordinates.  This, along with the presence of Pro-241, would suggest 




Figure IV-4:  Clinical rifamycins modeled into the hPXR binding pocket. 
 
To probe for hPXR activation, the commercially available in vitro assay for hPXR 
activation (Puracyp, Inc.) was used.  The dose-response plots for the hPXR assay are 
shown in Figure IV-5.  RMP exhibited a high maximal degree of activation (~12-fold) 
and an EC50 value of ~2 !M.  RLZ did not display hPXR activation at concentrations as 
high as 25 !M.  But RLZ did show ~2-fold receptor activation along with ~2-fold loss of 
cell viability at 100 !M.  Analogue 2d was fit to a dose-response curve that revealed a 6-
fold maximal activation of hPXR and an EC50 of ~6 !M.  Analogue 2d also started to 
exhibit loss of cell viability at 25 !M; therefore, the 100 !M data point was not used in 
the dose-response curve fit (Figure IV-6 and Table IV-A3 in Appendix IV-3).   Analogue 
2e shows hPXR activity very similar to that of RLZ, with no activation or loss of cell 
viability below 25 !M and ~3-fold activation and ~25% loss of cell viability at 100 !M.  
Analogues 2b and 2c were essentially identical with ~3-fold hPXR activation at 6.25 !M 
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Figure IV-6:  Effect of Rifampin (top) and Benzoxazinorifamycins (bottom) on DPX2 




Microsome Stability and Pharmacokinetics (PK)    
RLZ (2a) and analogue 2b were evaluated for metabolic stability in human 
microsomes.  Both were relatively stable with estimated half-lives of 65 and 54 min, 
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respectively (Table IV-3).  Similarly, the estimated half-life of 2a in mouse microsomes 
was 53 min while that of 2b was 141 min. 




% Remaining compound after 
30 min incubation in 
microsomes  t1/2 (min)  
Compound Mouse Human Mouse Human 
2a (RLZ) 67 73 53 65 
2b 86 68 141 54 
 
The PK of analogue 2b was assessed using a suspension prepared in 
carboxymethylcellulose (0.05% CMC).  In the single dose study, 2b was detected in the 
blood but the signal was below the lower limit of quantitation.  The Cmax was 0.0185 µM 
at a Tmax of 1 h.  However, analogue 2b appeared to accumulate in the blood of mice that 
were dosed once daily for 5 consecutive days with a Cmax of 1.74 µM at a Tmax of 2 h, 
which is 100-fold higher than that observed after a single oral dose (Figure IV-A4 in 
Appendix IV-4).  In the lung tissue of these mice, 2b was also detected at a concentration 
of 1.79 ug/g (around 0.4 µM), but only exceeded the MIC of 0.02 µM for ~4 h (Figure 
IV-A4). 
Discussion 
Recent determinations of the three-dimensional structures of rifamycins bound to 
RNAP provide a conceptual framework for structure-based discovery of improved 
rifamycins (27, 28).  In addition, the design of these novel analogues was based on 
benzoxazinorifamycins that have shown improved antimicrobial activity against MTB (8, 
9).  Previously, C-5’ benzoxazinorifamycin and C-3’ hydroxy derivatives have been 
synthesized where RLZ was selected as the most promising derivative (9).  Apart from an 
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obscure report on the synthesis of a small series of simple benzoxazinorifamycin C-3’ 
monoethers (38), there are no examples of more elaborate ethers that have been 
incorporated onto a rifamycin S scaffold utilizing the strategy outlined here.  These 
analogues are the first example (as far as we know) where structure-based design has 
been utilized to elaborate the ansa-napthalene core in a novel way that would lead to 
enhanced binding affinity to both WT MTB RNAP and RifR mutants. 
Although modeling was based on Thermus thermophilus RNAP, the rifamycin 
binding site is highly conserved among prokaryotes (27, 39); therefore, this structure 
provides a good foundation for understanding how proposed rifamycin analogues may 
interact with the MTB RNAP.  The designed analogues ranged in size, flexibility, and 
spatial variation with the likelihood of increasing potency by one or more of the 
following: (a) making additional contacts with the sigma factor, !, and/or !’ regions of 
the RNAP and (b) interfering with the binding of the sigma factor and/or further 
occluding the channel.  The modeled complexes seen in Figure IV-3 and Figure IV-A1 
(A-D) illustrate that the benzoxazinorifamycins have the potential to interact with 
different regions of RNAP. 
Previously, the effect of RLZ on E. coli and Mycobacterium avium RNAPs was 
examined and compared to RMP.  The IC50 value of RLZ was higher than RMP for both 
RNAPs (E. coli: RLZ, 0.138 "M; RMP, 0.122 "M; M. avium: RLZ, 0.213 "M; RMP 
0.085 "M).  Therefore, it was concluded that the greater antibacterial activity of RLZ (a 
more hydrophobic compound) is due to greater permeability into the cell (40).  Here, the 
IC50 values of RLZ and analogues 2b – 2d were determined for the WT and the three 
RifR mutants (Table IV-1).  The lower limit of detection of the rolling circle transcription 
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assay is an IC50 value of ~5 nM, so it is quite possible that these analogues have true IC50 
values that are much lower; therefore, a more sensitive assay needs to be developed to 
determine the very low IC50 values.  RLZ and all other analogues inhibit the WT MTB 
RNAP at 10
-9
 M (nM) range with and without SigA.  The IC50 values for RLZ with the 
RifR mutants of MTB were much higher, in the 10
-4
 M (~100 !M) range.  Increasing the 
concentration of RifR RNAPs to 100 nM and the binding of SigA seemed to stabilize the 
MTB RNAPs, which allowed the IC50 values of each analogue to be determined and 
compared to the one another. Here the IC50 values of RLZ with RifR RNAPs were similar 
to those observed for RMP (listed underneath Table IV-1).  Previously, RLZ has been 
reported to be active against RifR strains including the D435V mutant, but RifR MTB 
strains with mutations at His445 and Ser450 (major mutation sites) were still resistant to 
RLZ (13, 15-18).  However, our data indicates that RLZ has a higher apparent IC50 value 
for the D435V mutant than the other two RifR mutants (Table IV-1).  The results from 
this very limited series of analogues provide proof of principle that the potency of 
rifamycins towards RifR MTB RNAPs can be substantially improved and the range of 
inhibition by the analogue depends on the type of RifR mutation. 
RLZ was the most potent under both MABA and LORA conditions.  The MABA 
MIC90 value was comparable to what has been reported previously for MTB H37RV strain 
(MIC90 value 0.004 !M) (16).  Analogues 2b – 2e  had improved antimicrobial activity 
compared to RMP but were less potent than RLZ.  However analogue 2e  had a much 
higher LORA MIC90 value (> 6.72 !M) where the addition of the RLZ side chain into the 
5’-position of 2e  introduces another basic moiety, which may impede its transport across 
the cell membrane of the non-replicating bacterial strain of the LORA. 
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In addition to designing analogues that might be more potent against WT and 
RifR RNAPs, these novel compounds were also expected to reduce Cyp450 induction 
effects.  Cyp450 induction effects (due to activation of the hPXR) decrease with a 
progression from the RMP (hydroquinone core) to the RLZ (markedly modified quinone 
core) scaffold.  The relative potency of CYP3A4 induction is RMP > rifapentine > 
rifabutin > RLZ (41, 42).  Within this same order of structural subclasses, there is also a 
trend of RLZ possessing increased potency against drug-susceptible isolates of slow-
growing mycobacteria and better in vivo efficacy in mice (14).  Analysis of a recent 
structure of RMP (1) bound to the hPXR suggests that these elaborations may have the 
significant added benefit of reducing the affinity of the analogues for hPXR, thereby 
reducing CYP450 induction activity (22).  The hPXR ligand-binding pocket is large, 
flexible, and capable of adapting itself to bind a large variety of ligands (22).  It appears 
the tails of these benzoxazinorifamycins may prevent binding to hPXR by projecting into 
rigid, sterically encumbered regions of hPXR.  Therefore, the diminished binding to 
hPXR would then presumably reduce induction of CYP450s. 
The activation of hPXR by these novel analogues was then assessed.  RLZ as 
reported previously does not activate the hPXR (41).  Unfortunately, the other analogues 
did exhibit hPXR activation up to a certain concentration before cell toxicity was 
observed (Figure IV-6).  The apparent toxicities (in this cell line) of 2b and 2c is 
currently unexplained.  Further studies in this and other cell lines are needed to confirm 
this toxicity and to probe the responsible mechanism.  The lower toxicities of 2d and 2e 
show that improved rifamycin analogues are possible.  It seems likely that the flexible 
side chains may allow for the side chains to adopt a conformation that minimizes the 
 129 
clash with the hPXR ligand binding pocket.  The observation that 2e is very similar to 
RLZ in hPXR activation is consistent with this hypothesis since 2e is a very close 
analogue of RLZ and has both sides chains, thereby reducing their degrees of freedom.  It 
should be noted that at least for the wild-type RNAP, there is ~1000 fold difference 
between the RNAP IC50 and the threshold for apparent cytotoxicity.  Nevertheless, the 
lower toxicity of and hPXR activation by 2e shows that novel rifamycin analogues with 
improved side effects can be made. 
Mouse and human microsomal studies of analogue 2b show it to have excellent 
metabolic stability relative to RLZ (2a).  The pharmacokinetics of 2b showed 
accumulation of the compound in plasma after multiple dosing with an apparent half-life 
of ~1-2 h, suggesting that compound levels are above the MIC ~7-8 h if the decay is 
linear.  This is corroborated by studies in lung tissue where levels of 2b exceeded the 
MIC of 0.02 µM for only ~4 h.  These studies suggest non-optimal pharmacokinetics for 
this compound, and that further SAR will be necessary to find a compound to take to in 
vivo efficacy studies. 
Conclusions 
We have utilized recent determinations of the three-dimensional structures of 
rifamycins bound to RNAP to design and synthesize a novel subclass of 
benzoxazinorifamycins (2b – 2e), possessing a range of size, flexibility, and spatial 
variation to interact with the sigma hairpin loop and other regions of the RNAP complex.  
Relative to RLZ (2a), these analogues generally displayed superior affinity toward WT 
and RifR mutants of the MTB RNAP but lower antitubercular activity in cell culture 
(under both aerobic and anaerobic conditions).  We have also utilized information from 
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the crystal structure of RMP (1) bound to hPXR as part of our design strategy toward 
analogues 2b – 2e , and have determined that analogue 2e  displays lowered affinity for 
hPXR relative to RMP (1) and similar to RLZ (2a), thereby suggesting a potential for 
reduced CYP450 induction activity.  Mouse and human microsomal studies of analogue 
2b show it to have excellent metabolic stability; mouse pharmacokinetics in plasma and 
lung show accumulation of 2b, but with a half-life suggesting non-optimal 
pharmacokinetics.
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The structure of 2a68 was used as the starting point in our modeling studies (28).  
In brief, modifications made to the structure prior to its use in the modeling were as 
follows.  All water molecules and metals greater than 12 Å from RBN were removed.  
Four magnesium ions within 12 Å were converted to water molecules.  Partially missing 
residues were repaired.  Connection points for completely missing residues were greater 
than 35 Å from RBN, and were kept fixed in space during the energy minimizations.  All 
N and C termini, either real or as a result of missing residues, were acetylated and 
amidated respectively.  RBN was removed from the complex.  Hydrogen atoms were 
added to the proteins and the force field set to AMBER99 and charged.  Modifications 
were made to the RBN structure to produce the proposed analogue while keeping the 
unmodified atoms of RBN fixed in relation to the RNAP complex. 
A series of energy minimizations were then conducted to relax the positions of the 
modified atoms using the AMBER99 force field to gradients of 0.01.  Positions of 
hydrogen atoms were first relaxed with energy minimization.  Repaired residues except 
for their C alpha atoms, termini, and hydrogen atoms were then relaxed.  Lastly, the 
complete repaired residues, termini, and hydrogen atoms were relaxed.  Resulting 
confirmations of the repaired residues and termini were checked.  Bond orders for RBN 
were corrected, hydrogen atoms added, and the force field set to MMFF94x and charged.  
Positions of hydrogen atoms were relaxed with energy minimization using the MMFF94x 
force field to a gradient of 0.01.  RBN was returned to the complex in its original pose. 
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A second series of energy minimizations were then conducted using the 
MMFF94x force field to gradients of 0.01.  Positions of hydrogen atoms were first 
relaxed followed by positions of hydrogen atoms and all water molecules.  Atoms of the 
RBN were then included in the minimizations.  Lastly, positions of all RBN, water, and 
hydrogen atoms and protein residues having one or more atoms within 12 Å from RBN 
were relaxed with energy minimization.  The naphthalene ring of RBN drifted 
approximately 1 Å toward the cleft of the complex from their crystallographic positions 
with relatively minor movements of the protein residues well within the 2.5 Å resolution 
of the starting structure. 
 
Figure IV-A1 (A-D):  Interaction surfaces at 4.5 Å between the compound tail and 
surrounding RNAP for benzoxazinorifamycins 2a and 2c-e  in 




Chemistry and Synthesis 
The RLZ literature (43) suggested a strategy of annulating the benzoxazino 
moiety onto rifamycin S (12) with a suitably protected monoether (e.g., TBS) of 2-
aminoresorcinol, followed by ether deprotection and then side chain installation off the 
nascent phenol by any number of alkylation methodologies.  This was investigated, but 
yields were very poor and the scope of alkylation possibilities was quite limited (data not 
shown).  We opted instead to annulate a fully tethered 2-aminoresorcinol monoether onto 
the rifamycin S framework in a single step.  This allowed us to consider a wide range of 
tethers off the “southeastern” part of the rifalazil-type template, and more importantly, 
minimized difficult synthetic transformations and product purifications involving the 
complex rifamycin S core to a single last step.  Thus, we set our sights initially on 
developing a robust procedure to intermediate 5 , which would serve as a key starting 
material for introduction of our chosen tethers.  While there are two reports for the 
synthesis of this compound (44, 45)
 
neither was deemed practical for our needs.  Instead, 
we pursued a two-step procedure.  Accordingly, dialkylation of 2-nitroresorcinol (3), 
similar to the literature procedure (46), gave a 95% yield of dibenzyl ether 4  which was 
then cleanly mono-debenzylated to  nitrophenol 5 (44) in 82% yield.  With 5  now in 
hand, we were ready to install our target tethers.  Phenolic alkylation with 2-
(diethylaminoethyl)ethyl chloride hydrochloride under standard conditions provided 6  in 
87% yield.  Hydrogenation of 6  utilizing Pearlman’s catalyst simultaneously reduced the 
nitro function and hydrogenolyzed the benzyl protecting group to give the 2-
aminoresorcinol ether 7  in 81% yield.  A similar sequence of reactions was followed to 
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provide ethers 11a, 11b.  Alkylation of 5  with 1,4-dibromobutane gave 8  in 93% yield, 
which was subsequently aminated with two mono-substituted piperazines to afford 
compounds 9a and 9b in 68% and 99% yields, respectively.  t-Boc deprotection of 9b 
followed by acylation of 9c  with 2-(1H-imidazol-1-yl)acetic acid provided 10 , the amide 
congener of 9a, in 72% yield.  Hydrogenation of 9a and 10  was conducted as described 
for 6  to provide the remaining 2-aminoresorcinol ethers 11a and 11b, respectively, in 
nearly quantitative yields.  Each 2-aminoresorcinol ether (7 , 11a, 11b) was then 
annulated onto rifamycin S (12) to provide target compounds 2b – 2d in 35 – 74% yields 
following a two-stage purification utilizing medium pressure and then preparative plate 
silica gel chromatography.  No effort was made to optimize the condensation reaction 
with rifamycin S, but we feel that this has the potential to be an efficient transformation. 
Having achieved the synthesis of our desired “one-armed” target molecules, we 
decided to make a single proto-type “two-armed” RLZ congener (2e) to test the 
chemistry of its synthesis and the effect of the additional side chain on biological activity.  
Thus, condensation of 2d with N-isobutylpiperazine under oxidative conditions as 
described for the synthesis of RLZ (2a) (43) gave a 74% yield of 2e  following rigorous 
purification.  The structural assignments of 2b – 2e  were supported by diagnostic peaks 
in the 
1








Reagents and conditions: (a)  benzyl bromide (for 3) and 1,4-dibromobutane (for 5), 
Cs2CO3, DMF, 25 °C, 12-16 h, 93-95%; (b)  BCl3, DCM, -78 °C, 1 h, 82%; (c)  
Et2NCH2CH2Cl ! HCl, Cs2CO3, acetone, 50 °C, 3 h, 93% (d)  20% Pd/C, H2 (40 psi), 25 
°C, 20-40 h, MeOH:HOAc (9:1) for 6 ; MeOH:10% aq HCl (9:1) for 9a,10 ; 81 – 98%; 
(e) 1-[2-(1H-imidazol-1-yl)ethyl]piperazine or 1-Boc-piperazine, DIPEA, CH3CN, reflux, 
12-18 h, 68-99%; (f)  TFA, DCM, 25 °C, 3 h;  (g)  2-(1H-imidazol-1-yl)acetic acid, 
DIPEA, EDC!HCl, HOBT, DMF, 25 °C, 16 h, 72% from 9b; (h)  7 , 11a, or 11b; p-
dioxane or 1,2-DCE, MnO2, 25 °C – reflux, 35 – 74%; (i) for 2d, 1-(2-
methylpropyl)piperazine, DMSO, MnO2, 2 h, 74%. 
 
Synthesis of RLZ and analogues 
(((2-Nitro-1,3-phenylene)bis(oxy))bis(methylene))dibenzene (4) 
 A mixture of 2-nitroresorcinol (3; 2.0 g, 12.9 mmol), Cs2CO3 (10.5 g, 32.2 
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mmol), benzyl bromide (3.39 ml, 28.4 mmol) and DMF (35 mL) was stirred at room 
temperature for 12 h. The mixture was diluted with ethyl acetate and washed sequentially 
with 1% aq HCl and brine. The organic phase was dried and concentrated to leave a 
yellow oil, which was diluted with 2-propanol to precipitate pure product. The solids 
were collected to leave 4 (4.35 g, 95%) as light yellow crystals: mp 87.5 - 88!C (lit(46) 
80!C); Rf  0.26 (hexanes : ethyl acetate, 5 : 1); 
1
H NMR (CDCl3) ! 7.3 (m, 10 H), 7.23 (t, 
J = 8.5 Hz, 1 H), 6.64 (d, J = 8.5, 2 H), 5.16 (s, 4 H); 
13
C NMR (CDCl3) ! 150.9, 135.6, 
130.9, 128.7, 128.2, 127.0, 106.2, 71.0; MS (ES
+




A solution of dibenzyl ether 4 (3.0 g, 8.95 mmol) in dichloromethane (80 mL) at -
78!C was treated drop-wise with boron trichloride (13 mL, 1M in heptane) during which 
the color changed to dark purple. The reaction was monitored by TLC and stirred at -78!
C until all starting material was consumed (1 h).  Methanol (5 mL) was added drop-wise 
and the mixture was brought to room temperature, cautiously diluted with 5% aq sodium 
bicarbonate, and then extracted with dichloromethane (2x).  The combined extracts were 
dried and concentrated to an orange oil that was purified by flash silica gel 
chromatography eluting with hexanes : ethyl acetate (5 : 1). Product fractions were 
pooled and concentrated to give 5 (1.79 g, 82%) as a bright yellow solid: mp 67 - 67.5 !
C; Rf  0.24 (hexanes : ethyl acetate, 5 : 1); 
1
H NMR (CDCl3) ! 10.18 (brs, 1 H), 7.4 (m, 2 
H), 7.3 (m, 4 H), 6.72 (d, J = 8.5 Hz, 2 H), 6.6 (d, J = 8.5 Hz, 2 H), 5.21 (s, 2 H); 
13
C 
NMR (CDCl3) ! 155.7, 154.7, 135.6, 135.4, 128.7, 128.2, 126.9, 111.0, 105.1, 71.4; MS 
(ES
+






A mixture of nitrophenol 5 (1.31 g, 5.4 mmol), 2-(diethylaminoethyl)ethyl 
chloride hydrochloride (1.2 g, 7 mmol), Cs2CO3 (4.37 g, 13.4 mmol) and acetone (20 
mL) was stirred at 50!C for 3 h. The mixture was filtered and the filtrate was 
concentrated to a residue that purified by flash silica gel chromatography eluting with 
hexanes : ethyl acetate (5 : 1). Product fractions were pooled and concentrated to leave 6 
(1.71 g, 93%) as a light yellow oil: Rf = 0.22 (CH2Cl2 : methanol, 95 : 5); 
1
H NMR 
(CDCl3) ! 7.3 (m, 6 H), 6.62, (dd, J1 = 3.6 Hz, J2 = 14.1 Hz, 2 H), 5.16 (s, 2 H), 4.1 (t, J = 
10.5 Hz, 2 H), 2.8 (t, J = 10.5 Hz, 2 H), 2.6 (q, J = 11.9 Hz, 4 H), 1.0 (t, J = 11.9 Hz, 6 
H); 
13
C NMR (CDCl3) ! 151.2, 150.8, 135.6, 130.9, 128.6, 128.2, 127.0, 105.9, 105.6, 
70.9, 68.5, 51.2, 47.9, 11.9; MS (ES
+




2-(Diethylamino)ethyl ether 6 (1.8 g, 5.2 mmol) was dissolved in 10% acetic acid 
in methanol (50 mL) in a 250 mL Parr hydrogenation bottle. Catalyst (20% Pd(OH)2/C, 
0.1 g) was added and the mixture was hydrogenated at 40 psi H2 for ~20 h. The reaction 
mixture was rapidly filtered over Celite®, and the filtrate was concentrated and diluted 
with ethyl acetate. The solution was washed with 5% aq sodium carbonate, dried, and 
concentrated to a brown solid that was triturated in hot hexanes.  The solids were 
collected and dried to leave 7 (0.95 g, 81%): mp 91 - 91.5!C; Rf 0.21 (CH2Cl2 : 
methanol, 85 : 15); 
1
H NMR (CDCl3) ! 6.55 (t, J = 7.7 Hz, 1 H), 6.4 (m, 2 H), 4.07 (t, J = 
5.8 Hz, 2 H), 2.91 (t, J = 5.8 Hz, 2 H), 2.7 (m, 4 H), 1.1 (t, J = 7.1 Hz, 6 H); 
13
C NMR 








To a mixture of DMF (5 mL), 1,4-dibromobutane (5 mL) and Cs2CO3 (1.66 g, 5.1 
mmol) was added slowly a solution of nitrophenol 5 (0.5 g, 2.0 mmol) in DMF (5 mL). 
The mixture was stirred at room temperature for 16 h, and then DMF was removed in 
vacuo to leave an oil that was distributed between 1% aq HCl and ethyl acetate. The 
organic phase was dried and concentrated to a light yellow oil that was purified by flash 
silica gel chromatography eluting with hexanes : ethyl acetate (6 : 1). Product fractions 
were pooled and concentrated to give 8 (0.702 g, 93%) as a light yellow oil: Rf 0.45 
(hexanes : ethyl acetate, 2 : 1); 
1
H NMR (CDCl3) ! 7.36 (m, 5 H), 7.26 (m, 1 H), 6.61 (m, 
2 H), 5.16 (s, 2 H), 4.08 (t, J = 5.8 Hz, 2 H), 3.46 (t, J = 6.3 Hz, 2 H), 2.02 (m, 2 H), 1.92 
(m, 2 H); 
13
C NMR (CDCl3) ! 151.1, 150.9, 135.6, 131.0, 128.7, 128.2, 127.0, 106.1, 
105.6, 70.9, 68.4, 33.4, 28.9, 27.5; MS (ES
+




A solution of bromobutyl ether 8 (1.0 g, 2.6 mmol), 1-[2-(1H-imidazol-1-
yl)ethyl]piperazine (0.52 g, 2.9 mmol; Oakwood Products Inc.), N,N-
diisopropylethylamine (5 mL) and acetonitrile (18 mL) was heated at reflux overnight. 
The solution was concentrated and the residue was distributed between dichloromethane 
and 5% aq sodium carbonate. The organic phase was dried and concentrated to an orange 
oil that was purified by flash silica gel chromatography eluting with dichloromethane : 
methanol : NH4OH (90 : 10 : 0.5). Product fractions was pooled and concentrated to 
leave 9a (0.86 g, 68%) as an oil: 
1
H NMR (CDCl3) ! 7.53 (s, 1 H), 7.36-7.22 (m, 6 H), 
7.03 (s, 1 H), 6.97 (d, J = 1.1 Hz, 1 H), 6.61 (m, 1 H), 5.15 (s, 1 H), 4.05 (t, J = 6.3 Hz, 2 
H), 4.01 (t, J = 6.5 Hz, 2 H), 2.67 (t, J = 6.5 Hz, 2 H), 2.48 (bs, 8 H), 2.36 (t, J = 6.5 Hz, 2 
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H), 1.79 (m, 2 H), 1.61 (m, 2 H); 
13
C NMR (CDCl3) ! 151.3, 150.8, 137.4, 135.6, 132.8, 
130.9, 129.2, 128.7, 128.2, 127.0, 119.3, 105.8, 105.6, 70.9, 69.3, 58.6, 57.8, 53.3, 53.0, 
44.7, 26.9, 23.1; MS (ES
+
) m/z 480.1 (M+H)
+
. 
tert-Butyl 4-(4-(3-(benzyloxy)-2-nitrophenoxy)butyl)piperazine-1-carboxylate (9b) 
A solution of bromobutyl ether 8 (0.4 g, 1.05 mmol), 1-Boc-piperazine (0.282 g, 
1.514 mmol) N,N-diisopropylethylamine (4 mL) and acetonitrile (10 mL) was heated at 
reflux for 12 h. The solution was concentrated and distributed between ethyl acetate and 
brine. The organic phase was dried and concentrated to residue that was purified by flash 
silica gel chromatography eluting with ethyl acetate. Product fractions were pooled and 
concentrated to leave 9b (0.505 g, 99%): 
1
H NMR (CDCl3) ! 7.36 (m, 4H), 7.31 (m, 1 
H), 7.24 (m, 1 H), 6.61 (m, 2 H), 5.16 (s, 2 H), 4.06 (t, J = 6.2 Hz, 2 H), 3.41 (t, J = 7.0 
Hz, 4 H), 2.36 (t, J = 7.0 Hz, 4 H), 1.80 (m, 2 H), 1.62 (m, 2 H), 1.46 (s, 9 H), 1.26 (t, J = 
7.2 Hz, 2 H); 
13
C NMR (CDCl3) ! 154.9, 151.5, 150.9, 135.8, 131.0, 128.8, 128.3, 127.1, 








Trifluoroacetic acid (2 mL) was added dropwise to a solution of 9b (0.505 g, 1.04 
mmol) in dichloromethane (8 mL), and the resultant mixture was stirred at room 
temperature for 3 h.  The solution was concentrated to leave 9c (0.52 g, quantitative) as 
the crystalline trifluoroacetate salt.  This was then dissolved into DMF (10 mL) and N,N-
diisopropylethylamine (3 mL), and the mixture was stirred at room temperature for 10 
min followed by treatment with 1-ethyl-3-[3-dimethylamino propyl]carbodiimide 
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hydrochloride (EDC!HCl; 0.22 g, 1.14 mmol), N-hydroxybenzotriazole (HOBt; 0.175 g, 
1.14 mmol) and 2-(1H-imidazol-1-yl)acetic acid (0.197 g, 1.56 mmol; Tokyo Chemical 
Industry Co. Ltd.) After stirring under N2 for 16 h, DMF was removed in vacuo and the 
residue was distributed between dichloromethane and 5% aq sodium carbonate. The 
organic phase was dried and concentrated to an oil that was purified by flask silica gel 
chromatography eluting with dichloromethane : methanol : NH4OH (95 : 5 : 0.5). Product 
fractions were pooled and concentrated to give 10 (0.37 g, 72%) as a yellow oil: 
1
H NMR 
(CDCl3) ! 7.49 (s, 1 H), 7.36 (m, 5 H), 7.26 (m, 1 H), 7.09 (s, 1 H), 6.95 (s, 1 H), 6.61 
(m, 1H), 5.16 (s, 2 H), 4.75 (s, 2 H), 4.07 (t, J = 5.9 Hz, 2 H), 3.62 (m, 2 H), 3.44 (m, 2 
H), 2.42 (t, J = 4.9 Hz, 4 H), 2.39 (t, J = 7.2 Hz, 2 H), 1.81 (m, 2 H), 1.62 (m, 2 H); 
13
C 
NMR (CDCl3) ! 164.4, 151.3, 150.8, 138.0, 135.6, 131.0, 129.5, 128.7, 128.2, 127.0, 







Compound 9a (0.86 g, 1.8 mmol) was dissolved in a mixture of 10% aq HCl (10 
mL) and methanol (90 mL) in a Parr hydrogenation bottle. Catalyst (20% Pd(OH)2/C, 
0.05 g) was added and the mixture was hydrogenated at 40 psi H2 for ~40 h. The reaction 
mixture was rapidly filtered over Celite®, and the filtrate was concentrated and diluted 
with ethyl acetate. The solution was washed with 5% aq sodium carbonate, dried, and 
concentrated to give 11a (0.61 g, 95%) as a brown solid:
 1
H NMR (CDCl3) ! 7.56 (s, 1 
H), 7.05 (s, 1 H), 6.96 (s, 1 H), 6.52 (t, J = 7.2 Hz, 1 H), 6.44 (s, 1 H), 6.37 (d, J = 8.0 Hz, 
1 H), 3.98 (m, 4 H), 2.66 (t, J = 6.2 Hz, 2 H), 2.49 (bs, 8 H), 2.41 (t, J = 6.5 Hz, 2 H), 
1.78 1.68 (m, 2 H); 
13
C NMR (CDCl3) ! 147.6, 145.5, 128.6, 124.9, 119.4, 117.3, 108.7, 
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103.7, 68.1, 58.4, 58.2, 53.0, 50.4, 44.7, 27.5, 23.3; MS (ES
+





Compound 10 (0.37 g, 0.75 mmol) was dissolved in a mixture of 10% aq HCl (5 
mL) and methanol (45 mL) in a Parr hydrogenation bottle. Catalyst (20% Pd(OH)2/C, 
0.02 g) was added and the mixture was hydrogenated at 40 psi H2 for ~40 h. Workup as 
described above for the synthesis of 11a gave 11b (0.27 g, 98%) as a brown solid: 
1
H 
NMR (CD3OD) ! 7.78 (s, 1 H), 7.13 (s, 1 H), 7.06 (s, 1 H), 6.58 (m, 1 H), 6.43 (m, 2 H), 
5.08 (s, 2 H), 4.03 (t, J = 5.9 Hz, 2 H), 3.66 (s, 2 H), 3.62 (s, 2 H), 2.75 (s, 2 H), 2.65 (m, 
4 H), 1.82 (m, 4 H); 
13
C NMR (CD3OD) ! 174.8, 165.8, 148.0, 145.8, 138.1, 126.0, 
123.0, 121.3, 118.2, 107.8, 103.5, 67.7, 57.3, 52.1, 51.8, 43.5, 40.9, 26.8, 22.2, 20.1; MS 
(ES
+




A mixture of aminophenol 7 (0.336 g, 1.5 mmol), rifamycin S (12; 2.085 g, 3 
mmol) and 1,4-dioxane (20 mL) was stirred at room temperature overnight. The mixture 
was then concentrated to a black solid that was dissolved in 20 mL of methanol and 
treated with MnO2 (0.3 g, 3.45 mmol). The mixture was stirred at room temperature for 
30 min, filtered over Celite®, and the filtrate concentrated to a dark residue that was 
purified by flash silica gel chromatography eluting with dichloromethane : methanol (95 : 
5 to 90 : 10). Product fractions were pooled and concentrated to give partially purified 2b 
as a deep purple solid. Further purification by preparative TLC was conducted on a 20 
mg scale, eluting the plate with dichloromethane : methanol (90 : 10). The yield was 
~55%:  Rf 0.58 (dichloromethane : methanol, 85 : 15); HPLC tR 6.1 min (95.4% purity); 
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1
H NMR (CDCl3) ! 7.48 (t, J = 8.4 Hz, 1 H), 6.92 (d, J = 8.2 Hz, 2 H), 5.98 (d, J = 15.4 
Hz, 2 H), 5.14 (bs, 2 H), 4.97 (m, 1 H), 4.41 (t, J = 11.6, 2 H), 3.29 (s, 2 H), 3.13 (s, 1 H), 
3.08 (s, 3 H), 3.01 (d, J = 9.3, 2 H), 2.65 (m, 4 H), 2.29 (s, 3 H), 2.09 (s, 3 H), 2.05 (s, 3 
H), 1.79 (s, 3 H), 1.70 (m, 2 H), 1.60 (m, 2 H), 1.25 (s, 3 H), 1.15 (t, J = 7.1 Hz, 6 H), 





; HRMS (MALDI) calcd for C49H61N3O13 [(M + H)
+
], 900.4277; found 
900.4269. 
Benzoxazinorifamycin (2c) 
A mixture of aminophenol 11a (80 mg, 0.22 mmol), rifamycin S (12; 220 mg, 
0.32 mmol) and 1,2-dichloroethane (10 mL) was stirred at room temperature for 16 h. 
The reaction mixture was then concentrated to a black solid that was dissolved in 10 mL 
of methanol and treated with MnO2 (80 mg, 0.92 mmol). The mixture was stirred at room 
temperature for 30 min, filtered over Celite®, and concentrated to a dark residue that was 
purified by flash silica gel chromatography eluting with dichloromethane : methanol : 
NH4OH (94 : 6 : 0.5). Product fractions were pooled and concentrated to give a solid that 
was further purification by preparative TLC, eluting the plate with dichloromethane : 
methanol (92 : 8). The product band was processed to give 2c (170 mg, 74%) as a dark 
purple solid: HPLC tR 5.15 min (91.7% purity); 
1
H NMR (CDCl3) ! 7.56 (s, 1 H), 7.48 (t, 
J = 8.4 Hz, 1 H), 7.04 (s, 1 H), 6.98 (s, 1 H), 6.92 (d, J = 8.3 Hz, 1 H), 6.80 (d, J = 8.2 Hz, 
1 H), 5.97 (m, 2 H), 5.12 (bs, 2 H), 4.94 (m, 1 H), 4.24 (t, J = 5.6 Hz, 2 H), 4.03 (t, J = 
6.5 Hz, 2 H), 3.09 (s, 3 H), 3.01 (d, J = 9.3 Hz, 1 H), 2.68 (m, 2 H), 2.52 (bs, 11 H), 2.29, 
(s, 3 H), 2.09 (s, 3 H), 2.05 (s, 6 H), 1.80 (s, 5 H), 1.69 (m, 2 H), 1.60 (m, 2 H), 1.25 (s, 3 
H), 0.93 (s, 3 H), 0.75 (s, 3 H), 0.64 (s, 3 H); MS (ES
+




(MALDI) calcd for C49H61N3O13 [(M + H)
+
], 1035.5074; found 1035.5095. 
Benzoxazinorifamycin (2d) 
Reaction of a mixture of aminophenol 11b (30 mg, 0.08 mmol), rifamycin S (12; 
102 mg, 0.15 mmol) and 1,2-dichloroethane (4 mL) and subsequent purification was 
carried out exactly as described above for the synthesis of 2c to provide 2d (29 mg, 
34.5%) as a dark purple solid: HPLC tR = 5.11 min (91.8% purity); 
1
H NMR (CDCl3) ! 
7.50 (m, 2 H), 7.10 (s, 1 H), 6.95 (m, 2 H), 6.87 (d, J = 8.3 Hz, 1 H), 5.98 (s, 1 H), 5.96 
(s, 1 H), 5.30 (s, 2 H), 4.95 (m, 1 H), 4.76 (m, 2 H), 4.25 (m, 2 H), 3.68 (s, 1 H), 3.63 (s, 
1 H), 3.49 (s, 1 H), 3.44 (s, 1 H), 3.11 (s, 3 H), 3.03 (s, 1 H), 2.58 (m, 2 H), 2.51 (m, 4 H), 
2.29 (s, 3 H), 2.09 (s, 3 H), 2.06 (s, 3 H), 1.86 (d, J = 8.5 Hz, 1 H), 1.80 (s, 3 H), 1.68 (s, 









RLZ analogue (2e) 
A mixture of benzoxazinorifamycin 2d (5.5 mg, 0.005 mmol), 1-(2-
methylpropyl)piperazine (2.3 mg, 0.016 mmol; Oakwood Products Inc.), MnO2 (5 mg, 
0.055 mmol) and DMSO (0.5 mL) was stirred at room temperature for 24 h and then 
filtered over Celite
®
. The filtrate was concentrated and purified by preparative TLC, 
eluting with dichloromethane : methanol (90 : 10). The product band was processed to 













Confirmation of MTB RNAP subunits and MTB RNAPs Inhibition 
Before moving further with the studies, it was important to confirm the bands 
observed on the SDS-PAGE were the MTB RNAP subunits rather than E. coli subunits 
or a mixture of the two.  Previously, the identity of MTB ! subunit was confirmed by 
Michigan Proteome Consortium via mass spectrometry.  Furthermore, the identity of the 
contaminating proteins were also determined as we especially wanted to confirm the band 




Figure IV-A3:  SDS-PAGE of WT MTB RNAP after size exclusion chromatography.  
Lane 1, LMW standard; Land 2, WT MTB RNAP. 
 
The seven bands (labeled A-G in Figure IV-A3) were sent to Applied Biomics 
where the identity of each band was determined.  As can be seen in Appendix Table IV-
A1, band A contains both MTB # and #’ subunits and MTB ! subunit is band E.  
However, the MTB $ subunit was not confirmed because band G (assumed to be MTB $ 
subunit) resulted in being 50S ribosomal protein L28 (MW 9 kDa).  To be certain that the 
MTB $ subunit does not share homology with 50S ribosomal protein L28, the amino acid 
!
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sequences of the two proteins were aligned and very low sequence identity/homology 
was observed.  Therefore, the faint band right above band G could possibly be the MTB 
! subunit (since the MW of MTB ! subunit is 11.8 kDa).  Although MTB ! subunit has 
not been confirmed, the ! subunit has been reported to assist in assembling the RNAP 
and does not affect the activity of the enzyme.  Therefore, the confirmation of the main 
catalytic MTB RNAP subunits (", #, #’) is sufficient to eliminate the uncertainty of E. 
coli RNAP being present. To conclude, the activity observed in the assays was due to the 
MTB RNAP and not E. coli RNAP.  It was important to confirm that the E. coli sigma 
factor was not bound to the MTB RNAP since the assay for rifalazil analogues and the in 
vitro plasmid based transcription assay require using the MTB sigma factor, SigA.  The 
MTB SigA can be added knowing that the E. coli sigma factor is not already bound.  
Band C at ~70 kDa was confirmed to not be the E. coli $
70
.  The amino acid sequence of 
E. coli $
70
 and the fused UDP-L-Ara4N formyltransferase/UDP-GlcA C-4’-





Table IV-A1:  MTB RNAP Subunit Confirmation 
Band/Method MW Identity (%) 
A 
(NanoLC) 
146.6 kDa (beta’) 
129.8 kDa (beta) 
DNA-directed RNA polymerase beta’ and 
beta subunits (M. bovis) (100%) 
B 
(MALDI-TOF/TOF) 
104.9 kDa Oxoglutarate dehydrogenase (succinyl-
transferring), E1 component (E. coli) (100%) 
C 
(MALDI-TOF/TOF) 
74.2 kDa Fused UDP-L-Ara4N 
formyltransferase/UDP-GlcA C-4’-
decarboxylase (E. coli) (100%) 
D 
(MALDI-TOF/TOF) 
44 kDa Dihydrolipoamide succinyltransferase 
(Shigella boydii) (100%) 
E 
(MALDI-TOF/TOF) 
37.7 kDa DNA-directed RNA polymerase alpha 
subunit (MTB) (100%) 
F 
(MALDI-TOF/TOF) 
42.7 kDa Penicillin-binding protein pbpA (MTB) 
(90%) *low confidence 
G 
(MALDI-TOF/TOF) 
9 kDa 50S ribosomal protein L28 (Reinekea sp.) 
(100%) 
 
The NanoLC method was preferred for Band A since it is more sensitive and able to 








Table IV-A2:  Log IC50s and Standard Errors of the Fits for RLZ (2a) and Analogues (2b – 2e) against RNAP 
Log IC50
a








































































 The log IC50 values are such that the IC50 values will be in !M.  Negative log IC50 values reflect IC50 values less than !M (e.g., in the 
nM range).  Values were fit to a four parameter logistic regression model with the top and bottom limits set at 100 and 0 respectively.  
b
 The average error is ~10 %, which roughly translates to 20-25% in the IC50.  
c








Table IV-A3:  Mean Relative Fluorescence Units (RFU)
a
 for RMP (1) and Benzoxazinorifamycins (2a – 2e) in the hPXR Activation 
Assay 
 
  RMP (1)   2a (RLZ) 2b 2c 2d 2e 
20 !M 48427 100 !M 35250 11137 10881 11625 29476 
10 !M 59067 25 !M 63418 11591 12218 43077 24305 
5 !M 61839 6.25 !M 70784 43495 49297 66941 47757 
1 !M 64852 1.56 !M 73704 68860 60314 68172 50761 
0.5 !M 59756 0.39 !M 74950 69532 63570 68936 43211 
0.1 !M 63078 0.098 !M 72399 71149 65632 68628 43120 
a , 






Microsome Stability and Pharmacokinetic (PK) Studies 
Microsome stability 
Test compound stock solutions were prepared at 200 µM in acetonitrile.  Two 
microliters was added to 198 uL PBS containing 1 mg/mL human or mouse microsome.  
After mixing, 25 uL aliquots were dispensed in triplicate in 96-well plates.  Control and 
reaction wells received 25 uL of PBS and of 2 mM NADPH in PBS, respectively.  Plates 
were incubated for 30 min at 37 °C with shaking at 600 rpm.  Internal standard solution 
(150 !L) was added to each well to quench the reaction.  For controls, quenching was 
done prior to incubation.  Plates were centrifuged at 4000g for 30 min. at 4°C and the 
supernatant was collected for analysis.  The percentage of compound remaining and half-
life of compound in microsomes were calculated according to the following formula: 
Percentage remaining =  
Half-life (min) = !
 
Pharmacokinetics of Analogue 2b 
(Previously described methods were followed (47, 48))   
Single dose study:  Analogue 2b was prepared in 0.5% CMC at 1 mg/mL.  
Healthy female BALB/c mice were administered 10mg/kg of the suspension via oral 
gavage.  Two mice per time point were used and 0.4 mg/kg fentanyl was given 15 min 
prior to bleeding by intraperitoneal injection.  For each mouse, at least 100 !L of venous 
blood was collected via retro-orbital bleeding in BD Vacutainer® spray-coated K2EDTA 










ice.  Blood was transferred to polypropylene tubes and centrifuged at 4,000g for 30 min 
at 4˚C.  The harvested plasma was transferred to new polypropylene tubes and stored at -
80˚C until analysis.  To each sample, 3x volume of chilled acetonitrile was added 
containing 0.2 !M internal standard (IS).  The solution was vortexed and then 
subsequently centrifuged at 10,000g for 15 min.  Calibration standard samples were 
prepared by spiking the stock solution of analogue 2b in acetonitrile into mouse plasma to 
yield the following concentrations: 0.097656, 0.195313, 0.390625, 0.78125, 1.5625, 
3.125, 6.25, 12.5, 25, 50 µM.  Supernatant was injected into an LC-MS/MS for analysis.  
In addition, a blank (blank plasma extracted with 3x volume of IS) and a double blank 
(blank plasma extracted with 3x volume of pure acetonitrile) were prepared.  The 
concentration of 2b in blood sample for each time point was then determined.  
Multiple dose study:  Mice were dosed once daily for 5 consecutive days by oral 
gavage.  Blood samples at time points 0.5, 1, 2, 4, 8 and 24h were collected and analyzed 
in the same way as the single dose study.  After collecting the blood, the mice were 
sacrificed by carbon dioxide asphyxiation.  Lung tissue was  aseptically removed, rinsed 
in 3 mL PBS, air dried on sterilized gauze pads,  weighed and suspended in 4x 
(solvent/tissue; w/v) PBS buffer.  Lung tissue was homogenized, mixed and extracted 
with 3x acetonitrile containing internal standard at 0.2 µM and centrifuged at 10,000 g for 
15 min at 4 ˚C.  The supernatant was collected for LC-MS/MS analysis.  Calibration 
standard lung samples were prepared by spiking the stock solution of compound (in 
methanol or acetonitrile) into homogenized mouse lungs and extracting with 3x volume 
acetonitrile to yield the following concentrations: 0.024, 0.049, 0.098, 0.195, 0.39, 0.78, 
1.56, 3.12, 6.25, 12.5, 25, 50 µM.  In addition, a blank (blank lung tissue extracted with 
!
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3x volume of IS) and a double blank (blank lung tissue extracted with 3x volume of pure 
acetonitrile) were prepared.  The concentration of 2b in lung tissue for each time point 
was then determined.  
(a) Single dose 
!
(b) Multiple dose 
!
Figure IV-A4:  Linear plasma mean concentration vs. time profile for analogue 2b in (a) 



































Figure IV-A5:  Linear lung tissue mean concentration vs. time profile for analogue 2b in 
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Developing a Direct Binding Assay Using a Dansyl-Conjugated Rifamycin 
 
Rifampin (RMP) is a tight binding inhibitor of wild-type (WT) RNA polymerase 
(RNAP), forming a stable noncovalent 1:1 complex.  RMP binds to and inhibits both the 
core RNAP and the holoenzyme (1-3).  The binding constant (KD; equilibrium 
dissociation constant) for prokaryotic RNAP is in the range of 10
-8
 M (4-7).  Previously, 
the KD has been determined for WT E. coli RNAP to be 10
-9
 M via radiochemical and 
fluorescence assays (5, 6, 8); however, the KD value for WT and rifamycin-resistant 
(RifR) MTB RNAPs has not been reported. 
Recently, Feklistov and colleagues have chemically attached fluorescein to the E. 
coli sigma factor (!
70
) to study rifamycin-RNAP interaction (8, 9), but there are no 
reports of developing a direct binding assay using a fluorophore-labeled rifamycin.  To 
characterize the interactions between MTB RNAP and our synthetic rifamycin analogues, 
we decided to develop a direct binding assay using a fluorescently labeled rifamycin.  
This would enable the use of competition binding assays to determine binding constants 
for an array of rifamycin analogues.  The dansyl group was selected as the fluorophore 
for our first attempt because it has been previously used to prepare fluorescent drug 
analogues (10, 11) and has a long history of use in probing binding interactions. 
The KD values of rifamycins and MTB RNAPs will allow for changes in binding 
free energy to be calculated.  We will then correlate the changes in binding free energy to 
!
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the predicted changes in molecular interactions between the rifamycins and the RNAP 
(based on the published crystal structure models (12, 13)).  Our goal is to use this 
information to enhance our understanding of the molecular mechanisms responsible for 
resistance and guide the development of new analogues with improved binding to the 
MTB RNAP and RifR mutants. 
Materials and Methods 
Unless otherwise specified, all reagents were purchased from Sigma-Aldrich (St. 




 Universal RNA Polymerase template was from Epicentre 
(Madison, WI).  Carbenicillin (disodium salt), corning microplates, bactotryptone, and 
yeast extract were from Fisher Scientific (Hampton, NH).  The E. coli BL21 (DE3) 
CodonPlus-RIPL and Epicurian coli XL2-Blue Ultracompetent cells were from Agilent 
Technologies (Santa Clara, CA).  Quanti-iT
TM
 RiboGreen RNA Reagent and 
RNaseOUT
TM
 Recombinant Ribonuclease Inhibitor were from Invitrogen (Carlsbad, 
CA).  The Ni-NTA His•Bind! resin was from Novagen (San Diego, CA).  The nucleotide 
triphosphates (NTPs) were from Roche Applied Science (Indianapolis, IN).  PhastGel 
Precast Gels and SDS Buffer Strips were from VWR (Arlington Heights, IL).  The Bio-





 mutations) was a generous gift from Dr. Michael Hubband 
(Pfizer Scientific).  Rifamycin S was from AAPharmaSyn LLC.  Rifampin was from 
Boche Scientific.  Dansyl chloride and dansyl amide were from Sigma-Aldrich. 
Synthesis of Dansyl-Conjugated Rifamycin (HX52) 
The dansyl-conjugated rifamycin (HX52) was synthesized by Hao Xu (3
rd
 year 




Figure V-1: Dansyl-conjugated Rifamycin (Compound 6; HX52)
!
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The WT and RifR MTB RNAPs and MTB SigA were prepared as described 
earlier in Chapter II and IV. 
In vitro Transcriptional Activity of MTB RNAPs and Dose Response Curves 
The RNAP activity and inhibition was estimated by the production of RNA 
synthesis as described (14).  The IC50 values were determined via dose response studies 
(Table V-1).  HX52 (6) was tested in duplicate (n=2).  The final concentration of the WT 
MTB RNAP was 10 nM, whereas the final concentrations of the RifR RNAPs were 100 
nM in the reactions. 
Determination of Minimal Inhibitory Concentration (MIC) Against MTB H37Rv 
Strains 
The compound was also evaluated for MIC90 vs. MTB H37RV using the 
Microplate Alamar Blue Assay (MABA) and the Low Oxygen Recovery Assay (LORA) 
(14-16).  Additionally, the MIC90 values were determined for E. coli by the microdilution 
method described previously (17, 18). 
HX52 Absorbance/Fluorescence Studies 
Absorbance and fluorescence spectra were measured using the Synergy H1 





In this work, the dansyl-conjugated rifamycin (HX52, 6) was synthesized by Hao 
Xu using the scheme illustrated in Figure V-1.  The dansyl group reacted with the 
secondary amine of (3) to yield the dansyl amide derivative (4)  that was then modified 
and attached to rifamycin S. 
Inhibition Studies 
The IC50 values of HX52 against WT and RifR MTB RNAPs were determined 
(Table V-1).  This dansyl-conjugated rifamycin does potently inhibit the WT MTB 
RNAP (with and without sigma factor, !
A
) with the IC50 values in the 10
-9
 M (nM) range; 
whereas, the RifR MTB RNAPs (+!
A
) were inhibited at higher concentrations with the 
IC50 values in the 10
-6
 M (!M) range. 
Table V-1.  In vitro RNAP IC50 Values (!M) for HX52 
 
 IC50 values 
WT RNAP (-!
A
) (Cf = 10 nM) 0.0146 
WT RNAP (+!
A
) (Cf = 10 nM) 0.0152 
D435V (+!
A
) (Cf = 100 nM) 343 
H445Y (+!
A
) (Cf = 100 nM) 267 
S450L (+!
A
) (Cf = 100 nM) 97 
 
The MIC90 values are also reported against the MTB virulent strain (H37RV) and 
three selected E. coli strains (Table V-2).  HX52 inhibited MTB with MIC90 values 9 nM 
and 0.93 !M for MABA and LORA, respectively.  The MIC90 values were higher for E. 




Table V-2.  HX52 MIC90 values against MTB and E. coli 
 
 MIC90 values (!M) 
MTB (H37RV)  
MABA 0.009 
LORA 0.93 
E. coli strains  
TG2 > 100 
DH5! > 100 




Compound HX52 was initially dissolved in DMSO to make a high concentration 
stock.  The compound was then diluted in RNAP storage buffer (10 mM Tris-HCl (pH 
7.9), 0.1 mM EDTA, 0.1 mM DTT, 0.1 M NaCl) to the final concentration of 100 nM in 
a total volume of 100 "L.  The dansyl conjugated compound excitation and emission 
maxima vary between 350-370 nm and 490-540 nm, respectively.  Unfortunately, when 
the sample, in the above buffer, was excited at 350 nm, there was no fluorescence 
emission observed (400-600 nm).  The absorbance of different rifamycins was measured 
from 250-600 nm (Figure V-2).  The dansyl-conjugated rifamycin (HX52) has a broad 
peak around the 350-370 nm region.  Possible explanations for this lack of fluorescence 
include: the tetracyclic chromophore (benoxazinonaphthyl) of the rifamycin moiety 
might quench the fluorescence of the dansyl group or fluorescence could be quenched 




Figure V-2:  Absorbance Spectra of Rifamycins. 
To investigate which of these explanations might apply, the following steps were 
taken.  The NMR of D–Cl and HX52 confirmed that the starting material and the end 
product were pure and stable (data not shown).  To see if the tetracyclic moiety of 
rifamycin quenches the fluorescence of the dansyl group, a direct comparison of 
fluorescence emission spectra of compound 5  and HX52 would have been ideal.  
Unfortunately, all of compound 5  was used to synthesize HX52 thus the fluorescence 
could not be determined.  Instead the fluorescence of dansyl amide (CAS# 1431-39-6; 
!ex=340 nm; !em=555–565 nm) was measured because dansyl amide is a fluorescent side 
product observed when D–Cl is attached to amino acids (Figure V-3).  We would have 
expected to see a similar fluorescence emission spectrum of our dansyl-conjugated 
rifamycin as the one observed for dansyl amide since the dansyl group reacted with an 
amine to form a dansyl amide derivative.  The dansyl amide was incubated with RMP to 
!
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determine if fluorescence is quenched in the presence of rifamycins but the data was 
inconclusive. 
 
Figure V-3:  Fluorescence emission spectrum of Dansyl-amide (in blue) in RNAP storage 
buffer.  The sample was excited at 340 nm and the emission spectrum was 
measured from 400-700 nm.  DMSO (control) can be seen in red. 
 
It is possible that the fluorescent dansyl tail is stacking on top of the tetracyclic 
moiety of HX52, thereby quenching the fluorescence.  To probe this, compound HX52 
was preincubated with RNAP for 10 min at 37
o
C, with the idea that the key interactions 
between the rifamycin core and RNAP would free the dansyl tail, but unfortunately 
fluorescence was not observed under these conditions (data not shown).  The dansyl 
group is a sensitive probe where the fluorescence is polarity/pH dependent; therefore, the 
HX52 itself was dissolved in different solvents (methanol, acetone, acetonitrile) and 
tested in different buffers (Tris buffers, bicarbonate buffers, phosphate buffers) at 
different pH values but still no fluorescence was observed (data not shown).  To make 
sure that a component of the buffer was not quenching the fluorescence, the compound 
!
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was tested in water and the same results were seen.  However, the compound was 
fluorescent when it was dissolved in 100% DMSO.  Optimal fluorescence was observed 
when !ex=360 nm with emission spectra from 400-700 nm.  The DMSO concentration 
was titrated in RNAP buffer (Figure V-4) to determine the effect of DMSO concentration 
on fluorescence.  Fluorescence was not seen at less than 60% DMSO.  Optimal 
fluorescence was observed at high DMSO concentrations (80-100% DMSO).  To 
determine if fluorescence could be seen when bound to RNAP, the compound was 
preincubated with the RNAP but fluorescence was not observed (data not shown). 
 
Figure V-4:  Fluorescence emission spectra of dansyl-conjugated rifamycin (HX52) in 






Previously, the reported equilibrium dissociation constant for wild-type E. coli 
RNAP and RMP is 10
-9
 M at 37
o
C determined via radioactive and fluorescence assays (5, 
6, 8, 19).  The radioactive assay consisted of using dextran-coated charcoal and 
radiolabeled [
14
C] RMP to determine the KD value (5, 19).  The [
14
C] RMP was mixed 
with the enzyme where the unbound RMP was adsorbed on the charcoal and the larger 
antibiotic-enzyme complex remained in solution.  The KD has also been determined via 
direct fluorescence titration where the binding of RMP leads to the partial quenching of 
the RNAP tryptophan residue (20).  Recently, Feklistov et al. have calculated the 
association, dissociation, and equilibrium constants by measuring rifampin-RNAP via 
monitoring the quenching of the fluorescence emission of fluorescein-labeled sigma 
factor (8).  Fluorescein, a fluorescent probe, was inserted at residue 517 of !
70
.  The 
probe was the FRET donor and the naphthyl group of rifampin was the FRET acceptor 
(9). 
Fluorescent probes are relatively small modifying agents used to label protein, 
nucleic acids, and drugs.  Advantages of a fluorescent assay include: nonradioactive, does 
not require separation of bound and free ligand, higher sensitivity, and adaptable to low 
volumes (10, 21).  There are a wide range of fluorescent probes available: fluorescamine, 
dialdehydes, ATTO-TAG reagents, FITC and other isothiocyanates, succinimidyl esters, 
and sulfonyl chlorides (www.invitrogen.com).  We elected to add the dansyl probe to 
make the rifamycin fluorescent.  Dansyl chloride (a sulfonyl chloride) is a well known 
reagent that has been utilized in areas such as pharmacology, toxicology, organic 
synthesis, and biochemistry (11).  Furthermore, it is useful in preparing fluorescent drugs 
!
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that are expected to bind to hydrophobic sites in proteins, membranes, or other biological 
receptors. 
The dansyl-conjugated rifamycin (HX52) was synthesized and assayed in 
inhibition studies.  The compound behaves similar to other rifamycins and binds to the 
WT MTB RNAP with a strong affinity and exhibits loss of affinity with the RifR MTB 
RNAPs.  From the MTB MIC90 values, it can be seen that the compound is able to 
permeate through the mycobacterial cell wall.  However, higher MIC90 values were 
observed with E. coli (including the !tolC strain) indicating that the compound is less 
able to permeate through Gram-negative bacteria and the higher MIC90 values do not 
appear to be due to efflux pump activity. 
Previously, dansyl-conjugated analogues have been reported to be highly 
fluorescent ("ex=350 nm; "em=490–540 nm).  Therefore, the addition of the dansyl probe 
to a rifamycin was expected to make the dansyl-conjugated rifamycin compound 
fluorescent.  Unfortunately, this dansyl-conjugated rifamycin (HX52) was not fluorescent 
in aqueous buffers.  Most likely the dansyl probe overlaps with the tetracyclic moiety of 
our synthesized rifamycin probe (due to the length and flexibility of the linker), which 
quenches the fluorescence.  As mentioned earlier, the intrinsic chromophore within 
rifamycins can be used as acceptors in fluorescence resonance energy transfer (FRET) 
measurements (6, 9, 20).  When the compound is in DMSO (a highly polar, aprotic 
solvent), the dansyl probe is presumably free in solution and fluorescent.  This is 
problematic because RNAP is not stable in #30% DMSO solutions and fluorescence of 
HX52 itself is not observed at that concentration of DMSO (19).  When HX52 was in less 




Unfortunately, the dansyl-conjugated rifamycin resulted in a nonfluorescent 
derivative.  In the future, a different fluorophore can be introduced that is not so sensitive 
to the assay conditions or else reduce the length of the linker such that the dansyl group 
cannot overlap with the rifamycin chromophore and quench the fluorescence.  Another 
option to attach the fluorophore to the RNAP/sigma factor (as described earlier by 
Feklistov and colleagues) or use radiolabeled RMP.  Due to the fact that rifamycins are 
retained by nitrocellulose filters, a nitrocellulose filter binding assay cannot be used to 
study rifamycin-RNAP interactions (22).  Once a direct binding assay has been 
established, the effects of WT and mutant MTB RNAPs will be analyzed to determine the 
equilibrium binding constant.  The KD values will allow the loss of binding free energy to 
be calculated.  This value will help answer the following questions: Does this value 
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Abbreviations used:  TB, tuberculosis; RNAP, DNA-dependent RNA polymerase; SigA, 
MTB housekeeping sigma factor A; WT, wild-type; RifR, Rifamycin-resistant; MTB, 
Mycobacterium tuberculosis; KD, equilibrium dissociation constant; D-Cl, dansyl-
chloride; HX52, dansyl-conjugated rifamycin; RMP, rifampin; NTP, ribonucleotide 
triphosphate; EDTA, ethylenediaminetetraacetic acid; DTT, dithiothreitol; RNA, 
ribonucleic acid; MABA, Microplate Alamar Blue Assay; LORA, Low Oxygen-
Recovery Assay; IC50, concentration of rifamycin resulting in 50% inhibition of 
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Tuberculosis (TB), an infectious disease caused by Mycobacterium tuberculosis 
(MTB), remains an important global public health problem (1, 2), mainly because of the 
number of multi-drug resistant and extensively-drug resistant strains that have become 
more prevalent over the years (3).  The existing anti-TB drugs are unable to treat these 
resistant strains and the number of new anti-TB drugs in clinical trials is limited to only 
nine candidates (4, 5).  Novel drug targets are proving to be increasingly difficult to 
identify and effectively attack.  One approach is to revisit proven targets and attempt to 
address deficiencies such as drug resistance.  In order to modify antibiotics to control the 
resistant strains, a better understanding of resistance needs to be achieved at the 
molecular level.  The mechanism of known drugs (e.g., rifampin and other rifamycins) 
needs to be thoroughly understood that will then lead to improved drug design and a 
better understanding of the resistant (e.g., RifR) mutants to guide further research. 
Rifampin (RMP) is a semi-synthetic rifamycin derivative that demonstrates strong 
bactericidal activity via inhibition of RNA polymerase (RNAP).  The mechanism of 
inhibition reported and confirmed (via crystal structure) for rifamycins is the “steric 
occlusion model” where rifamycins bind to the !-subunit and clash with the 5’-phosphate 
of the growing RNA chain during the initiation stage of transcription (6, 7).  Resistance 
to RMP is mainly due to point mutations within the 81 base pair region (amino acids 424-
!176 
456, MTB numbering) of the !-subunit, which alter the rifamycin-binding site leading to 
decreases in affinity for the rifamycins.  The three most prevalent RifR mutations found 
in MTB clinical isolates are Asp435Val, His445Tyr, and Ser450Leu, which result in 
disrupting key interactions between the enzyme and RMP (7-9).  Even though these 
mutations have been clinically isolated and studied in resistant MTB strains, no in vitro 
studies of purified resistant MTB RNAPs with rifamycins have been reported.  It is 
conceivable that a more potent rifamycin, which could potentially be active against these 
resistant strains, can be developed from the information obtained from these in vitro 
studies.  The purpose of this dissertation is to address the issue of rifamycin resistance in 
MTB and screen novel rifamycin analogues against RifR MTB RNAPs. 
We report the construction of co-overexpression vectors containing rpo genes that 
co-express the core subunits of wild-type and RifR mutants of MTB RNAP preceded by a 
single T7 promoter.  The three aforementioned amino acids were each mutated to the 
most prevalent substitution found in the MTB clinical isolates in the rpoB gene via site 
directed mutagenesis.  Initially, only the expression of MTB " subunit was observed; 
therefore, conditions (e.g., expression cell lines, expression temperature, and 
concentration of IPTG) were varied to express all 4 subunits.  The expression of MTB 
RNAP was successful in E. coli BL21 (DE3) CodonPlus RIPL cell line when expressed 
at 19
o
C for 20-24 hours.  The enzyme was then purified via nickel affinity 
chromatography and gel filtration.  The in vitro activity of the wild-type and RifR mutant 
MTB RNAPs was assessed via rolling circle transcription assay.  The final concentration 
of enzyme that was determined to be optimal (lowest concentration that gives a consistent 
and reliable signal) was 10 nM.  The apparent IC50 values for three key rifamycins 
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(rifampin, rifabutin, and rifaximin) were determined via dose response studies and these 
results indicate that the mutant RNAPs demonstrate greater than 10
3
-fold losses in 
affinity for rifamycins relative to wild-type MTB RNAP. 
Along with screening known rifamycins, a novel series of rifamycin S and 
rifampin analogues incorporating 8-amino, 8-thio, and 1,8-pyrazole substituents was also 
assayed.  The most prevalent mutation seen in clinical isolates is the mutation of amino 
acid Ser450 to Leu where the Ser450 residue directly interacts with the C-8 hydroxyl 
group of RMP via a hydrogen bond thus the Ser450Leu mutation affects the binding of 
the rifamycin (7-9).  The results from this screen confirm that the C-8 hydroxyl of RMP 
does form a hydrogen bond with Ser450 and that rifamycin resistance in the Ser450Leu 
mutant is due to loss of this hydrogen bond and loss of affinity for rifamycins.  
Unfortunately, none of the C-8 analogues displayed superior potency to their parent 
scaffolds.   
In addition, we report the screening of benzoxazinorifamycin derivatives.  The 
design of these analogues was based upon recent crystal structures in order to develop a 
more potent rifamycin by making additional contacts with the other RNAP subunits. (7, 
10).  The sigma factor and core RNAP were preincubated to form a holoenzyme prior to 
the addition of the analogue in case the analogue does make additional contacts with the 
sigma factor.  Overall, these novel benzoxazinorifamycin analogues displayed superior 
affinity toward wild-type and RifR mutants of the MTB RNAP compared to RMP but the 
IC50 values were still in the 10
-6
 M (!M) range with the RifR MTB RNAPs. 
RMP is a potent inducer of cytochrome P450 3A4 (CYP3A4, a drug metabolizing 
enzyme); whereas, rifalazil is not thus suggesting the design of rifamycins can be 
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improved where CYP3A4 induction is absent.  The expression of CYP3A4 is up-
regulated when the human pregnane X receptor (hPXR) is activated.  In order to 
determine if these novel series of rifamycins (C-8 analogues and benzoxazinorifamycin 
analogues) activate the receptor, the analogues were assessed using the hPXR activation 
assay.  Some of the analogues of the latter series exhibited lowered activation of hPXR 
suggesting a potential for reduced Cyp3A4 induction activity.  These studies demonstrate 
proof of principle for this subclass of rifamycins and support further expansion of 
structure-activity relationships (SAR) toward uncovering analogues with development 
potential. 
Previously, it has been reported that Gram-positive bacteria (particularly 
mycobacteria) are more sensitive to rifamycins than Gram-negative bacteria (11).  The 
IC50 values of known rifamycins for wild-type and RifR mutants of MTB and E. coli 
RNAPs (wild-type and corresponding mutants) were determined and found to be very 
similar; therefore, the difference in sensitivity toward rifamycins is not due to the RNAP.  
The correlation between the sensitivity of rifamycins and permeability into cells was 





).  The MIC values were drastically lower in the EC2880 strain, 
consistent with previous reports that the differential sensitivity of MTB and E. coli to 
rifamycins is not related to the RNAP, but rather has to do with efflux pump activity in E. 
coli. 
In addition to screening rifamycin derivatives, work on the development of two 
additional assays (direct binding assay and MTB promoter based plasmid assay) was 
carried out.  Due to the limitations of the rolling circle transcription assay, a more 
!179 
sensitive direct binding assay needs to be developed to determine the affinity of MTB 
RNAPs and rifamycins.  The equilibrium dissociation constant (KD) of wild-type and 
RifR RNAPs will then be compared.  The loss of free energy for each mutation will then 
be correlated to what interaction(s) is/are being disrupted.  The focus has been on 
developing the direct binding assay by attaching a fluorophore (e.g., dansyl group) 
directly to the rifamycin to determine the KD value.  Unfortunately the fluorescence of a 
rifamycin-dansyl probe was quenched in aqueous buffer.  To conclude if the fluorescence 
is essentially quenched due to the naphthyl ring of the rifamycin, a variety of different 
fluorophores and linkers need to be tested.  Another disadvantage of the rolling circle 
transcription assay is the non-native promoterless DNA nanocircle template.  Therefore, 
to enhance the affinity of the MTB RNAP for the template, a MTB promoter-based 
plasmid has been constructed using the P1 and P3 promoters of the MTB rrn operon that 
would be recognized by the MTB holoenzyme.  The promoter region is followed by 
malachite green aptamer repeat sequences, which allows the amount of the malachite 
green aptamer mRNA transcribed to be directly measured via fluorescence upon the 
addition of malachite green.  Once the optimal conditions are determined, this assay will 
be followed up by high-throughput screening of small molecule libraries that might lead 
to the discovery of potential lead compounds that bind at the same position of rifamycins 
or at other positions that act against the antibiotic resistant strains. 
Prior to our studies, the E. coli RNAP and rifampin had been extensively studied 
but little is known about the molecular mechanisms involved in resistance due to the lack 
of in vitro studies of RifR MTB RNAPs.  The successful expression and purification of 
wild-type and RifR MTB RNAPs from co-overexpression vectors allowed us to directly 
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investigate the level of inhibition by known and novel rifamycins.  The similar IC50 
values determined for known rifamycins with MTB and E. coli RNAPs (WT and RifR) 
allowed us to conclude that the difference in sensitivity between MTB and E. coli is not 
due to the RNAP.  The issue of sensitivity was further investigated by using a mutant E. 
coli strain (deficient in the TolC efflux pump) where the strain was much more sensitive 
to rifamycins suggesting that the difference in sensitivity is due to the E. coli efflux 
pumps.  The C-8 modifications (8-amino, 8-thio, and 1,8-pyrazole) did not result in a 
more effective rifamycin against the most prevalent mutation (Ser450Leu) found in MTB 
clinical isolates.  This study also confirmed that the C-8 position is limited in the number 
of modifications at this position since it is involved in critical interactions with key 
residues of the RNAP.  The next set of analogues was based on rifalazil and crystal 
structure information since rifalazil is more potent than RMP and does not induce 
CYP3A4.  The benzoxazinorifamycin analogues were designed to make additional 
contacts with the RNAP.  While the desired level of inhibition was not obtained, the 
limited number of compounds synthesized provided proof of concept for expansion of 
SAR in this series.  The linker was also thought to lower the affinity of the 
benzoxazinorifamycins to the hPXR binding site because of the additional bulk, but since 
the hPXR binding site is large and able to adapt to different ligands, activation was still 
observed which could be due to the flexibility of the linker.  The results from these 
studies will lead us to improve the design of rifamycins to develop a more potent 
rifamycin against RifR RNAPs. 
In the future, the completion of the direct binding assay and the in vitro MTB 
promoter based plasmid transcription assay experiments allow for a greater understanding 
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of the interactions between rifamycins with the wild-type and mutant MTB RNAP.  The 
small molecules identified from the HTS can then be transformed into new broad-
spectrum antibiotics since prokaryotic RNAPs are conserved.  Furthermore, it would be 
beneficial to obtain structural information by X-ray crystallography of the MTB RNAP 
bound to various rifamycins, especially the benzoxazinorifamycin analogues.  These 
experiments will hopefully provide useful information to understand the molecular 
mechanisms responsible for resistance and guide the development of new analogues with 
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Construction of MTB Promoter Based Plasmid 
 
In prokaryotes, gene expression is mediated by the holoenzyme (core RNAP + 
sigma factor) (1).  An in vitro transcription assay mimics these conditions by using a 
DNA template with a specific promoter that is recognized by the sigma factor.  For the 
assay, a strong promoter is required to be confident it will recognized by the holoenzyme 
hence leading to the expression of the gene following the promoter.  Previously, E. coli 
has been the best-studied prokaryote where the E. coli RNAP and promoters are well 
known.  However, mycobacterial promoters are not well characterized since majority of 
the promoters are weak (2).  Mycobacterial promoters have also been difficult to study 
because the promoters do not function well in E. coli (1, 2).  Due to the fact that 
prokaryotic RNAPs recognize different promoters, the activity of MTB RNAP will be 
assessed directly using a native mycobacterial template that will be recognized by the 
housekeeping MTB sigma factor, (SigA, !
A
), which is one of the thirteen MTB sigma 
factors, all of the !
70
 type (1, 3, 4). 
In general, prokaryotic promoters contain two hexamers at -35 and -10 from the 
transcription start point (TSP).  Different parts of the sigma factor recognize different 
regions of the promoter (! region 2.4 binds to the -10 region and ! region 4.2 binds to the 
-35 region of the promoter) (1, 3, 5).  The -10 region of mycobacterial promoters is 
similar to E. coli but the -35 region is not as strongly conserved (2, 6).  The consensus 
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sequence recognized by SigA is TTGAC(A/T) (-35 hexamer) N18/17 TATA(A/C)T (-10 
hexamer) (1, 5).  Only a few strong MTB promoters have been identified that transcribe 
the following genes: 16S rRNA, cpn-60 gene, and 85A antigen gene (6-9).  Even though 
the slow-growing MTB has a low content of RNA, the majority (80%) of the RNA pool 
is the ribosomal RNA (rRNA), which is an essential component that is involved in 
decoding the mRNA and interacting with the tRNA.  MTB has a single ribosomal RNA 
(rrn) operon containing the genes for 16S, 23S, and 5S rRNA that is driven by two 
promoters, P1 and P3 (10, 11).  The complete promoter region of rrn operon is 
approximately 650 bp, but previous studies have shown that a 310 bp fragment 
containing the +1 of mature 16S rRNA and both P1 and P3 rrn promoters is highly active 
(8).  The P3 promoter has been identified as the stronger rrn promoter in MTB, 
approximately twice as active as P1.  The sequence of the P3 promoter is TTGACT (-35 
hexamer) N18 TAGACT (-10 hexamer), similar to the consensus sequence recognized by 
SigA (8).  Therefore, our lab will use the MTB rrn operon (containing the P1 and P3 
promoters) as the promoter region. 
 
Appendix Figure–1: The 369 bp sequence of MTB rrn operon containing the P1 and P3 
promoter.  The -35 and -10 regions of both promoters are 
highlighted in yellow.  The transcription sites are indicated after the 




Another important component of the assay is the detection of the transcribed 
product.  Previously, radioisotopically tagged ribonucleotides have been used in in vitro 
transcription assays.  Some disadvantages involved with this method include: high 
reagent costs, high disposal costs, and variable reagent shelf life (12).  A non-
radioisotopic approach is to measure the RNA via Ribogreen, a fluorescent dye.  A 
disadvantage to this method is the dye binds to both RNA and DNA; therefore, an 
additional step is required that removes DNA by DNase digestion and ultrafiltration (12).  
Molecular beacons can also be used to detect the mRNA.  These exist in RNA hairpin 
structures in the absence of target with the fluorophore in close proximity to the 
quencher.  When the molecular beacon binds to the specific target, a strong fluorescence 
signal is observed due to the dissociation of the hairpin (concurrent with annealing to the 
target RNA) and the consequent physical separation of the fluorophore and quencher 
moieties.  This method allows for high signal to noise ratio, but is prohibitively expensive 
to be used for an HTS assay (13).  Another method is use an aptamer, which is short 
single stranded RNA that binds to a molecule with high binding affinity and specificity 
(14, 15).  To visualize the amount of mRNA produced in this assay, we have elected to 
insert the malachite green aptamer (MGA) gene sequence after the MTB P1/P3 promoter.  
MGA has been reported to bind to triphenylmethane dyes (i.e., malachite green (MG)) 
and upon binding a ! 2,000 fold increase in fluorescence signal is observed (16).  The 
fluorescence emission spectra is measured at an excitation wavelength of 610 nm with 




Appendix Figure–2:  The malachite green aptamer (MGA) mRNA sequence.  The 
4xMGA and 8xMGA repeat sequences are shown underneath 
with the MGA sequence underlined. 
 
Professor Jaya Sivaswami Tyagi (All India Institute of Medical Sciences) was 
kind enough to send us the prrn plasmid containing the 369 bp rrn operon (with P1 and 
P3 promoter) followed by the gfp gene (Appendix Figure–1) (9).  The plasmid is in an E. 
coli-mycobacterial shuttle plasmid (pFPV-27) and is hygromycin B antibiotic resistant.  
The plasmids containing MGA (pLee345.3.3 and pTJ141) were a generous gift from 
Professor Nilsen-Hamilton (Iowa State University).  Plasmid pLee345.3.3 has the 
sequence of four repeats of MGA (4xMGA) and plasmid pTJ141 has eight repeats 
(8xMGA) where each MGA repeat sequence is separated by 7 bases.  Since the aptamer 
domain is only 38 nucleotides long (Appendix Figure–2), the multiple repeats of MGA 
might enhance fluorescence signal further. 
Once the plasmids were received, unique restriction sites were incorporated to 
allow for subcloning the MGA repeats into the MTB promoter containing plasmid 
(Appendix Figure–3).  It was challenging to identify unique sites because we did not have 
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the sequence file of prrn.  The unique sites used were Bsu361 and PacI.  These sites were 
introduced into prrn plasmid via site-directed mutagenesis.  After the Bsu361 site was 
inserted after the P3 TSP, the sequence of several plasmids showed there was a deletion 
of a single nucleotide at various positions of the P3 promoter: !T from P3 spacer region, 
!T from P3 -10 region, and !G before P3 TSP.  QC primers were designed to insert +T 
to the -10 region, but after multiple trials, the reaction was still unsuccessful.  For MGA 
sequence, the sites were introduced via PCR. 
 
Appendix Figure–3:  MTB Promoter based plasmid + MGA.  All the oligonucleotides 
used to sequence and construct the plasmid are listed in Appendix 
Table 1. 
 
After the restriction sites were introduced, the PCR product of 4xMGA and 
8xMGA and prrn (containing the Bsu361 and PacI sites) were treated with Bsu361 and 
PacI via sequential digestion.  The PCR product of the MGA repeats was subcloned into 
treated prrn.  Along the way plasmids containing only two repeats of the MGA were also 
obtained.  The resulting plasmids that we have constructed are listed below 
(unfortunately we were unable to get a plasmid that did not contain a deletion):  
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• prrn (!T from P3 spacer region) + 2xMGA 
• prrn (!G before P3 TSP) + 2xMGA 
• prrn (!T from P3 spacer region) + 4xMGA 
• prrn (!T from P3 -10 region) + 4xMGA 
• prrn (!G before P3 TSP) + 4xMGA 
• prrn (!T from P3 spacer region) + 8xMGA 
• prrn (!G before P3 TSP) + 8xMGA 
Now that these plasmids have been constructed, initial studies need to be 
conducted including one that determines if the holoenzyme binds to the DNA template 
via DNA binding assays.  Control experiments (with no inhibitor present) will then be 
setup to find the optimal conditions for the in vitro transcription assay.  Furthermore, the 
MGA sequence from the original plasmids (pLee345.3.3 and pTJ141) is preceded by the 
T7 promoter thus the amount of MGA synthesized by T7 RNAP can be isolated and 
quantified to determine a standard curve using MG.  The amount of fluorescence 
observed with the MTB promoter assay can be used to quantify the amount of RNA 
transcribed.  Rifampin and rifamycin analogues will then be assayed with the wild-type 
and mutant MTB RNAPs.  In the absence of rifamycins, the MTB RNAP will be 
expected to transcribe the MGA domain and when MG is added a distinct fluorescence 
signal will be observed; whereas, in the presence of rifamycins, the aptamer domain will 
not be transcribed because the RNAP will be inhibited thus no fluorescent signal. 
Once preliminary runs are successful, the assay can then be developed into an 
HTS assay.  Small molecule libraries will be screened using the different MTB RNAPs.  
Any hits will be confirmed and characterized via secondary assays (e.g., in vitro 
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MGA•MG binding assay to screen for inhibitors of MG binding to MGA and the direct 
binding assay (see Chapter V) to probe for competition with rifamycins).  Ideally the 
HTS will identify novel scaffolds that inhibit the MTB RNAP with a different 
mechanism of action than the rifamycins thus not subject to cross-resistance. 
In this appendix, we have described an approach to analyze in vitro transcription 
in the presence of MTB RNAP using the malachite green aptamer that specifically binds 
to malachite green.  The SigA driven MTB RNAP binds to the MTB rrn operon 
promoters hence leads to the transcription of the malachite green aptamer mRNA.  This 
method is convenient with reduced steps, which makes it favorable to be developed into a 
HTS assay.  The advantages of this method include: reduced cost, fewer steps, high 
signal to noise ratio, high binding affinity of target, and non-radiolabeled nucleotides.  
Since RNAP is conserved among prokaryotes, small molecules that target and inhibit 




Appendix Table 1.  Oligonucleotides Used to Construct the Plasmids. 
 
O ligonucleotides      Primer Sequence (5’-3’) 
(Q C/PC R Primers) 
pr rn Plasmid  
(Add Bsu361 site after P3 TSP start site and PacI site after translation start site) 
prrn QC FWD Primer (+Bsu361)  gtattagactggcagggtcgccccTaagGgggcggaaacaagcaagcgtgttg 
prrn QC REV Primer (+Bsu361)  caacacgcttgcttgtttccgcccCcttAggggcgaccctgccagtctaatac 
prrn QC FWD Primer (+PacI)  ctggctcaggacgaacgctggcggcTtaatTaAtagtgaattcgatatcaagcttatc 
prrn QC REV Primer (+PacI)   gataagcttgatatcgaattcactaTtAattaAgccgccagcgttcgtcctgagccag 
(Insert “T” in the -10 box of the second promoter (P3)) 
prrn QC FWD Primer (+T)   gccggatttgtattagacTggcagggtcgcccctaag 
prrn QC REV Primer (+A)   cttaggggcgaccctgccAgtctaatacaaatccggc 
(To amplify WT MTB rrn promoter + GFP) 
PCR FWD Primer     gaagctGGATCCcccgggctgcagg 
PCR REV Primer     agcttcGCATGCctgcaggtctggac 
 
(Q C/PC R Primers) 
(p4xM G A Plasmid; pL ee345.3.3) 
p4xMGA PCR FWD (+Bsu361)  cagcgaCCTAAGGagcacgtcgacggatcccgac 
p4xMGA PCR REV (+PacI)   gaagctTTAATTAAtccgctctagaggatccattcg 
 
(p8xM G A Plasmid; pTJ141) 
p8xMGA PCR FWD (+Bsu361)  cagcgaCCTAAGGctcttcaggtaagtcgacggatcccgac 
p8xMGA PCR REV (+PacI)   gaagctTTAATTAAtccaccgctctagaggatccattcgttacc 
 
(to amplify 4xMGA and 8xMGA from original plasmids pLee345.3.3 and pTJ141) 
PCR FWD Primer (4x/8xMGA)  cagaGATTACGAATTTAATACGACTC 
PCR REV Primer (4x/8xMGA)  gagtCTAGTAAAAAGCGGACCGAAGTC 
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Appendix Table 1.  (continued) 
 
O ligonucleotides      Primer Sequence (5’-3’) 
PCR primers (to amplify MTB rrn promoter region (including ~150 bp upstream) + 4x/8xMGA without GFP sequence) 
PCR FWD Primer     cagaCTTGGTCGATACCAAGCCATTTC 





1. P. Sachdeva et al., The sigma factors of Mycobacterium tuberculosis: regulation 
of the regulators. Febs Journal 277 , 605 (Feb, 2010). 
2. N. Agarwal, A. K. Tyagi, Mycobacterial transcriptional signals: requirements for 
recognition by RNA polymerase and optimal transcriptional activity. Nucleic 
Acids Res. 34 , 4245 (Sep, 2006). 
3. S. Rodrigue, R. Provvedi, P.-E. Jacques, L. Gaudreau, R. Manganelli, The Sigma 
factors of Mycobacterium tuberculosis. FEMS Microbiology Reviews 30 , 926 
(2006). 
4. J. H. Lee, P. C. Karakousis, W. R. Bishai, Roles of SigB and SigF in the 
Mycobacterium tuberculosis sigma factor network. J. Bacteriol. 190 , 699 (Jan, 
2008). 
5. R. Manganelli, R. Provvedi, S. Rodrigue, J. Beaucher, L. Gaudreau, I. Smith, 
Sigma factors and global gene regulation in Mycobacterium tuberculosis. J. 
Bacteriol. 186 , 895 (Feb, 2004). 
6. M. D. Bashyam, D. Kaushal, S. K. Dasgupta, A. K. Tyagi, A study of the 
mycobacterial transcriptional apparatus: Identification of novel features in 
promoter elements. J. Bacteriol. 178 , 4847 (Aug, 1996). 
7. J. A. GonzalezyMerchand, M. J. Colston, R. A. Cox, The rRNA operons of 
Mycobacterium smegmatis and Mycobacterium tuberculosis: Comparison of 
promoter elements and of neighbouring upstream genes. Microbiology-(UK) 142 , 
667 (Mar, 1996). 
8. A. Verma, A. K. Sampla, J. S. Tyagi, Mycobacterium tuberculosis rrn promoters: 
Differential usage and growth rate-dependent control. J. Bacteriol. 181 , 4326 
(Jul, 1999). 
9. S. Chauhan, J. S. Tyagi, Cooperative binding of phosphorylated DevR to 
upstream sites is necessary and sufficient for activation of the Rv3134c-devRS 
operon in Mycobacterium tuberculosis: Implication in the induction of DevR 
target genes. J. Bacteriol. 190 , 4301 (Jun, 2008). 
!
! 194 
10. Y. E. Ji, M. J. Colston, R. A. Cox, Nucleotide-Sequence and Secondary Structures 
of Precursor 16s Ribosomal-RNA of Slow-Growing Mycobacteria. Microbiology-
(UK) 140 , 123 (Jan, 1994). 
11. A. Verma, A. K. Kinger, J. S. Tyagi, Functional-Analysis of Transcription of the 
Mycobacterium tuberculosis 16s RNA-Encoding Gene. Gene 148 , 113 (Oct, 
1994). 
12. P. Kuhlman, H. L. Duff, A. Galant, A fluorescence-based assay for multisubunit 
DNA-dependent RNA polymerases. Analytical Biochemistry 324 , 183 (Jan, 
2004). 
13. W. Tan, K. Wang, T. J. Drake, Molecular beacons. Current Opinion in Chemical 
Biology 8 , 547 (Oct, 2004). 
14. J. E. Weigand, B. Suess, Aptamers and riboswitches: perspectives in 
biotechnology. Appl. Microbiol. Biotechnol. 85 , 229 (Nov, 2009). 
15. M. Mandal, R. R. Breaker, Gene regulation by riboswitches. Nature Reviews 
Molecular Cell Biology 5 , 451 (Jun, 2004). 
16. J. R. Babendure, S. R. Adams, R. Y. Tsien, Aptamers switch on fluorescence of 
triphenylmethane dyes. J. Am. Chem. Soc. 125 , 14716 (Dec, 2003). 
 
!
